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My PhD work has been focused towards four different targets: HIV-1 RT, Candida 
albicans, Monoamine oxidase, and G-Quadruplex. 
Thus in order to give the reader a clearer exposition this report has been divided in 
four different chapters. 
Each of the chapters has his own numbering for pages, figures, schemes, tables 
and references. 
The main part of my work has been dedicated to HIV-1 RT, thus this chapter is the 
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1.1 Historical overview 
 
In 1980, Michael Gottlieb, an imunologist of the Los Angeles UCLA Medical Center 
analysed three cases of young homosexual men presenting clinical signs such as weight 
loss, mycosis, fever, oral Candida , and pneumonia. 
In early May 1981, local clinicians and the Epidemic Intelligence Service (EIS) Officer 
stationed at the Los Angeles County Department of Public Health, prepared a report of 
five cases of Pneumocystis carinii pneumonia (PCP) among previously healthy young men 
in Los Angeles and submitted it for Morbidity and Mortality Weekly Report (MMWR) 
publication. [1] 
All of the men were described as homosexuals; two had died. 
The editorial note, that accompanied the published report, stated that the case 
histories suggested a cellular-immune dysfunction related to a common exposure and a 
disease acquired through sexual contact. 
In June 1981, the Centers for Disease Control (CDC) developed a team to identify 
risk factors and to develop a case definition for national surveillance. In March 1983, CDC 
issued recommandations for prevention of a sexual, drug related, and occupational 
transmission based infection on these early epidemiologic studies and before the cause of 
the new, unexplained illness was known. 
In 1983, Montagnier and colleagues isolated a T-lymphotropic retrovirus, named 
lymphadenopathy-associated virus (LAV) and, almost simultaneously, Robert Gallo 
published on the frequent detection and isolation of cytopathic retroviruses from patients 
with AIDS or at risk for AIDS. [2, 3] The same year Levy and colleagues isolated from AIDS 
patients in S.Francisco a retrovirus that was named Aids Related Virus (ARV). [4]  
The three viruses were then cloned and characterised and are now known as 
Human Immunodeficiency Virus type 1 (HIV-1). [5] 
1985 is an important year for the proceeding of the AIDS related knowledge 
• Tests to identify the virus are marketed 
• First clinical trials in USA aimed to the identification of drugs to fight 
the virus 
• First ever conference on AIDS was held in Atlanta (USA), where 
interaction between scientific groups from all the world began. 
In 1987, the Food and Drugs Administration (FDA) approved Azidovudine (AZT), the 
first molecule to treat the HIV infection. 
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Between 1995 and 1997, David Ho findings on viral dynamics provide, not only a 
kinetic picture of HIV-1 pathogenesis, but also theoretical principles to guide the 
development of treatment strategies. [6, 7] 
There are more than 20 antiretroviral drugs approved for the clinical treatment of 
HIV infected patients targeting different steps of the HIV replication cycle. [8] These drugs 
can be efficiently associated for the so called highly active antiretroviral therapy (HAART). 
[9] 
Currently we have at our disposal a rich armamentarium of drugs that change the 
prognosis of HIV infected patients from high probability of mortality to a chronic 
infection. 
 
1.2 HIV Pathogenesis and Prevention 
 
Despite rigorous and multifaceted approaches to the prevention of HIV infection, 
∼39.000 new infections occur annually in the United States, a number that has not 
changed significantly in the last years. [10]  
Prevention methods that have been successful in certain populations need to be 
adapted in order to target other groups and must be provided to more people.  
In particular it is important to pursue prevention approaches that are based on our 
growing understanding of the pathogenic mechanisms of HIV disease.  
Such strategies include the identification and treatment of coinfections, including 
sexually transmitted infections; the use of topical microbicides; the circumcision of men; 
the use of antiretroviral drugs for preexposure prophylaxis; the reduction of the viral load 
in order to decrease transmission rates; and the development of vaccines. 
All these modalities focus on the pathogenesis of HIV disease, in the sense that they 
involve preventing the initial entry of HIV into the body, blocking the spread of infection, 
or slowing the progression of disease once infection is established. 
The early events in HIV disease take place rapidly, and once they occur, infection is 
permanently established. [11] The events associated with primary HIV infection are likely 
critical determinants of the subsequent course of HIV disease. 
So far, preventing or interfering with these early events is an important goal of all 
prevention efforts that focus on pathogenic events. 
When HIV is transmitted during sexual activity, dendritic cells at or near the 




These cells bind with high affinity to the HIV envelope glycoprotein gp120 and can 
retain infectious particles for days, thus facilitating the presentation of the virus to 
susceptible cells. 
The replication cycle of HIV in its target cell begins with the binding of viral gp120 to 
the CD4 molecule, its receptor on the host-cell surface. 
Once gp120 binds to CD4, fusion with the host cell membrane follows, and infection 
is established. An early burst of viremia and rapid dissemination of virus to lymphoid 
organs, particularly the gut-associated lymphoid tissue, are major factors in the 
establishment of the chronic and persistent infection that is a hallmark of HIV disease. 
[13–15]  
Despite the vigorous cellular and humoral immune responses seen during primary 
HIV infection, the virus succeeds in escaping immune-mediated clearance. Hence, once 
infection is established, it is never eliminated completely from the body. 
Paradoxically, HIV seems to thrive on immune activation. Chronic immune 
activation results in increased viral replication and immune cell depletion, immune cell 
dysfunction, and aberrant lymphocyte turnover. [13] 
Treating coinfections that potentially increase immune activation and provide a 
permissive environment for HIV replication is a promising, pathogenesis-associated 
approach to preventing HIV disease.  
There is considerable epidemiologic evidence for a link between the presence of 
other sexually transmitted diseases, particularly genital-ulcer diseases, and the risk of HIV 
transmission. [16] 
Recent studies have strengthened the evidence for this association. It has been 
reported that patience with recent or incident syphilis had a >4-fold increased risk for HIV 
acquisition. [17] 
The same authors found that recent incidents of herpes simplex virus–2 (HSV-2) 
infection was associated with a ∼4-fold increased risk of HIV acquisition. [18] 
It had been assumed that the biologic mechanism for an increased risk of HIV 
infection in individuals with sexually transmitted diseases (STDs) was the impaired 
integrity of the mucosa, but, it has been reported that [18] the risk of HIV infection was 
increased for individuals who were asymptomatic for HSV-2 infection (i.e., persons who 
did not have clinically apparent or self-reported genital ulcers), as well as for individuals 
with symptomatic HSV-2 infection.  
This and other studies suggest that additional mechanisms, such as immune 
activation, also may play a role. So far, the prevention and treatment of STDs, both 
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ulcerative and nonulcerative, offers promise as a strategy for preventing HIV infection. 
[16] 
There is an increasing evidence on other infections such as helminthic infections, 
tuberculosis, and malaria increasing susceptibility to HIV infection or worsening 
progression of HIV disease. [19-25] 
Concerning the sexual transmission of HIV, the use of topical microbicides could 
represent a valid approach for HIV infection prevention, in particular for women that are 
subjected to male-controlled modalities of protection. 
These compounds have varying mechanisms of action, but the activities of all of the 
compounds focus on early mucosal events in pathogenesis. 
In this respect, it has been recently reported that medically performed adult male 
circumcision significantly reduced a man’s risk of acquiring HIV through heterosexual 
intercourse. [26, 27] 
Male circumcision could protect against HIV acquisition by several mechanisms. [26, 
27] 
• The highly vascularised inner foreskin tissue contains a high density of 
Langerhans’ cells as well as increased numbers of CD4+ T cells, 
macrophages, and other cellular targets for HIV.  
• In contrast to the dry environment of the keratinized area on the outer 
surface of the foreskin, the moist environment under the foreskin may 
promote the presence or persistence of microbial flora, which, via 
inflammatory modification, may lead to even higher concentrations of target 
cells for HIV in the foreskin and a higher density of HIV-susceptible cells.  
• The inner mucosa of the foreskin is more susceptible to microabrasion, 
providing a portal of entry for HIV, and the higher rates of ulcerative STDs in 
uncircumcised men may also increase susceptibility to HIV infection. 
Hence, eliminating the foreskin diminishes some of the targets for the virus, and 
allows a more protective skin surface barrier against HIV. [28, 29] 
Preexposure and postexposure chemoprophylaxis represent another important 
area of prevention research. It has been reported that tenofovir and emtricitabine have 
good safety profiles. Moreover they exhibit long half-life and, so far, may exert protection 
even if some doses are missed.  
The most direct approach is the treatment of infected individuals with combination 
antiretroviral treatment, which, in a majority of individuals, can reduce plasma levels of 
virus to undetectable levels. [30] 
In an analysis of transmission rates in the Women and Infants Transmission Study, 
the rate of maternal-fetal transmission was 23.4% when the viral load of the mother was 




Thus, although not considered to be “prevention research,” studies of the 
pathogenesis of HIV disease could provide us with important opportunities to develop 




1.3 Virus Structure 
 
The genome and proteins of HIV (human immunodeficiency virus) have been the 
subject of extensive research since the discovery of the virus in 1983. [2, 3] Each virion 
comprises a viral envelope and associated matrix enclosing a capsid, which itself encloses 
two copies of the single-stranded RNA genome and several enzymes. The discovery of the 
virus itself was not until two years after the first major cases of AIDS associated illnesses 




Figure 1. Schematic illustration of HIV structure 
 
HIV structure is different from other retroviruses. It has a icoshedral shape with 120 
nm in diameter (around 60 times smaller than a red blood cell). 
HIV-1 is composed of two copies of single-stranded RNA enclosed by a conical 
capsid comprising the viral protein p24, typical of lentiviruses (Figure 1). The RNA 
component is 9749 nucleotides long. [32, 33] 
This is in turn surrounded by an envelope originating from the host-cell. The single-
strand RNA is tightly bound to the nucleocapsid proteins, p6, p7 and enzymes that are 
indispensable for the development of the virion, such as reverse transcriptase and 
integrase. 
The nucleocapsid (p7 and p6) associates with the genomic RNA (one molecule per 
hexamer) and protects the RNA from digestion by nucleases. 
A matrix, composed of an association of the viral protein p17, surrounds the capsid, 
ensuring the integrity of the virion particle.  




The envelope is formed when the capsid buds from the host cell, taking some of the 
host-cell membrane with it. The envelope includes the glycoproteins gp120 and gp41. 
As a result of its role in virus-cell attachment, the structure of the virus envelope 
spike, consisting of gp120 and gp41, is of particular importance. 
The first model of its structure was compiled in 2006 using cryo-electron 
tomography and suggested that each spike consists of a trimer of three gp120–gp41 
heterodimers. [34] 
However, evidence for a single-stalk “mushroom” model, with a head consisting of a 
trimer gp120 and gp41 stem, which appear as a compact structure with no obvious 
separation between the three monomers, anchoring it to the envelope was published 
shortly after. [35]  
There are various possibilities as to the source of this difference, as it is unlikely that 
the viruses imaged by the two groups were structurally different.[36] 
More recently, further evidence backing up the heterodimer trimer-based model 




1.4 Organisation of the Viral genome 
 
The integrated form of HIV-1, also known as the provirus, is approximately 9.8 
kilobases in length. [38] 
The provirus genome is flanked by a repeated sequence known as the long terminal 
repeats (LTRs) on each side. The genes of HIV are located in the central region of the 
proviral DNA and encode at least nine proteins (Figure 2). [39] 
These proteins are divided into three classes:  
1. HIV structural proteins, Gag, Pol, and Env 
2. The regulatory proteins, Tat and Rev 












The gag gene gives rise to the 55-kilodalton (kD) Gag precursor protein, also called 
p55, which is expressed from the unspliced viral mRNA.  
During translation, the N terminus of p55 is myristoylated, [40] triggering its 
association with the cytoplasmic aspect of cell membranes.  
The membrane-associated Gag polyprotein recruits two copies of the viral genomic 
RNA along with other viral and cellular proteins that triggers the budding of the viral 
particle from the surface of an infected cell.  
After budding, p55 is cleaved by the virally encoded protease (a product of the pol 
gene) during the process of viral maturation into four smaller proteins designated MA 
(matrix [p17]), CA (capsid [p24]), NC (nucleocapsid [p9]), and p6. [41] 
The MA polypeptide is derived from the N-terminal, myristoylated end of p55. Most 
MA molecules remain attached to the inner surface of the virion lipid bilayer, stabilizing 
the particle.  
A subset of MA is recruited inside the deeper layers of the virion where it becomes 
part of the complex which escorts the viral DNA to the nucleus. [42] 
These MA molecules facilitate the nuclear transport of the viral genome because a 
karyophilic signal on MA is recognized by the cellular nuclear import machinery. This 
phenomenon allows HIV to infect nondividing cells, an unusual property for a retrovirus. 
[43] 
The p24 (CA) protein forms the conical core of viral particles. Cyclophilin A has been 
demonstrated to interact with the p24 region of p55 leading to its incorporation into HIV 
particles. [44, 45] 
The interaction between Gag and cyclophilin A is essential because the disruption of 
this interaction by cyclosporine A inhibits viral replication. [46] 
The NC region of Gag is responsible for specifically recognizing the so-called 
packaging signal of HIV. [47] 
The packaging signal consists of four stem loop structures located near the 5' end of 
the viral RNA, and is sufficient to mediate the incorporation of a heterologous RNA into 
HIV-1 virions. [48] 
NC binds to the packaging signal through interactions mediated by two zinc-finger 
motifs. NC also facilitates reverse transcription. [49] 
The p6 polypeptide region mediates interactions between p55 Gag and the 
accessory protein Vpr, leading to the incorporation of Vpr into assembling virions. [50] 
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The p6 region also contains a so-called late domain which is required for the 
efficient release of budding virions from an infected cell.  
  
1.5.2 Gag-Pol Precursor 
 
The viral protease (Pro), integrase (IN), and reverse transcriptase (RT) are always 
expressed within the context of a Gag-Pol fusion protein. [51] 
The Gag-Pol precursor (p160) is generated by a ribosomal frame shifting event, 
which is triggered by a specific cis-acting RNA motif [52] (a heptanucleotide sequence 
followed by a short stem loop in the distal region of the Gag RNA).  
When ribosomes encounter this motif, they shift approximately 5% of the time to 
the pol reading frame without interrupting translation. 
The frequency of ribosomal frameshifting explains why the Gag and the Gag-Pol 
precursor are produced at a ratio of approximately 20:1. 
During viral maturation, the virally encoded protease cleaves the Pol polypeptide 
away from Gag and further digests it to separate the protease (p10), RT (p50), RNase H 
(p15), and integrase (p31) activities. 
These cleavages do not all occur efficiently, for example, roughly 50% of the RT 




The HIV-1 protease is an aspartyl protease [53] that acts as a dimer. Protease 
activity is required for cleavage of the Gag and Gag-Pol polyprotein precursors during 
virion maturation as described previously.  
The three-dimensional structure of the protease dimer has been determined. [54, 
55] 
Knowledge of this structure has led to a class of drugs directed toward inhibiting the 
HIV protease function. These antiviral compounds have greatly improved treatment for 




The pol gene encodes reverse transcriptase. Pol has RNA-dependent and DNA-
dependent polymerase activities.  
During the process of reverse transcription, the polymerase makes a double-
stranded DNA copy of the dimer of single-stranded genomic RNA present in the virion.  
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RNase H removes the original RNA template from the first DNA strand, allowing 
synthesis of the complementary strand of DNA.  
Viral DNA can be completely synthesized within 6 hours after viral entry, although 
the DNA may remain unintegrated for prolonged periods. [59] 
Many cis-acting elements in the viral RNA are required for the generation of viral 
DNA.  
For example, the TAR element, a small RNA stem-loop structure located at the 5' 
end of viral RNAs and containing the binding site for Tat, is required for the initiation of 
reverse transcription. [57] 
The predominant functional species of the polymerase is a heterodimer of p66 and 
p51.  
All of the pol gene products can be found within the capsid of free HIV-1 virions. 
Because the polymerase does not contain a proof-reading activity, replication is error-
prone and introduces several point mutations into each new copy of the viral genome. 
The crystal structure of HIV-1 RT has been determined. [58] 
 
1.5.5 Integrase (IN) 
 
The IN protein mediates the insertion of the HIV proviral DNA into the genomic DNA 
of an infected cell. This process is mediated by three distinct functions of IN. [59] 
First, an exonuclease activity trims two nucleotides from each 3' end of the linear 
viral DNA duplex.  
Then, a double-stranded endonuclease activity cleaves the host DNA at the 
integration site.  
Finally, a ligase activity generates a single covalent linkage at each end of the 
proviral DNA. 
It is believed that cellular enzymes then repair the integration site. No exogenous 
energy source, such as ATP, is required for this reaction. 
The accessibility of the chromosomal DNA within chromatin, rather than specific 
DNA sequences, seems to influence the choice of integration sites. [60] 
Sites of DNA kinking within chromatin are thus "hot-spots" for integration, at least 
in vitro. [61] 
It is possible to promote integration within specific DNA regions by fusing integrase 
to sequence-specific DNA binding proteins. [62] 
Preferential integration into regions of open, transcriptionally active, chromatin 
may facilitate the expression of the provirus. Viral genes are not efficiently expressed 






The 160 kD Env (gp160) is expressed from singly spliced mRNA. 
First synthesized in the endoplasmic reticulum, Env migrates through the Golgi 
complex where it undergoes glycosylation with the addition of 25 to 30 complex N-linked 
carbohydrate side chains that are added at asparagine residues.  
Env glycosylation is required for infectivity. [64] 
A cellular protease cleaves gp160 to generate gp41 and gp120. 
The gp41 moeity contains the transmembrane domain of Env, while gp120 is 
located on the surface of the infected cell and of the virion through noncovalent 
interactions with gp41. 
Env exists as a trimer on the surface of infected cells and virions. [65] 
Interactions between HIV and the virion receptor, CD4, are mediated through 
specific domains of gp120. [66] 
The structure of gp120 has recently been determined. [67] The gp120 moeity has 
nine highly conserved intrachain disulfide bonds.  
In gp120 fare also present five hypervariable region, designated V1 through V5, 
whose amino acid sequences can vary greatly among HIV-1 isolates.  
One of this regions, called the V3 loop, is not involved in CD4 binding, but is rather 
an important determinant of the preferential tropism of HIV-1 for either T lymphoid cell 
lines or primary macrophages. [68] 
Sequences within the V3 loop interact with the HIV co-receptors CXCR4 and CCR5, 
which belong to the family of chemokine receptors and partially determine the 
susceptibility of cell types to given viral strains. [69, 70] 
The V3 loop is also the principal target for neutralizing antibodies that block HIV-1 
infectivity. [71] 
The gp120 moeity also interacts with the protein DC-SIGN (Dendritic Cell-Specific 
Intercellular adhesion molecule-3-Grabbing Non-integrin) which is expressed on the 
surface of dendritic cells. Interaction with DC-SIGN increases the efficiency of infection of 
CD4 positive T cells. [72] 
Further, it is believed that DC-SIGN can facilitate mucosal transmission by 
transporting HIV to lymphoid tissues. 
The gp41 moiety contains an N-terminal fusogenic domain that mediates the fusion 
of the viral and cellular membranes, thereby allowing the delivery of the virions inner 
components into the cytoplasm of the newly infected cell. [73] 
A new class of antiviral therapeutics, which prevent membrane fusion, are showing 








Tat is a transcriptional transactivator that is essential for HIV-1 replication. [74] The 
72 and 101 amino acid long forms of Tat are expressed by early fully spliced mRNAs or 
late incompletely spliced HIV mRNAs, respectively. Both forms function as transcriptional 
activators and are found within the nuclei and nucleoli of infected cells.  
Tat is an RNA binding protein, unlike conventional transcription factors that interact 
with DNA. [75, 76] Tat binds to a short-stem loop structure, known as the transactivation 
response element (TAR), that is located at the 5' terminus of HIV RNAs. Tat binding occurs 
in conjunction with cellular proteins that contribute to the effects of Tat. The binding of 
Tat to TAR activates transcription from the HIV LTR at least 1000-fold.  
The mechanism of Tat function has recently been elucidated. It acts principally to 
promote the elongation phase of HIV-1 transcription, so that full-length transcripts can be 
produced. [77, 78] In the absence of Tat expression, HIV generates primarily short (>100 
nucleotides) transcripts.  
Stimulation of polymerase elongation is accomplished by the recruitment of a 
serine kinase which phosphorylates the carboxylterminal domain (CTD) of RNA 
polymerase II (Figure 3). 
This kinase, which is known as CDK9, is part of a complex which binds directly to 
Tat. [79]  
Tat function requires a cellular co-factor, known as Cyclin T, which facilitates the 








The cellular uptake of Tat released by infected cells has been observed, [78] 
although the impact of this phenomenon on pathogenesis is unknown. 
On the other hand, Tat has been shown to activate the expression of a number of 
cellular genes including tumor necrosis factor beta [81] and transforming growth factor 
beta (TNF-β), [82] and to downregulate the expression of other cellular genes including 




Rev is a 13-kD sequence-specific RNA binding protein. [85] It is produced from fully 
spliced mRNAs, and acts to induce the transition from the early to the late phase of HIV 
gene expression. [86] 
Rev, which is encoded by two exons, accumulates within the nuclei and nucleoli of 
infected cells. It binds to a 240-base region of complex RNA secondary structure, called 
the Rev response element (RRE), that lies within the second intron of HIV. [87] 
Rev binds to a "bubble" within a double-stranded RNA helix containing a non-
Watson-Crick G-G basepair. [88] 
This structure, known as the Rev high affinity binding site, is located in a region of 
the RRE known as stem loop 2.  
The binding of Rev to the RRE facilitates the export of unspliced and incompletely 
spliced viral RNAs from the nucleus to the cytoplasm. Normally, RNAs that contain introns 
(ie, unspliced or incompletely spliced RNA) are retained in the nucleus. 
High levels of Rev expression can lead to the export of so much intron containing 
viral RNA that the amount of RNA available for complete splicing is decreased, which, in 
turn, reduces the levels of Rev expression. 
Therefore, this ability of Rev to decrease the rate of splicing of viral RNA generates a 
negative feedback loop whereby Rev expression levels are tightly regulated. [89])  








An arginine-rich RNA binding mediates interactions with the RRE. A multimerization 
domain is required for Rev to function. [91]  
Rev is believed to exist as a homo-tetramer in solution. [92] It also contains an 
effector domain, which is a specific nuclear export signal (NES). [93, 94]  
The export of the viral RNA by Rev is through a pathway typically used by the small 
nuclear RNAs (snRNAs) and the ribosomal 5s RNA rather than the normal pathway for 
cellular mRNAs. [94] Rev Export is mediated through interactions with the NES receptor 
known as CRM1. NES mutants of Rev are dominant negative. [90] 
Inhibition is caused by the formation of non-functional multimers between NES-
mutant and wild type Rev monomers. [95] 
Rev is absolutely required for HIV-1 replication: proviruses that lack Rev function 
are transcriptionally active but do not express viral late genes and thus do not produce 
virions.  
 
1.7 Accessory Proteins 
 
In addition to the gag, pol, and env genes, contained in all retroviruses, and the tat 
and rev regulatory genes, HIV-1 contains four additional genes: nef, vif, vpr and vpu, 
encoding the so-called accessory proteins. 
HIV-2 does not contain vpu, but instead harbors another gene, vpx. 
The accessory proteins are not absolutely required for viral replication in all in vitro 
systems, but represent critical virulence factors in vivo.  
Nef is expressed from a multiply spliced mRNA and is therefore Rev independent. In 
contrast, Vpr, Vpu, and Vif are the product of incompletely spliced mRNA, and thus are 
expressed only during the late Rev-dependent phase of infection from singly spliced 
mRNAs. 





Nef (an acronym for negative factor) is a 27-kD myristoylated protein that is 
encoded by a single exon that extends into the 3' LTR. Nef, an early gene of HIV, is the 
first viral protein to accumulate in detectable levels in a cell following HIV-1 infection. [86] 
Its name is a consequence of early reports, claiming that Nef downregulated 
transcriptional activity of the HIV-1 LTR.  
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However, it is no longer believed that Nef has a direct effect on HIV gene 
expression. 
Nef has been shown to have multiple activities, including the downregulation of the 
cell surface expression of CD4, the perturbation of T cell activation, and the stimulation of 
HIV infectivity.  
Nef acts post-translationally to decrease the cell-surface expression of CD4, the 
primary receptor for HIV. [96] 
It increases the rate of CD4 endocytosis and lysosomal degradation. [97]  
The cytoplasmic tail of CD4, and in particular a dileucine repeat sequence contained 
in its membrane proximal region, is key for the effect of Nef on CD4. [90]  
CD4 downregulation appears to be advantageous to viral production because an 
excess of CD4 on the cell surface has been found to inhibit Env incorporation and virion 
budding. [98, 99] 
Nef also downregulates the cell surface expression of Class I  major 
histocompatibility complex (MHC), albeit to a lesser degree. [100] 
The downregulation of Class I MHC decreases the efficiency of the killing of HIV 
infected cells by cytotoxic T cells.  
Nef perturbs T cell activation. Studies in the Jurkat T cell line indicated that Nef 
expression has a negative effect on induction of the transcription factor NF-kappa B and 
on IL-2 expression. [101] 
In contrast, results obtained in Nef transgenic mice revealed that Nef led to 
elevated T cell signalling. [102]  
The expression of a CD8-Nef chimeric molecule in Jurkat cells had either positive or 
negative effects depending on the cellular localization of the hybrid Nef molecule. [103] 
When the CD8-Nef protein accumulated in the cytoplasm, there was a block in 
normal signaling through the T cell receptor. 
When the CD8-Nef chimera was expressed at high levels on the cell surface, 






Figure 5. Nef activity network 
Together, these observations suggest that Nef can exert pleiomorphic effects on T 
cell activation depending on the context of expression. 
Consistent with this model, Nef has been found to associate with several different 
cellular kinases that are present in helper T lymphocytes.  
Nef also stimulates the infectivity of HIV virions. [104] 
HIV-1 particles produced in the presence of Nef can be up to ten times more 
infectious than virions produced in the absence of Nef. 
Nef is packaged into virions, where it is cleaved by the viral protease during virion 
maturation. [105] 
The importance of this event, however, is not clear. Virions produced in the absence 
of Nef are less efficient for proviral DNA synthesis, although Nef does not appear to 
influence directly the process of reverse transcription. [106] 
The downregulation of CD4 and the effect on virion infectivity by Nef are genetically 
distinct as demonstrated by certain mutations that affect only one of these two activities. 
[107] 
There is compelling genetic evidence that the Nef protein of simian 
immunodeficiency virus is absolutely required for high-titer growth and the typical 
development of disease in adult animals. [108] 
It is possible, however, for Nef-defective mutants of SIV to cause disease in 
newborn animals. [109] 
Further, Nef-defective virions do cause an AIDS-like disease in infected animals 






The Vpr protein is incorporated into viral particles. Approximately 100 copies of Vpr 
are associated with each virion. [111] 
Incorporation of Vpr into virions is mediated through specific interactions with the 
carboxyl-terminal region of p55 Gag, [56] which corresponds to p6 in the proteolytically 
processed protein.  
Vpr plays a role in the ability of HIV to infect non dividing cells by facilitating the 
nuclear localization of the preintegration complex (PIC). [112] Vpr is present in the PIC. 
However, rather than tethering additional nuclear localization signals to the PIC, Vpr 
may act as a nucleocytoplasmic transport factor by directly tethering the viral genome to 
the nuclear pore. 
Consistent with this model, Vpr expressed in cells is found associated with the 
nuclear pore and can be biochemically demonstrated to bind to components of the 
nuclear pore complex. [113] Vpr can also block cell division. [114] 
Cells expressing Vpr accumulate in the G2 phase of the cell cycle. [115]  
The expression of Vpr has been shown to prevent the activation of the 
p34cdc2/cyclin B complex, which is a regulator of the cell cycle important for entry into 
mitosis. [116, 117] 
Accordingly, expression of a constitutively active mutant of p34cdc2 prevents the 
Vpr-induced accumulation of cells in the G2 phase of the cell cycle.  
Vpr has also been shown to interact with the cellular protein uracil-DNA glycosylase 
(UNG). [118] 
The biological consequences of this phenomenon have yet to be determined. 
Another enzyme involved in the modification of deoxyuracil (dUTP), deoxyuracil 
phosphatase (dUTPase), is expressed by two lentiviruses that do not contain a vpr gene: 
equine infectious anemia virus and feline immunodeficiency virus. 
It is believed that the dUTPase depletes the dUTP within the cell thus preventing 




The 16-kD Vpu polypeptide is an integral membrane phosphoprotein that is 
primarily localized in the internal membranes of the cell. [120] 
It is expressed from the mRNA that also encodes env. Vpu is translated from this 
mRNA at levels tenfold lower than that of Env because the Vpu translation initiation 
codon is not as efficient. [121] 
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The two functions of Vpu, the down-modulation of CD4 and the enhancement of 
virion release, can be genetically separated. [122] 
In HIV-infected cells, complexes formed between the viral receptor, CD4, and the 
viral envelope protein (Env) in the endoplasmic reticulum cause the trapping of both 
proteins in this compartment. 
Thus, the formation of intracellular Env-CD4 complexes interferes with virion 
assembly. 
Vpu liberates the viral envelope by triggering the ubiquitin-mediated degradation of 
CD4 molecules complexed with Env. [123] 
Vpu also increases the release of HIV from the surface of an infected cell. In the 





Vif is a 23-kD polypeptide that is essential for the replication of HIV in peripheral 
blood lymphocytes, macrophages, and certain cell lines. [125] 
In most cell lines, Vif is not required, suggesting that these cells may express a 
protein that can complement Vif function. 
These cell lines are called permissive for Vif mutants of HIV. 
Virions generated in permissive cells can infect non permissive cells but the virus 
subsequently produced is non infectious.  
Complementation studies indicate that it is possible to restore the infectivity of HIV 
Vif mutants by expression of Vif in producer cells but not in target cells. [126] 
These results indicate that Vif must be present during virion assembly. Thus, Vif is 
incorporated into virions of HIV. [127] 
This phenomenon, however, might be nonspecific because Vif is also incorporated 
into heterologous retroviruses such as murine leukemia viruses. [128] 
Studies producing HIV from heterokaryons generated by the fusion of permissive 
and non-permissive cells revealed that non-permissive cells contain a naturally occurring 
antiviral factor that is overcome by Vif. [129] 
Further support for a model that Vif is counteracting an antiviral cellular factor 
comes from the observation that Vif proteins from different lentiviruses are species 
specific. [130] 
For instance, HIV Vif can modulate the infectivity of HIV-2 and SIV in human cells 
while SIV Vif protein does not function in human cells. 
This observation suggests that cellular factors, rather than viral components, are 
the target of Vif action. 
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Vif-defective HIV strains can enter cells but cannot efficiently synthesize the proviral 
DNA. [126] 
It is not clear whether the Vif defect affects reverse transcription per se, viral 
uncoating, or the overall stability of the viral nucleoprotein complex. Vif mutant virions 
have improperly packed nucleoprotein cores as revealed by electron microscopic 
analyses. [131] 
 
1.8 HIV life cycle 
 
The HIV life cycle consist of several steps, starting from the attachment of the virus 
to the host cell membrane and finishing with the release of progeny virions from the cell, 
as summarized in Figure 6. 
It starts with a specific interaction of the viral glycoprotein gp120 sited on the outer 




Figure 6. HIV life cycle 
 
This reaction leads to a conformational change allowing the interaction of gp120 
with the chemokine co-receptors CXCR4 and CCR5. 
This step is then followed by further conformational changes that expose a 
fusogenic peptide, which anchors into the host cell membrane. 
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Once the viral envelope and cell membrane have fused, the virion is decapsidated 
releasing the viral RNA into the host cell’s cytoplasm. 
Through the reverse transcription, the viral RNA is transcribed to viral double-
stranded DNA. 
This process is catalyzed by an RNA-dependent DNA polymerase, known as reverse 
transcriptase (RT), which is encoded by the viral genome. 
Then, the viral DNA is integrated into the host chromosome, and after transcription 
and translation into viral proteins using the cells’ machinery, the assembly of the Gag and 
Gag-Pol polyproteins occurs near the cell membrane. 
During viral assembly, two copies of single-stranded viral RNA are incorporated into 
the virion, which then buds off from the cell, taking with it part of the host cell 
membrane. 
Soon after budding, viral protease cleaves the Gag-Pol polyprotein to generate a 
mature, functional virion. 
Generally, antiviral drugs could, in principle, be targeted at either viral proteins or 
cellular proteins. 
The first approach is likely to yield more specific, less toxic compounds, with a 
narrow spectrum of activity, but a higher likelihood of virus drug resistance development. 
However, the second approach might afford anti-HIV drugs with a broader activity 
spectrum and less chance of resistance but higher likelihood of toxicity. [132-134] 
From the Medicinal Chemistry point of view, each of these steps is a possible 
druggable target to combat the HIV infection (Figure 6). 
In this project I have focused my attention on the design and synthesis of 
unconventional Reverse Transcriptase inhibitors (RTis). 
 
1.9 Reverse Trancription 
 
The retrotranscription process is a key step in the early phases of HIV infection. It 
consists of the conversion of the viral ssRNA genome into integration-competent dsDNA, 
and requires both viral and cellular elements, among which the most important is the 
virus-coded RT protein. 
In each viral particle two copies of (+)ssRNA are enclosed coding both structural and 
non structural proteins and having, in the 5’- and 3’-ends, two identical sequences. [135]  
Proximal to the 5’-end of the viral genome there is a 18 nucleotides long segment, 
termed primer binding site (PBS), which is complementary to the 3’-end 18 nucleotides of 





Figure 7. Schematic illustration of the retrotranscription process 
 
Once the cellular tRNA is hybridized to the PBS, it serves as RNA primer and the RT 
associated DNA polymerase function can initiate the first (-)strand DNA synthesis using 
the viral RNA genome as a template. 
Then, when tRNA elongation reaches the ssRNA 5’-end a first (-)strand strong-stop 
DNA is encountered. 
The synthesis of the (-)strand DNA generates an RNA:DNA hybrid that is selectively 
degradated by the RT-associated ribonuclease H (RNase H) function. 
Therefore the hydrolysis of the RNA strand of the RNA:DNA hybrid [136] leaves the 
nascent (-)strand DNA free to hybridize with the complementary sequence at the 3’-end 
of one of the two viral genomic ssRNAs.  
A strand transfer therefore occurs from the R region at the 5’-end of the genome to 
the equivalent R region at the 3’-end. 
Once (-)strand transfer has occurred, (-)strand synthesis can continue along the viral 
RNA starting from its 3’-end, while the RNase H function cleaves the RNA strand of the 
RNA:DNA at numerous points. 
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Although most of the RNase H cleavages do not appear to be sequence specific, 
there are two specific purine-rich sequences, known as the polypurine tracts (PPTs), that 
are resistant to the RNase H hydrolysis and remain annealed to the nascent (-)strand 
DNA. 
These two well-defined sites are located in the central part of the HIV-1 genome. In 
particular, the 3’-end PPT defines the 5’-end of the viral coding (+)strand DNA synthesis 
since this PPT serves as primer. [137, 138] 
The (+)strand DNA synthesis continues until it reaches the 5’-end of the (-)strand 
DNA, and also uses the 18 nucleotides PBS sequence of the tRNA as a template. 
Noteworthy, the 19th base from the 3’-end of tRNALys3 is a methyl-A, and the 
presence of such modified base blocks the RT, generating a (+)strand strong-stop DNA. 
Subsequently, the RNase H function cleaves the RNA segment of the tRNA:DNA 
hybrid, freeing the PBS sequence of the (+)strand DNA and allowing it to anneal to the 
complementary site near the 3’-end of the extended (-)strand DNA. [139] 
After this key step, a bidirectional synthesis occurs to complete a viral dsDNA that 
has a 90 nucleotides single-stranded flap at the center. 
In all probability a host mechanism occurs to solve this unusual situation and, most 




Figure 8. Flap removal operated by the flap endonuclease-1 (FEN-1) 
 
The process is terminated by a specific cleavage that removes the PPT primers and 
exposes the integration sequence to ease the insertion of the viral dsDNA into the cell 
chromosome.  
On this basis RT has been considered to be a major target for HIV chemotherapy 
and indeed it has been the subject of extensive research through crystal structures 
determinations, biochemical assays and single-molecule analyses. 
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RT consists of two subunits of different length, p66 and p51, generated by a viral 
protease cleavage of a virus-coded polyprotein. 
p66 and p51 share a common amino terminus and are combined in a stable 
asymmetric heterodimer. [140] 
Analysis of the crystal structure of RT reveals that p66 is composed of two spatially 
distinct catalytic domains, polymerase domain and RNase H domain (Figure 9). 
In more detail p66 is composed of the polymerase domain (residues 1-318), the 





Figure 9. Reverse transcriptase catalitic sites 
 
The polymerase domain shows a characteristic highly conserved structure that 
resembles a right hand, consisting of fingers domain (residues 1-85 and 118-155), palm 
domain (residues 86-117 and 156-237), and thumb domain (residues 238-318). 
Regarding the p51 subunit a different folding is observed, due to the lack of the 
RNase H domain. 
Although with different relative positions, all the other subdomains are identical to 
those of p66, however no enzymatic activity is associated with the p51 subunit which 
performs a merely structural function, keeping the p66 subunit in the proper folding to 
perform all the catalytic functions. 
Several distinct activities, all indispensable for the retrotranscription process, are 
associated to RT: RNA- and DNA-dependent DNA synthesis, RNase H activity, strand 
transfer and strand displacement synthesis. [143] 
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The synthesis of the viral DNA is catalyzed by both RT associated RNA- and DNA 
dependent DNA polymerase activities (RDDP and DDDP, respectively) with a mechanism 
similar to that of all others polymerases. [144] 
The polymerase active site is located in the middle of palm, fingers and thumb 
subdomains. Noteworthy is the palm subdomain which plays a key role for the substrate 
binding since its β12–β13 sheets extensively interact with the phosphate backbone and 
are termed the “primer grip”. [145] Moreover three aspartic acid residues (D110, D185 
and D186), located in the palm subdomain of p66, bind the divalent ion co-factor (Mg2+) 
through their catalytic carboxylates groups, and are essential for catalysis Fig. (1). [146] 
Firstly RT binds to the template primer on the priming binding site; this interaction 
is stabilized by a change of the conformation of the p66 thumb (from closed to open) and 
is an essential step in DNA synthesis. Afterwards, the dNTP binds at the nucleotide 
binding site to form an RT:DNA:dNTP ternary complex. [147] 
Then the dNTP is trapped by a conformational change of the fingers which precisely 
aligns the α-phosphate of the dNTP to the 3’-OH of the primer inside the polymerase 
active site (this is actually the rate limiting step). 
The enzyme is then ready to catalyze the formation of a phosphodiester bond 
between the primer 3’-OH and the dNMP with the release of a pyrophosphate which is 
free to exit from the catalytic site. 
Finally either a translocation of the elongated DNA primer frees the nucleotide-
binding site for the next incoming dNTP or RT can dissociate from the complex. 
The RNase H domain is located on the other side of the p66 subunit, 60 Å from the 
polymerase active site (Figure 9) equivalent to 17 nucleotides of a DNA:DNA hybrid 
and/or 18 nucleotides of a RNA:DNA hybrid. [148] 
RT is able to degrade selectively the RNA portion of an RNA:DNA hybrid and to 
remove the priming tRNA and PPT. This RNase H function is essential for virus replication 
since RNase H deficient viruses are non-infectious. [149] 
It is worthy of note that the strand transfer process is a crucial step in the reverse 
transcription and consists of the annellation of two ssNAs to permit the continuation of 
the DNA synthesis. In both (-) and (+)strand transfers the ssNA develops secondary 
structures: the R region consists of a strong-structured motif TAR hairpin and a poly(A) 
hairpin. [150] 
Furthermore a stable hairpin structure can be formed by the PBS sequence at the 
3’-end of the (-)strand DNA. 
In this respect, the viral-coded nucleocapsid (NC) protein plays a crucial role in 
helping the RT to perform this step and could be considered as a promising target for 
drug design. [151, 152] 




This reaction termed pyrophosphorolysis requires either a pyrophosphate (PPi) or 
an NTP (ie ATP) as acceptor [153, 154] and leads to the formation of a dinucleotide 
tetraphosphate (formed by the excised dNMP and the acceptor ATP substrate) and a free 
3’-OH end as reaction products. 
 
1.10 Reverse Transcriptase Inhibitors 
 
1.10.1 Inhibitors of the RDDP Function 
 
Two classes of RTIs, that target the viral enzyme with two different mechanisms of 
action, are included in the approved combination treatments used for HIV-1 handling. 
The first class comprises compounds known as Nucleoside/Nucleotide RT Inhibitors 
(NRTIs/NtRTIs), while the second class comprises compounds known as Non-Nucleoside 
RT Inhibitors (NNRTIs). NRTIs are analogs of the natural substrate (dNTP) and inhibit RDDP 
function by a competitive mechanism at the active site. 
To act on such a mechanism, these inhibitors must necessarily lack a free OH group 




Figure 10. Mechanism of action of NRTIs 
 
Zidovudine (AZT, 3’-azidothymidine) was identified as the first NRTI acting as pro-
drug. It requires successive phosphorylation steps and operates through its triphosphate 
metabolite. [156] 
The active form of the drug is used as a false substrate during reverse transcription 











Zidovudine, AZT  
 
Figure 11. Zidovudine structure  
 
Currently eight NRTIs are clinically available, structurally resembling either 
pyrimidine or purine analogues. 
In the pyrimidine nucleoside analogues both thymine and cytosine analogues are 
included.  
Between the most representative thymine analogues 3’-azido-2’,3’-
dideoxythymidine (zidovudine, AZT) and 2’,3’-didehydro-2’,3’-dideoxythymidine 
(stavudine, d4T) are worth noting while cytosine analogues are (-)-2’,3’-dideoxy-3’-
thiacytidine (lamivudine, 3TC), 2’,3’-dideoxycytidine (zalcitabine, ddC) which, however, is 
no longer recommended due to its peripheral neuropathy, (-)-2’,3’-dideoxy-5-fluoro-3’-























































































Figure 12. Clinically available NRTIs and NtRTIs 
 
Purine nucleoside analogues include (1S-4R)-4-[2-amino-6-(cyclo-propylamino)-9H-
purin-9-yl]-2-cyclopentane-I-methanol (abacavir, ABC) and 2’,3’-dideoxyinosine 
(didanosine, ddI) as guanine and adenine analogues. 
Unfortunately drug resistant viral mutants can gain a competitive advantage over 
wt virus under selective drug pressure, almost becoming the dominant species. 
Generally two different mechanisms lead to HIV-1 resistance to NRTIs. 
The first consists of NRTI discrimination leading to a reduction of the incorporation 
rate, the second consists of NRTI excision that unblocks NRTI-terminated primers. 
Typically, discrimination occurs due to steric hindrance leading to a selective 
alteration of the NRTI binding and/or incorporation rate. 
Regarding NRTI excision it is mostly increased through mutations, located around 
the dNTP binding pocket and also in termed thymidine analogs mutations (TAMs). 
NRTI resistance could also be conferred by mutations in the connection and RNase 
H domains. [158-162] 
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The NtRTIs, such as adefovir [9-(2-phosphonylmethoxyethyl) adenine (PMEA)] and 
tenofovir [(R)-9-(2- phosphonylmethoxypropyl) adenine (PMPA)] are acyclic phosphonate 
analogues of adenine, and, therefore, only need two phosphorylation steps to be 
converted into the active drug. Like the NRTIs they act as obligatory chain terminators. 
[163] 
Along with exploration of the NRTI binding pocket to obtain analogous molecules 
with improved drug-like properties and effective against many NRTI drug-resistant RT 
variants [164], recently, two families of compounds have been reported as new classes of 
“nucleotide-competing RT inhibitors” (NcRTIs).  
The first is represented by indolopyridones (INDOPY) derivatives. Although 
structurally different from classic NRTI it seems that this series can occupy the active site 




Figure 13. NcRTI: a) INDOPY binding site: mutational studies suggested that the INDOPY 
binding site is close to M184 and Y115. The DNA template is represented in cartoon and the 
aspartate catalytic triad in sticks (pdb code 1rtd [166]); b) DAVP-1 binding mode (pdbcode 3isn 
[167] ); c) Chemical structures of INDOPY-1 and DAVP. 
 
The observed resistance associated to mutation of Y115 + M184 give support to this 
hypothesis (Figure 13a). [165, 166] 
The second class includes 4-dimethylamino-6-vinylpyrimidine derivatives (DAVP) 
whose binding site is close to the polymerase active site as illustrated in Figure 13b. [167] 
In contrast to the NRTI class, NNRTIs are a family of compounds characterized by a 















































Figure 14. NNRTIs approved for therapy (PDB codes are reported in red) 
 
They act as noncompetitive inhibitors against the substrate and bind close to the 
polymerase active site provoking a distortion of the protein structure and inhibiting the 
polymerase activity.  
Worthnoting they do not need intracelluar activation. 
Many different classes of NNRTIs could be distinguished and 5 drugs, acting as 
NNRTIs, have been approved for HIV-1 treatment so far. 
It should be mentioned that, while in the case of first generation NNRTIs, like 
delavirdine and nevirapine, single mutations (Y181C, K103N and Y188C) could lead to 
drug resistance; in the case of the more bulky second generation NNRTIs, like efavirenz 
and dapivirine, more than one mutation is generally required to induce drug resistance. 
Although resistance and toxicity are some of the most important drawbacks of 
NNRTIs, an intense research activity is focused on this class of compounds and more than 
30 different classes of NNRTIs have been reported. [169, 170] 
More recently molecules with a higher flexibility, although less favored by a 
thermodynamic point of view, have been proposed as NNRTIs. [171, 172]  
Molecules like etravirine and rilpivirine are successful examples of this new 
approach as well as dapivirine which is currently under clinical evaluation. 
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NNRTIs inhibit RT by binding to the enzyme in a hydrophobic pocket (NNIBP) 
located in the palm domain of the p66 subunit of the heterodimeric RT, approximately 10 
Å from the catalytic site of the enzyme.  
This pocket contains the side chains of aromatic and hydrophobic amino acid 
residues Y181, Y188, F227, W229, Y318, P95, L100, V106, V108, V179, L234, and P236 
from the p66 subunit. 
The NNIBP is flexible and its conformation depends on the size, shape, and binding 
mode of the different NNRTI. 
It can accommodate a space of about 620-720 Å, which is approximately more than 
twice the volume occupied by most of the present NNRTIs. (Figure 15). [173]  
This explains the large variety of chemical scaffolds of this class of inhibitors whose 
shapes inspired authors to create imaginative names to describe them (e. g “butterfly” 




Figure 15. NNBP: a) surface map size and shape of the space available visualized with 
SiteMap [176]; b) hydrophobic (light grey), donor (diagonal stripes), and acceptor (dark grey fine 
stripes) maps. Efavirenz (EFV) is shown in ball and stick and interacting residues in the NNIBP in 
stick (pdbcode 1ikw) 
 
The NNIBP is not present in structures of HIV-1 RT that do not have a bound NNRTI 
(closed pocket form).  
Upon binding of ligands its opening is observed. In most cases the flipping of the 
aromatic side chains of Y181 and Y188 (e. g efavirenz pdbcode1ikw (Figure 16a) [177], or 
etravirine pdbcode 1suq [178] is a binding key feature. 
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For other ligands it is possible to notice the expansion of the pocket (e.g CP94,707 
pdbcode 1tv6 [179]) but not the flipping of tyrosines (Figure 16b) or the flipping of only 
one tyrosine as in the complex RT-TSAO-T (Figure 16c) (pdbcode 3qo9. [175]) 
The binding of NNRTI causes the dislocation of the β12- β13- β14 sheets that results 
in a movement of the primer grip away from the polymerization site sheet. [180] 
TSAO series also act by destabilizing heterodimeric p66/p51 HIV-1 RT. [181] 
Commonly observed resistance mutations in NNRTI-treated patients include L100I, 




Figure 16. NNRTI binding mode and comparison of NNIBP residues with unbound enzyme 
(pdb code 1dlo[182]). a) Efavirenz; b) CP94,707; c) TSAO-T. Y181, Y188 and W229 are visualized in 
sticks for the comparison. d-e-f) Chemical structure of inhibitors co-crystallized in the complexes 
examined 
 
These mutations occur alone or in combination and cause clinically relevant drug 
resistance, directly, by altering the size, shape, and polarity of different parts of the 
NNIBP or, indirectly, by affecting access to the pocket. 
To overcome this problem several attempts have been made either to optimize 
interactions between drug candidates and highly conserved amino acid residues in the 
NNIBP, such as W229 [183] or to design more flexible drug candidate, as in the case of 
diarylpyrimidine (DAPY). [171] 
In fact, etravirine has the ability to bind in multiple modes and this would permit 
the NNRTI to retain activity evading drug-resistant mutations. 
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Another possibility is to look for structures able to enter the NNIBP but that show 
less hydrophobic interaction and different key contacts. 
A promising example is calanolide A and its derivatives that exhibit enhanced 
activity against HIV-1 isolates most commonly with Y181C and K103N mutations. 
The putative binding mode reported and the biological study support this 
hypothesis. [184] 
 
1.10.2 Inhibitors of the RNase H Function 
 
As reported above RNase H function is essential for the reverse transcription but, 
until now no inhibitors, specific for this enzymatic activity have been introduced in 
therapy. 
Nevertheless, quite recently, some RNase H inhibitors (RNase HI) have been 
designed and studied. 
Generally they act by chelating the Mg2+ ions within the active site. Unfortunately 
this mechanism of action is quite unspecific, due to the possible interaction with other 
divalent ions in cellular enzymes. 
Moreover the RNase H active site is an open pocket that gives very few hints for the 
design of specific inhibitors. 
However several studies have demonstrated that the abolition of the HIV-1 RNase H 
activity stops viral replication. [185, 186] 
The three dimensional (3D) structure of HIV-1 RT including the RNase H domain is 
currently available providing a solid basis for rational drug design and the development of 
inhibitors. 
RNase H fold has a characteristic central beta-sheet which contains five strands. The 
central beta-sheet 4 is flanked by four alpha-helices, three on one side (1-2-3) and one on 
the other. 
Noteworthy, strand 2 is anti-parallel to the others. 
The active site of the RNase H domain is composed of four carboxylate residues 
forming a DEDD motif which binds catalytic Mg2+ ions (Figure 17). 
Most of inhibitors block the active site from binding hybrid DNA:RNA chelating the 
divalent metal ions (Mg2+) which are coordinated by the catalytic pattern D443, E478, 


















































































Figure 18. RNAse H inhibitors co-crystallized and relative pdb code 
 
β-thujaplicinol 1 [187] and α-hydroxytropolone 2 [188] are RNase inhibitors acting 
by coordinating the two metal ions in the active site, also pyrimidinol carboxylic acid 
derivatives 3,4,5 and N-hydroxyquinazolinedione 6 show this mechanism (Figure 18). 
[189, 190] 
Others scaffolds such as N-hydroxyimides derivatives [191] and diketo acids provide 
an alternative pharmocophoric solution to chelate the two metal ions in the active 
binding site. [192, 193] 
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Interestingly some RNAse H inhibitors bind the RT in an allosteric pocket to avoid 
duplication of site located between polymerase catalytic region and NNIBP 50 Å from the 
RNAse H catalytic site. 
Both hydrazone 7 [194] and naphthyridinone derivative (MK3) 8 are accommodated 
in this site. 
Moreover, MK3 and other analogous (9-10) were co-crystallized also in the catalytic 
site where in addition to the classic interaction with two Mn2+ ions other residues are 
involved in stabilizing of the complex R448, N474, Q475, S499, A538, H539, V552, and 
S553 (Figure 19). [195] 
It may conceivably be that occupancy of the allosteric pocket would not allow the 
correct anchorage of the RNA:DNA hybrid and its direction toward RNase H domain 




Figure 19. MK3 binding mode a) in the allosteric binding site (pdbcode 3LP2) and b) in the 
catalytic pocket (pdbcode 3LP3 
 
Moreover, other RT regions proximal to the RNase H domain could represent a 
novel and attractive target for allosteric inhibitory activity. 
Hence there is great attention to the development of vinylogous ureas [196] and 
inhibitors able to bind the area close to residue Q507. 
The binding to an allosteric pocket could cause a conformational change at the 
interface between the RNase H domain and the p51 domain. 
This would modify the orientation of the active site and influence its availability to 
act on the DNA:RNA substrate. [197] 
In addition, the binding of the catalytic pocket requires species able to chelate 
bivalent ions usually characterized by high toxicity. 
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For this reason the development of chelating compounds raises some worries. 
 
1.10.3 Dual Inhibitors 
 
Until now we have analyzed classes of compounds selective towards one of the RT 
associated activities. 
It is easy to understand what advantage there would be in the development of 
compounds inhibiting both RDDP and RNase H activity. 
Indeed dual inhibitors may completely block RT activities and show a new favorable 
drug resistance profile by binding to unexplored protein pockets. 
All known compounds with dual inhibitory activity have the same binding pocket in 
common. 
The allosteric pocket of RNase H is located in a strategic point close to the pocket 
where most of known polymerase inhibitors bind. As it was suggested by Himmel, this 
pocket communicates directly with the NNRTI pocket. [194] 
By binding to this allosteric pocket and to NNIBP residues these compounds seem to 
acquire dual activity. 
Sluis-Cremer was the first who reported the dual inhibitory activity of N-acyl 
hydrazone derivative. [198] A similar compound 7 was later co-crystallized by Himmel, 
confirming the hypothesis of an allosteric pocket. The same author reported that 
analogues of compound 7, bearing bulkier substituent in place of the 3,4-
dihydroxyphenile exhibit dual inhibitory activity. [194] 
However none of these compounds have been co-crystallized. 
Recently, activity data of a series of alizarine derivatives showing dual activity in the 
low micromolar range and also towards mutated RTs, commonly resistant to NNRTI has 






Figure 20. Putative binding mode of K49, best compound of alizarine derivatives serie 
 
The most active alizarine derivatives studied have bulky substituents and are able to 
go right through the allosteric pocket and interact with NNIBP (Figure 20). 
This study confirms the possibility of inhibiting both activities. However the rigidity 





2 Results and Discussion 
 
My research work is focused on the design of new HIV RT inhibitors of the two 
associated functions of the enzyme, RNA and DNA polymerase function and RNase H 
function. 
With the aim of finding new RNaseH inhibitors the medicinal chemistry research 
group of the department of life and environmental sciences, performed a successful 
ligand based virtual screening (VS) [200]: out of 69 compounds selected 26 are active 
towards RNase H and many of them are dual inhibitors. 
In particular hydrazonoindolin-2-one derivative (46, numbered as in the paper) was 
found to be active on RNase H (IC50 ~2 µM) and RDDP (IC50 ~ 1.4 µM). [200] 
Furthermore, compound 46 represents a remarkable new scaffold. 
Moreover it is not mutually exclusive if associated with both NNRTIs and RNase HIs, 
indicating that, in all probability, it does not bind either in the NNIBP or in the RNase HI 
pocket. [200] 
Molecular modeling analysis of the putative binding mode, combined with 
biochemical studies was useful to rationalize the activity.  
Such studies confirmed that the compound binds in an allosteric pocket. 
From the analysis of the binding mode along with its Grid Base Pharmacophore 
Model (GBPM) (Figure 21) [200, 201], the importance of hydrophobic portions 
corresponding to indolinone and thiazole moieties can be highlighted. 
These portions positively interact with hydrophobic residues V208, F227, Y188, 
W229. 
However the wide hydrophobic area suggests that the indolinone moiety could be 
substituted by bulkier groups, in the region exposed to the solvent both donors and 
acceptors are favored. 
The analysis of the pocket with SiteMap [202] allows for a better understanding of 






Figure 21. GBPM maps and binding mode of compound 46: a) DRY probe, b) N1 probe, c) O probe 
 
Therefore it could be observed that there is space in the left and right bottom 
portions of the pocket (Figure 22).  





Figure 22. Surface map: a) size and shape of the space of the pocket available visualized 
with SiteMap; b) hydrophobic (light grey), donor (diagonal stripes), and acceptor (dark grey fine 
stripes) favourable maps (pdbcode 3lp2) 
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In addition to spatial requirements evaluation, the examination of the distribution 
of hydrophobic, acceptor and donor maps is useful to understand a worthwhile strategy 
of lead optimization. 
It was noticed that there is a wide area where donor groups could have room. The 
donor map is located in the area facing the polymerase catalytic triad, while two acceptor 
maps are at the left and right part of it. This information, together with the 
pharmacophore model, should lead to the design of compounds with increased activity. 
The optimization procedure should be carried out also considering most common NNRTI 
induced mutations. Hence flexibility and care in avoiding key interactions with these 
residues may help the drug optimization process. Furthermore, besides compound 46, 
there are other promising scaffolds coming from VS study which show a similar behavior 
and can be better characterized and optimized. 
Starting from this observation we synthesised new series of compounds (EMAC 
2000-2096) in order to obtain further information on the SARs of these derivatives and to 
identify other possible scaffolds. 
Firstly we synthesised a new series of chalcones (EMAC 2000-2012, EMAC 2013-


























































































































































Figure 24. Structure of compounds 2013-2025 
 
All compounds were synthesised according to literature methods. [203, 204] 
Compounds EMAC 2000-2012 were synthesised by reaction of 1-methoxy-2-
naphtaldehyde with the appropriate methylarylketone in ethanol and 10% NaOH water 
solution.  
In the case of compounds EMAC 2013-2025, different synthetic pathway was 
followed; 1H-indole-3-carboxyaldehyde was reacted with the appropriate 
methylarylketone in ethanol/piperidine solution. 
In both series the expected “E” configuration was obtained as suggested by the 
CH=CH double bond coupling costants that ranges from 15 to 16 Hz. 
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To evaluate their capability to inhibit both functions of HIV RT the RNase H 
polymerase-independent cleavage assay was measured [192] using Poly(dC)-[3H]Poly(rG) 
hybrid as reaction substrate. 
Moreover the RDDP activity of HIV-1 RT was measured according to the procedure 
previously described. [207] 
























EMAC 2000 6 47 
F
 
EMAC 2001 5 23 
OCH3
 
EMAC 2002 6 9 
Cl
 
EMAC 2003 5 76 
NO2  
EMAC 2004 5 31 
 






















Test in progress 
RDS 1643  > 100 13 
Efavirenz  0,003 > 10 
aCompound concentration required to reduce the HIV-1 RT-associated RNase H activity by 50%. bCompound 
concentration required to reduce the HIV-1 RT-associated RNA-dependent DNA-polymerase activity by 50%. 
The activity was measured together with two known inhibitors of the RDDP and RNase H functions, 




Some of the compounds exhibit comparable activity towards the two associated 
functions of HIV-1 RT. 
In particular, EMAC 2002 and 2005 have an IC50 value in the low µM range. 
To gain a better comprehension of the mechanism of action and to identify the 
binding site of these new compounds we have performed some biochemical and 
computational investigation. 
All the known RNase H inhibitors that binds to the RNase H active site are Mg2+ 
chelating agents. 
Thus to verify if our compounds bind either in the RNase H active site or in an 
allosteric pocket we measured the effect of MgCl2 on the compounds EMAC 2000-2005 
Uv spectrum. 
Results showed that MgCl2 does not significantly change the compounds maximum 
of absorbance, suggesting that these compounds do not act by chelating the magnesium 




Figure 25. Magnesium chelating assay (in black: absence of Mg2+, in red presence of 6 mM 
MgCl2; a) EMAC 2000, b) EMAC 2001, c) EMAC 2002, d) EMAC 2003, e) EMAC 2004, f) EMAC 2005. 
 
To further confirm that our compounds do not bind to the RNase active site we 
measured the interference between the most active EMAC 2005 and a known inhibitor at 
the RNase H catalytic site (RDS1643) by the Yonetani Theorell plot. [208] 
This is a graphical method to analyze the multiple inhibition of an enzyme by two 
competing inhibitors.  
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This method not only distinguishes whether two inhibitors interact with the same 
site or different sites of the enzyme, but also gives an interaction constant (α) between 




Figure 26. Yonetani Theorell plot of increasing concentrations of EMAC 2005 vs RDS 1643;  
●[EMAC 2005] = 0, ○[EMAC 2005] = 2,5µM, ▼[EMAC 2005] = 5µM, ▲[EMAC 2005] = 10µM. 
 
This kinetic analysis quantitatively reconfirmed our previous finding that EMAC 
2005 and RDS 1642 interact independently with different sites of the enzyme and are not 
mutually exclusive. 
To investigate if EMAC 2005 binds to the NNRTIs binding pocket active site we 
performed the same kinetic experiment (Figure 27) with increasing concentrations of 





Figure 27. Yonetani Theorell plot of increasing concentrations of EMAC 2005 vs Efavirenz; 
●[EMAC 2005] = 0, ○[EMAC 2005] = 1,5µM, ▼[EMAC 2005] = 3,5µM, ▲[EMAC 2005] = 10µM. 
 
According to the kinetic analysis EMAC 2005 and Efavirenz are not mutually 
exclusive.  
Thus we can affirm that EMAC 2005 binds neither at the NNRTI binding pocket, nor 
at the RNase active site. 
In order to verify if compound EMAC 2005 binds in the allosteric site close to the 
NNRTIs binding pocket we tested its activity towards both associated activities of 
K103Nsn and Y181C RTs, two NNRTI resistant mutant enzymes, since derivatives which 
have been proposed to interact with the drug pocket, close to both NNRTI binding pocket 
and DNA polymerase active site, have shown a degree of cross resistance with NNRTI 
resistant RTs. 




Table 2. EMAC 2005 activity on mutants 








wt RT a IC50 (µM) K103N RT IC50 (µM) Y181C RT IC50 (µM) 
Compound 
RNase H RDDP RNase H RDDP RNase H RDDP 
EMAC 2005 6 ± 2 4 ± 1 59 ± 8 3 ± 1 >100 (79%) 8 ± 5 
EFV > 10 
0,013 ± 
0.008 
ND 0,68 ND 0,40 
 
Results showed that when tested on the K103N RT compound EMAC 2005 was 10 
fold less potent on the RNase H and almost the same active towards RT-associated RDDP. 
As it was expected, this result indicates that EMAC 2005 activity on RNase H activity 
is most likely associated to its binding close to the NNRTI binding pocket. 
On the contrary, no influence of K103N mutation on the RDDP activity was 
observed. 
In the case of Y181C mutation a more dramatic effect, with respect to K103N, can 
be observed. The activity towards RNase H activity is almost suppressed indicating that 
this residue is essential for exerting the inhibition of this function. 
Also in this case the activity towards the RT-associated RDDP is almost not affected, 
indicating that Y181 is not essential for the binding but only for the inhibiton of the RNase 
H function. This behavior might be explained either by two different poses in the 
hydrazones pocket, or by the interaction with an other pocket close to the RNase H site, 
whose structure is affected by the Y181C mutation.  
Prompted by these results we synthesized other series of compounds EMAC 2026-































































EMAC 2026 EMAC 2027 EMAC 2028
EMAC 2029 EMAC 2030 EMAC 2031
EMAC 2032 EMAC 2033 EMAC 2034
EMAC 2035  
 






























































































































































EMAC 2046 EMAC 2047 EMAC 2048
EMAC 2049 EMAC 2050 EMAC 2051



































































































































































































































































































































































































































The synthetic pathway to compounds EMAC 2026-2096 is reported in materials and 
methods (chemistry).  
Generally the appropriate aldehyde, either purchased or synthesized by Suzuki 
coupling reaction (EMAC 2056-2071), was reacted with thiosemicarbazide in isopropyl 
alcohol in the presence of catalytic amounts of acetic acid.  
The obtained thiosemicarbazone is then suspended in isopropyl alcohol in the 
presence of the appropriate α-halogenoarylketone to give the desidered thiazole 
derivative. 
All the compounds were obtained as free bases as revealed by halogen ions test 
with 1M solution of AgNO3. 
Most of the compounds were submitted for biological evaluations and the results 
are summarized in tables 3-7. 
In some cases it has been possible to evaluate the activity in HIV infected cells, 
thanks to the group of Prof. Cheng at the University of Yale. 
In table 3 the activity of compounds EMAC 2026-2035 is reported. 
Interestingly the biphenyl substituents in the position 4 of the thiazole ring (EMAC 
2031) leads to a complete loss of activity while a similar substitution in the chalcone 
series led to the best activity (EMAC 2005). 
However, compounds EMAC 2028, EMAC 2034, and EMAC 2035 exhibit a promising 
activity towards HIV infected cells with an EC50 of <5, 8 and <5 µM respectively. 
These data are comparable with the activity exhibited in the enzymatic assay 
towards RNase H function. 
Moreover these compounds are relatively not toxic and further biological 
experiments are in progress. 
In particular their activity towards the RT associated RDDP function will be 

































Test in progress 
CN
 
16 7 7 < 5 
NO2  
48 15 Test in progress 
Br
 
24 4 > 50 15 
 
51 9 Test in progress 
NO2
 
13 10 14 > 30 
OCH3
 
42 10 > 50 > 30 
Cl
 
14 7 50 8 
CH3
 
28 8 50 <  5 
Efavirenz > 100 0,003   
aCompound concentration required to reduce the HIV-1 RT-associated RNase H activity by 50%. bCompound 
concentration required to reduce the HIV-1 RT-associated RNA-dependent DNA-polymerase activity by 50%. 
cCompound concentration required to reduce MT-2 cell replication by 50% after 4 days incubation. 
dCompound concentration required to reduce the HIV-1replication by 50% in TZM-bl cells after 1 day 




Also in the case of compounds EMAC 2044 and EMAC 2045 a promising activity 
towards the HIV-1 replication was observed and a deeper investigation on their mode of 
action will be pursued (Table 4). 
 





















CC50  (µM) 
HIV-1 
d
EC50  (µM) 
Cl
Cl  
34  31  
F
 




Test in progress 
NO2  
28  28 > 50 > 30 
Br
 








100 98  
Test in progress 
Cl
 
28  33  > 50 2,5 
CH3
 
29 22 32 >30 
Efavirenz > 100 0,003   
aCompound concentration required to reduce the HIV-1 RT-associated RNase H activity by 50%. bCompound 
concentration required to reduce the HIV-1 RT-associated RNA-dependent DNA-polymerase activity by 50%. 
cCompound concentration required to reduce MT-2 cell replication by 50% after 4 days incubation. 
dCompound concentration required to reduce the HIV-1replication by 50% in TZM-bl cells after 1 day 
incubation. * Results are means of 3 experiments. 
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A similar behavior was observed for the analogous compounds EMAC 2046 and 
EMAC 2050, but introduction of different substituents with respect to previous 
compounds, lead to the best performing compounds (Table 5). 
. 






































Test in progress 
Br
 
13 40  > 50 2,5 
 
23  10 
NO2
 
40 26  
Test in progress 
OCH3
 
10 6  <2 23 
Cl
 
20  17  Test in progress 
CH3
 
17 17 35 > 30 
Efavirenz > 100 0,003   
aCompound concentration required to reduce the HIV-1 RT-associated RNase H activity by 50%. bCompound 
concentration required to reduce the HIV-1 RT-associated RNA-dependent DNA-polymerase activity by 50%. 
cCompound concentration required to reduce MT-2 cell replication by 50% after 4 days incubation. 
dCompound concentration required to reduce the HIV-1replication by 50% in TZM-bl cells after 1 day 




These data needs further investigation to rationalize the SARs of this scaffold and 
more data are needed in order to explain such discontinuous SARs. 
 





















CC50  (µM) 
HIV-1 
d
EC50  (µM) 
Cl
 
11.2 3.3 >50 >50 
F
 
8.2 2.0 >50 >50 
Br
 
13 4.0 >50 >50 
NO2
 
3.8 0.8 >50 >50 
 
3.5 0.8 >50 >50 
CN
 




6.2 1.4 >50 >50 
NO2
 
4.7 0.8 >50 >50 
CH3
 
10.6 1.0 >50 >50 
OCH3
 
23.0 3.0 >50 >50 
 




3.9 2.7 >50 >50 
aCompound concentration required to reduce the HIV-1 RT-associated RNase H activity by 50%. bCompound 
concentration required to reduce the HIV-1 RT-associated RNA-dependent DNA-polymerase activity by 50%. 
cCompound concentration required to reduce MT-2 cell replication by 50% after 4 days incubation. 
dCompound concentration required to reduce the HIV-1replication by 50% in TZM-bl cells after 1 day 
incubation. * Results are means of 3 experiments. 
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4,6  10,5  
F
 
5,1  9,5  
Br
 
4,3  8,5  
NO2
 
7,6  21,0  
 
7,1  12,0  
CN
 




6,0  11,5  
NO2
 
6,5  18,5  
CH3
 
8,5  18,5  
OCH3
 
8,5  14,5  
 








3,5  10,5  
Test in progress 
aCompound concentration required to reduce the HIV-1 RT-associated RNase H activity by 50%. bCompound 
concentration required to reduce the HIV-1 RT-associated RNA-dependent DNA-polymerase activity by 50%. 




Compounds EMAC 2072-2083 exhibit potent activity in the enzymatic assay almost 
all substitutions are well tolerated and moreover most of the compounds exhibit dual 
activity towards the two associated functions of HIV RT (Table 6). 
These results indicate that the combination of the indolinone ring together with the 
hydrazine spacer and the 4-substituted thiazole may constitute the best performing 
scaffold for dual inhibition. 
Prompted by these encouraging findings we performed a deeper characterization of 
these compounds. 
We selected compound EMAC 2077 for mode of action biochemical studies and 
computational investigation. 
Firstly we measured the effect of MgCl2 on EMAC 2077 Uv spectrum in comparison 





Figure 35. EMAC 2077 interaction with the Mg2+ RT cofactor: in red absence of Mg2+ and in 
blu presence of 6 mM Mg2+  
 
As previously observed for compounds EMAC 2000-2005, the addition of 6 mM of 
MgCl2 to the solution of EMAC 2077 does not significantly shift the maximum of 
absorbance indicating that this compound does not act by chelating the magnesium ion in 
the RNase H catalytic site. 
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Moreover, we performed kinetic analysis of EMAC 2077 in the presence of known 
inhibitors of both associated functions, RDDP and RNase H, Efavirenz and RDS 1643 
respectively. 
Figure 
36. EMAC 2077 kinetic analysis in the presence of Efavirenz 
 
 
Figure 37. EMAC 2077 kinetic analysis in the presence of RDS 1643 
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In both cases no interaction was observed. Thus we can assume that EMAC 2077 
neither binds in the same site of Efavirenz nor of RDS1643. 
The activity towards RT mutants K103N and Y181C was also measured, in order to 
verify if EMAC 2077 binds in the allosteric site close to the NNRTIs binding pocket. 
The results are summarized in Table 8. 
 












K103N RT IC50 (µM) Y181C RT IC50 (µM) 
“D”-ring 
RNase H RDDP RNase H RDDP 
CN
 
20.16±2.5  4.08±1.4  23.4±0.6  2 ±1  
EFV ND 0,68 ND 0,40 
 
Compound EMAC 2077 activity towards RNase H function is only sliglty affected by 
mutations, while almost no influence of mutation on the RT RDDP function is observed. 
These data are more than encouraging suggesting that this compound could be a 
valid hit compound for the development of new dual inhibitors of both RT associated 
functions. 
Docking experiments also confirmed that the most probable binding site of 
compound EMAC 2077 is the allosteric pocket between the NNRTIs binding pocket and 
the polymerase active site. [194] 
In Figure 38 the most favoured binding mode of compound EMAC 2077 is reported, 
in comparison with DHBNH. [194] 








Figure 38. Compound EMAC 2077 interactions with RT were analyzed using LigandScout 
[209]: the yellow spheres show hydrophobic contacts, green arrows (HB acceptor) violet circle 
(aromatic interaction) 
 
In the case of compound EMAC 2077, with respect to DHBNH, a deeper contact 
with important residues of the NNRTIs binding pocket is observed. 
This may be the explanation for the dual activity of EMAC 2077 in comparison to 
DHBNH that only inhibit the RNase H function. Moreover, an aromatic interaction 
between the thiazole ring of compound EMAC2077 and TRP229 is observed. This 
interaction is particularly interesting considering that TRP229 is a highly conserve residue 
of HIV-1 RT. 
Indeed more investigation are needed to better clarify the mode of action of such 
compounds and further synthetic effort should be dedicated to the achievement of more 
selective and less toxic derivatives. 
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Nevertheless the results of this research suggest that the allosteric site, between 
the NNRTIs binding pocket and the polymerase active site, is a druggable target to 




3 Materials and methods 
 
3.1 Chemistry  
 
Unless otherwise noted, starting materials and reagents were obtains from 
commercial suppliers and were used without purification. 
All melting point were determined by the capillary method on a Stuart SMP11 
melting point apparatus or on a Büchi-540 capillary melting points apparatus and are 
uncorrected. 
All samples were measured in DMSO-d6 solvent, DMF-d7 solvent and CDCl3 at 278.1 
K temperature on a Varian Unity 500 or with a Varian Unity 300 spectrometer. In the 
signal assignments the proton chemical shifts are referred to the solvent (1H: δ = 7.24 
ppm,). Coupling constants J are expressed in hertz (Hz). 
Elemental analyses were obtained on a Perkin–Elmer 240 B microanalyser. 
Analytical data of the synthesised compounds are in agreement with the theoretical data. 
HPLC-MS/MS analysis was performed using an HPLC-MS/MS Varian (Varian Palo 
Alto, CA, USA) system fitted with a 1200 L triple quadrupole mass spectrometer equipped 
with an electrospray ionization source (ESI). A Varian MS workstation version 6.8 software 
was used for data acquisition and processing. Rapid identification was achieved with 
direct infusion of the purified molecule, dissolved in methanol, on the mass spectrometer 
source.  
TLC chromatography was performed using silica gel plates (Merck F 254), spots 





COMPOUNDS EMAC 2000-2025 
 
In all investigated molecules the NMR analysis supports the “E” configuration 
(Figure 39). 








Figure 39. (E)-3-aryl-1-arylprop-2-en-1-one 
 
First series: (E)-3-(1-methoxynaphtalen-2-yl)-1-arylprop-2-en-1-one 
 












R= 4-Br, 4-F, 4-OCH3, 4-Cl, 3-NO2, 4-C6H5, 4-NO2, 4-CH3, H, 3,4-Cl, 2,4-F, 2,4-Cl, 4-CN  
 
Scheme 1. Synthesis of (E)-3-(1-methoxynaphtalen-2-yl)-1-arylprop-2-en-1-one derivatives 
EMAC 2000-2012. Reagents: (i) ethanol, NaOH 10 %. 
 
General procedure for (E)-3-(1-methoxynaphtalen-2-yl)-1-arylprop-2-en-1-one 
 
Chalcones were synthesized via Claisen-Schmidt condensation of substituted 
acetophenone with substituted benzaldehyde under basic conditions in ethanol.  
Crude chalcones were purified by recrystallization from a suitable solvent. [203, 204] 
All synthesized compounds were characterised by analytical and spectral data as 










Compound R M.W. Mp (C°) % Yield 
EMAC 2000 4-Br 367.24 110-112 67 
EMAC 2001 4-F 306.33 93-95 81 
EMAC 2002 4-OCH3 318.37 137-139 83 
EMAC 2003 4-Cl 322.78 108-109 53 
EMAC 2004 3-NO2 333.34 143-145 64 
EMAC 2005 4-C6H5 364.44 104-105 87 
EMAC 2006 4-NO2 334.34 133-135 63 
EMAC 2007 4-CH3 302.37 91-93 76 
EMAC 2008 H 288.34 108-110 79 
EMAC 2009 3,4-Cl 357.23 135-137 79 
EMAC 2010 2,4-F 324.32 94-96 67 
EMAC 2011 2,4-Cl 357.23 112-114 70 


































































































































1H-NMR (300 MHz, DMSO) δH 4.06 (s, 3H, OCH3), 7.33 (d, 1H, J: 9.15, Ar-CH), 7.41 (t, 1H, J: 
7.5, Ar-CH), 7.55 (t, 1H, J: 7.5, Ar-CH), 7.65 (d, 2H, J: 8.3, Ar-CH), 7.82 (d, 1H, J: 7.5, Ar-CH), 
7.85 (d, 1H, J: 15.6, -CH=), 7.9 (d, 1H, J: 9, Ar-CH), 7.93 (d, 2H, J: 8.32, Ar-CH), 8.25 (d, 1H, 












ethanol / NaOH 10%
 
 
1H-NMR (300 MHz, DMSO) δH 4.07 (s, 3H, OCH3), 7.11 (t, 1H, J: 8.65, J: 8.49, Ar-CH), 7.26 
(d, 2H, J: 9, Ar-CH), 7.42 (d, 1H, J: 7.15, Ar-CH), 7.50 (t, 1H, J: 8.49, Ar-CH), 7.57 (d, 1H, J: 
7.15, Ar-CH), 7.78 (d, 1H, J: 15.9, -CH=), 7.93 (d, 1H, J: 8.65, Ar-CH), 8.09 (d, 2H, J: 9, Ar-















ethanol / NaOH 10%
 
 
1H-NMR (300 MHz, DMSO) δH 3.9 (s, 3H, OCH3), 4.05 (s, 3H, OCH3), 7.00 (d, 1H, J: 8.99, Ar-
CH), 7.33 (d, 2H, J: 9, Ar-CH), 7.70 (t, 1H, J: 8, Ar-CH), 7.47 (d, 1H, J: 16, -CH=), 7.55 (t, 1H, 
J: 8, Ar-CH), 7.82 (d, 1H, J: 8, Ar-CH), 7.89 (d, 1H, J: 9, Ar-CH), 8.08 (d, 1H, J: 9, Ar-CH), 8.28 












ethanol / NaOH 10%
 
 
1H-NMR (300 MHz, DMSO) δH 4.06 (s, 3H, OCH3), 7.33 (d, 1H, J: 9.16, Ar-CH), 7.41 (t, 1H, J: 
7.83, Ar-CH), 7.49 (d, 2H, J: 8.48, Ar-CH), 7.53 (d, 1H, J: 15.65, -CH=), 7.55 (t, 1H, J: 7.82, 
Ar-CH), 7.74 (d, 1H, J: 8.16, Ar-CH), 7.90 (d, 1H, J: 9.65, Ar-CH), 8.01 (d, 2H, J: 8.32, Ar-CH), 












ethanol / NaOH 10%  
 
1H-NMR (300 MHz, DMSO) δH 4.10 (s, 3H, OCH3), 7.35 (d, 1H, J: 8.98, Ar-CH), 7.42 (t, 1H, J: 
7.82, Ar-CH), 7.58 (t, 1H, J: 8.5, Ar-CH), 7.72 (t, 1H, J: 7.82, Ar-CH), 7.83 (d, 1H, J: 8, Ar-CH), 
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7.93 (d, 1H, J:8.5, Ar-CH), 7.94 (d, 1H, J: 15.6, -CH=), 8.25 (d, 1H, J: 8.5, Ar-CH), 8.39 (d, 1H, 









ethanol / NaOH 10%
 
 
1H-NMR (300 MHz, DMSO) δH 4.07 (s, 3H, OCH3), 7.34- 7.50 (m, 2H, Ar-CH), 7.56 (t, 1H, J: 
8.1, Ar-CH), 7.69 (d, 2H, J: 7.8, Ar-CH), 7.75 (d, 2H, J: 7.8, Ar-CH), 7.83(d, 1H, J: 8.8, Ar-CH), 
7.88 (d, 1H, J: 8.0, Ar-CH), 7.91 (d, 2H, J: 8.2, Ar-CH), 7.95 (d, 1H, J: 15.9, -CH=), 8.04 (d, 













ethanol / NaOH 10%
 
 
1H-NMR (500 MHz, DMSO) δH 3.55 (s, 3H, OCH3) 7.34 (d, 1H, J: 9, Ar-CH) 7.42 (t, 1H, J: 7.5, 
Ar-CH), 7.57 (t, 1H, J: 7.5, Ar-CH), 7.89 (d, 1H, J: 15.5, –CH=), 7.93 (d, 1H, J: 9.5, Ar-CH), 
8.18 (d, 2H, J: 9 Ar-CH), 8.23 (d, 1H, J: 9, Ar-CH), 8.36 (d, 2H, J: 8.5, Ar-CH), 8.42 (d, 1H, J:  















ethanol / NaOH 10%
 
 
1H-NMR (500 MHz, DMSO) δH 2.44 (s, 3H, CH3), 4.05 (s, 3H, OCH3), 7.31 (d, 2H, J: 8.5, Ar-
CH, Ar-CH), 7.33 (d, 1H, J: 9, Ar-CH), 7.39 (t, 1H, J: 7.5, Ar-CH), 7.53 (t, 1H, J: 8, Ar-CH), 7.81 
(d, 1H, J: 8.5, Ar-CH), 7.87 (d, 1H, J: 15.5, -CH=), 7.88 (d, 1H, J: 9, Ar-CH), 7.98 d, 2H, J: 8, 










ethanol / NaOH 10%
 
 
1H-NMR (500 MHz, DMSO) δH 4.06 (s, 3H, OCH3), 7.33 (d, 1H, J: 8.5, Ar-CH), 7.4 (t, 1H, J: 8, 
Ar-CH), 7.52 (d, 2H, J: 7, Ar-CH), 7.54 (t, 1H, J: 8, Ar-CH), 7.58 (t, 1H, J: 7.5, Ar-CH), 7.81 (d, 
1H, J: 8, Ar-CH), 7.88 (d, 1H, J: 7.5, Ar-CH), 7.89 (d, 1H, J: 15.5, -CH=), 8.07 (d, 2H, J: 7.5, Ar-














ethanol / NaOH 10%
 
 
1H-NMR (500 MHz, DMSO) δH 4.07 (s, 3H, OCH3), 7.33 (d, 1H, Jm: 2, Jp: 1, Jo: 8, Ar-CH), 7.41 
(t, 1H, Jm: 1, Jo: 8.5, Ar-CH), 7.56 (t, 1H, Jm: 1, Jo: 8.5, Ar-CH), 7.59 (d, 1H, J: 8, Ar-CH), 7.81 
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(d, 1H, J: 8.5, Ar-CH), 7.81 (d,1H, J: 16, -CH=), 7.88 (d, 1H, Jo: 8, Jm:2, Ar-CH), 7.91 (d, 1H, J: 













ethanol / NaOH 10%
 
 
1H-NMR (500 MHz, DMSO) δH 4.04 (s, 3H, OCH3), 7.34 (d, 1H, J: 8.5, Ar-CH), 7.44 (t, 1H, J: 
8.5, Ar-CH ), 7.55 (t, 1H, J: 8.5, Ar-CH), 7.70 (d, 1H, J: 9, Ar-CH), 7.71 (d, 1H, J: 7.5, Ar-CH ), 
7.76 (d, 1H, J: 16, -CH=), 7.81 (d, 1H, J: 8.5, Ar-CH), 7.81 (s, 1H, Ar-CH), 7.89 (d, 1H, J: 9.5, 














ethanol / NaOH 10%
 
 
1H-NMR (500 MHz, DMSO) δH 4.05 (s, 3H, OCH3), 7.34 (d, 1H, J: 8.5, Ar-CH), 7.44 (t, 1H, 
Ar-CH), 7.54 (t, 1H, Ar-CH), 7.6 (d, 1H, J: 9, Ar-CH), 7.73 (d, 1H, J: 9.5, Ar-CH), 7.8 (d, 1H, 
Ar-CH), 7.87 (s, 1H, Ar-CH), 7.94 (d, 1H, J: 8, Ar-CH), 8.17 (d, 1H, J: 16.5, -CH=), 8.28 (d, 1H, 















ethanol / NaOH 10%
 
 
1H-NMR (500 MHz, DMSO) δH 4.07 (s, 3H, OCH3), 7.33 (d, 1H, J: 8.5, Ar-CH), 7.42 (t, 1H, J: 
7.5, Ar-CH), 7.56 (t, 1H, J: 7.5, Ar-CH), 7.70 (d, 2H, J: 9, Ar-CH), 7.82 (d, 1H, J: 8.5, Ar-CH), 
7.87 (d, 1H, J: 15.5, -CH=), 7.93 (d, 2H, J: 9, Ar-CH), 8.12 (d, 1H, J: 8.5, Ar-CH), 8.23 (d, 1H, 





Second series: (E)-3-indol-3-yl-1-arylprop-2-en-1-one derivatives  
 























Scheme 2. Synthesis of (E)-3-indol-3-yl-1-arylprop-2-en-1-one derivatives EMAC 2013-2025. 
Reagents: (i) ethanol, piperidine. 
 
General procedure for (E)-3-indol-3-yl-1-arylprop-2-en-1-one derivatives  
 
According to literature method, [205, 206] 3.45 mmol of indol-3-carboxaldehyde 
and 3.45 mmol of suitable acetofenone, in the presence of 2 mmol of piperidine added 
dropwise, were dissolved in 20 ml of ethanol and stirring for 24 h. The reaction mixture 
was neutralized with diluted HCl 10%; the solid was filtered and crystallised from 
appropriate solvent (Scheme 2). 
All synthesized compounds were characterised by analytical and spectral data as 














Compound R M.W. Mp (C°) % Yield 
EMAC 2013 4-Br 326.19 194-195 47 
EMAC 2014 4-F 265.28 173-174 30 
EMAC 2015 4-OCH3 277.32 159-160 20 
EMAC 2016 4-Cl 281.74 188-190 52 
EMAC 2017 3-NO2 292.29 194-196 80 
EMAC 2018 4-C6H5 323.39 250-253 82 
EMAC 2019 4-NO2 292.29 227-229 78 
EMAC 2020 4-CH3 261.32 140-144 71 
EMAC 2021 H 247.29 154-156 68 
EMAC 2022 3,4-Cl 316.18 212-214 80 
EMAC 2024 2,4-Ck 316.18 186-188 69 



































































































































1H-NMR (500 MHz, DMSO) δH 7.32 (m, 2H, Ar-CH), 7.46 (m, 1H, Ar-CH), 7.53 (d, 1H, J: 15, 
-CH=), 7.63 (d, 1H, Jm: 2.5, Ar-CH), 7.65 (d, 2H, J: 8.5, Ar-CH), 7.92 (d, 2H, J: 8.5, Ar-CH), 




















1H-NMR (500 MHz, DMSO) δH 7.18 (t, 1H, J: 8.5, Ar-CH), 7.32 (m, 2H, Ar-CH), 7.46 (m, 1H, 
Ar-CH), 7.49 (d, 2H, J: 8, JH-F: 6, Ar-CH), 7.54 (d, 1H, J: 15.5, Ar-CH), 7.63 (s, 1H, Jm: 2.5, Ar-
























1H-NMR (500 MHz, DMSO) δH 3.09 (s, 3H, OCH3), 7.18 (m, 1H, Ar-CH), 7.32 (m, 2H, Ar-
CH), 7.46 (m, 1H, Ar-CH), 7.47 (m, 1H, Ar-CH), 7.53 (d, 1H, J: 15, -CH=), 7.63 (d, 1H, Jm: 2.5, 




















1H-NMR (500 MHz, DMSO) δH 7.32 (m, 2H, Ar-CH), 7.46 (m, 1H, Ar-CH), 7.48 (d, 2H, J: 8, 
Ar-CH), 7.55 (d, 1H, J: 15.5, -CH=), 7.62 (d, 1H, Jm: 1.5, Ar-CH), 8.00 (m, 3H, J: 8, Ar-CH), 























1H-NMR (500 MHz, DMSO) δH 7.35 (m, 2H, Ar-CH), 7.47 (m, 1H, J: 9, Ar-CH), 7.56 (d, 1H, J: 
15.5, -CH=), 7.89 (d, 1H, Jm: 2.5, Ar-CH), 7.71 (t, 1H, J: 8, Ar-CH), 8.03 (m, 1H, J: 8, Ar-CH), 
8.19 (d, 1H, J: 15.5, Ar-CH), 8.37 (d, 1H, J: 7.5, Ar-CH),8.42 (d, 1H, J: 8, Ar-CH), 8.59 (br.s, 


















1H-NMR (500 MHz, DMSO) δH 7.33 (m, 2H, Ar-CH), 7.40 (m, 1H, Ar-CH), 7.48 (m, 3H, J: 
7.5, Ar-CH), 7.64 (s, 1H, Ar-CH), 7.65 (d, 1H, J: 15.5, -CH=), 7.78 (d, 2H, J: 7.5, Ar-CH), 7.74 
(d, 2H, J: 8, Ar-CH), 8.06 (m, 1H, Ar-CH), 8.15 (d, 2H, J: 7, Ar-CH), 8.14 (d, 1H, J:15.5, Ar-























1H-NMR (500 MHz, DMSO) δH 7.34 (m, 2H, Ar-CH), 7.47 (m, 1H, Ar-CH), 7.53 (d, 1H, J: 
15.5, -CH=), 7.67 (d, 1H, Jm: 2.5, Ar-CH), 8.01 (m, 1H, Ar-CH), 8.14 (d, 1H, J: 15.5, -CH=), 




















1H-NMR (500 MHz, DMSO) δH 2.44 (s, 3H, CH3), 7.31 (m, 4H, J: 8, Ar-CH), 7.46 (m, 1H, Ar-
CH), 7.60 (d, 1H, J: 15, -CH=), 7.61 (s, 1H, Ar-CH), 7.97 (d, 2H, J: 8, Ar-CH), 8.01 (m, 1H, Ar-





















1H-NMR (500 MHz, DMSO) δH 7.31 (m, 2H, Ar-CH), 7.45 (m, 1H, Ar-CH), 7.52 (t, 2H, J: 7.5, 
J: 7 Ar-CH), 7.57 (t, 1H, J: 7.5, Ar-CH), 7.61 (d, 1H, Jm: 2.5, Ar-CH), 7.6 (d, 1H, J: 15.5, -CH=), 






















1H-NMR (500 MHz, DMSO) δH 7.34 (m, 2H, Ar-CH), 7.46 (t, 1H, J: 8.5, Ar-CH), 7.48 (d, 1H, 
J: 15.5, -CH=), 7.59 (d, 1H, J: 8.5, Ar-CH), 7.65 (d, 1H, Jm: 2.5, Ar-CH), 7.87 (d, 1H, Jo: 8.5, Jm: 
2, Ar-CH), 8.01 (m, 1H, Ar-CH), 8.13 (d, 1H, Jm: 2, Ar-CH), 8.12 (d, 1H, J: 15.5, -CH=), 8.57 
























1H-NMR (500 MHz, DMSO) δH 7.18 (d, 1H, J: 15.5, -CH=), 7.3 (m, 2H, Jm: 2, Jo: 7.5, Ar-CH), 
7.35 (d, 1H, Jm: 2, Jo: 8, Ar-CH), 7.43 (d, 1H, Jm: 2, Jo: 8.5, Ar-CH), 7.46 (d, 1H, J: 8, Ar-CH), 
7.49 (d, 1H, Jm: 2, Ar-CH) 7.55 (d, 1H, Jm: 3, Ar-CH), 7.72 (d, 1H, J: 15.5, -CH=), 7.95 (d, 1H, 




















1H-NMR (500 MHz, DMSO) δH 7.33 (m, 2H, Ar-CH), 7.47 (m, 1H, Ar-CH), 7.51 (d, 1H, J: 
15.5, -CH=), 7.65 (d, 1H, Jm: 2.5, Ar-CH), 7.8 (d, 2H, J: 8.5, Ar-CH), 8.00 (m, 1H, Ar-CH), 8.13 




COMPOUNDS EMAC 2026-2035 
 
































R= 2,4-Cl, 4-F, 4-CN, 3-NO2, 4-Br, 4-C6H5, 4-NO2, 4-OCH3, 4-Cl, 4-CH3  
 
Scheme 3. Synthesis of 1-(anthracen-9-yl-methylene)-2-(4-arylthiazol-2-yl)hydrazine 





General procedure for 1-(anthracen-9-yl-methylene)-2-(4-arylthiazol-2-
yl)hydrazine derivatives 
 
Anthracene derivative were synthesized by a multi step reaction.  
The first synthetic step leads to the formation of 1-(anthracen-9-yl-
methylene)thiosemicarbazide by reacting antracene-9-carbaldehyde and 
thiosemicarbazide in 2-propanol and acid acetic as catalyst.  
In the second step, the thiazole ring is formed by reaction between 1-(anthracen-9-
yl-methylene)thiosemicarbazide and differently substituted α-halogen-acetophenones as 
outlined in the Scheme 3. 
All synthesized compounds were characterised by analytical and spectral data as 















Compound R M.W. Mp (C°) % Yield 
EMAC 2026 2,4-Cl 448.37 190 92 
EMAC 2027 4-F 397.47 228 80 
EMAC 2028 4-CN 404.49 243 85 
EMAC 2029 3-NO2 424.7 245 97 
EMAC 2030 4-Br 458.37 250 89 
EMAC 2031 4-C6H5 455.57 246-248 95 
EMAC 2032 4-NO2 424.47 253 99 
EMAC 2033 4-OCH3 409.5 233 83 
EMAC 2034 4-Cl 413.92 260-262 97 


























































































M.W.: 279.36 g/mol; R.f.: 0.81 (eluent: DCM:methanol 20:1); M.P.: 200°C; Yield: 90,31% 
 
1H-NMR: (300 MHz, DMSO) δH 11.76 (s,1H, NH) 9.44 (s, 1H, CH=N), 8.83 (s, 1H, Ar-CH ), 
8.68 (d, 2H, J: 8.68, Ar-CH ), 8.44 (brs, 1H, NH2), 8.26 (d, 2H, J: 8.18, Ar-CH ), 7.84 (br.s, 1H, 





























1H-NMR: (300 MHz, DMSO) δH 12.49 (brs, 1H, NH), 9.29 (s, 1H, CH=N), 8.7 (d+s, 3H, Ar-
CH), 8.17 (d, 2H, J: 8.34, Ar-CH), 7.95 (d, 1H, J: 8.01, Ar-CH), 7.73 (s, 1H, Ar-CH), 7.65 (m, 






























1H-NMR: (300 MHz, DMSO) δH 12.51 (brs, 1H, NH), 9.29 (s, 1H, CH=N), 8.7 (d+s, 3H, Ar-
CH), 8.18 (d, 2H, J: 8.34, Ar-CH), 7.95 (t, 2H, Ar-CH), 7.64 (m, 4H, Ar-CH), 7.36 (s, 1H, 
thiazole), 7.28 (t, 2H, Ar-CH) 
 
EMAC 2028 
























1H-NMR: (300 MHz, DMSO) δH 12.52 (brs, 1H, NH), 9.3 (s, 1H, CH=N); 8.71 (d+s, 3H, Ar-
CH), 8.18 (d, 2H, J: 8.17, Ar-CH), 8.10 (d, 2H, J: 8.16, Ar-CH), 7.92 (d, 2H, J: 8.03, Ar-CH), 






























1H-NMR: (300 MHz, DMSO) δH 12.58 (brs, 1H, NH), 9.29 (s, 1H, CH=N), 8.71(d+s, 3H, Ar-





























1H-NMR: (300 MHz, DMSO) δH 12.46 (s, 1H, NH), 9.29 (s, 1H, CH=N), 8.71 (d+s, 3H, J: 
8.34, Ar-CH), 8.18 (d, 2H, J: 8.35, Ar-CH), 8.42 (d, 2H, J: 8.51, Ar-CH), 7.58 (m, 6H, Ar-CH), 




























1H-NMR: (300 MHz, DMSO) δH 12.58 (s, 1H, NH), 9.31 (s, 1H, CH=N), 8.70 (d, 2H, J: 8.18, 
Ar-CH ), 8.72 (s, 1H, Ar-CH), 8.18 (d, 2H, J: 8.35, Ar-CH), 8.01 (d, 2H, Ar-CH), 7.75 (m, 4H, 





























1H-NMR: (300 MHz, DMSO) δH 12.56 (brs, 1H, NH)9.3 (s, 1H, CH=N), 8.7 (d+s, 3H, Ar-CH), 































1H-NMR: (300 MHz, DMSO) δH 9.31 (s, 1H, CH=N), 8.72 (d+s, 3H, J: 8.18, Ar-CH), 8.18 (d, 
2H, J: 8.01, Ar-CH), 7.84 (d, 2H, J: 8.68, Ar-CH), 7.65 (m, 4H, Ar-CH), 7.21 (s, 1H, thiazole), 





























1H-NMR: (300 MHz, DMSO) δH 12.45 (s, 1H, NH), 9.28 (s, 1H, CH=N), 8.7 (d+s, 3H, Ar-CH), 
8.17 (d, 2H, J: 8.51, Ar-CH), 7.93 (d, 2H, J: 8.68, Ar-CH), 7.63 (m, 4H, Ar-CH), 7.50 (d, 2H, J: 





























1H-NMR: (300 MHz, DMSO) δH 9.28 (s, 1H, CH=N), 8.7 (d+s, 3H, Ar-CH), 8.17 (d, 2H, J: 
8.34, Ar-CH), 7.78, (d, 2H, J: 8.01, Ar-CH), 7.7 (m, 4H, Ar-CH), 7.29 (s, 1H, thiazole), 7.25 (d, 





COMPOUNDS EMAC 2036-2045 
 





































R= 2,4-Cl, 4-F, 4-CN, 3-NO2, 4-Br, 4-C6H5, 4-NO2, 4-OCH3, 4-Cl, 4-CH3
 
Scheme 4. Synthesis of 3-[{2-[4-aryl-1,3-thiazol-2-yl]hydrazin-1-ylidene}methyl]-4H-
chromen-4-one derivatives EMAC 2036-2045. Reagents: (i) 2-propanol, AcOH; (ii) 2-propanol, 
reflux condition. 
 
General procedure for 3-[{2-[4-aryl-1,3-thiazol-2-yl]hydrazin-1-ylidene}methyl]-
4H-chromen-4-one derivatives  
 
Chromone derivative were synthesized by a multi step reaction.  
The first synthetic step leads to the formation of 1-[(4-oxo-4H-chromen-3-
yl)methylidene]amino]thiourea by reacting 4-oxo-4H-chromene-3-carbaldehyde and 
thiosemicarbazide in 2-propanol and acid acetic as catalyst.  
In the second step, the thiazole ring is formed by reaction between [(4-oxo-4H-chromen-
3-yl)methylidene]amino]thiourea and differently substituted α-halogen-acetophenones 
100 
 




All synthesized compounds were characterised by analytical and spectral data as 
listed in Table 15 and 16. 
 













Compound R M.W. Mp (C°) % Yield 
EMAC 2036 2,4-Cl 416.28 260 75 
EMAC 2037 4-F 365.38 212-215 75 
EMAC 2038 4-CN 372.4 275 95 
EMAC 2039 3-NO2 392.39 260 90 
EMAC 2040 4-Br 426.29 270 91 
EMAC 2041 4-C6H5 423.49 237-239 83 
EMAC 2042 4-NO2 392.39 282-284 99 
EMAC 2043 4-OCH3 377.42 230 30 
EMAC 2044 4-Cl 381.84 270 38 
EMAC 2045 4-CH3 361.42 245 74 
102 
 












































































































M.W.: 247.27 g/mol; R.f.: 0.3 (DCM: methanol 20:1); M.P.: 235 °C; Yield: 97.42% 

































MS (ESI+): 416.00 ([M+H]+) 
The 
 































MS (ESI+): 366.07 ([M+H]+) 
The 
 






























MS (ESI+): 373.07 ([M+H]+) 
The 
 































MS (ESI+): 393.06 ([M+H]+) 
The 
 




























MS (ESI+): 424.98 - 426.98 ([M+H]+) 
The 
 































MS (ESI+): 424.11 ([M+H]+) 
The 
 




























MS (ESI+): 393.06 ([M+H]+) 
The 
 
































MS (ESI+): 378.09 ([M+H]+) 
The 
 




























MS (ESI+): 383.03 ([M+H]+) 
The 
 


































MS (ESI+): 362.9 ([M+H]+) 
The 
 





COMPOUNDS EMAC 2046-2055 
 




































R= 2,4-Cl, 4-F, 4-CN, 3-NO2, 4-Br, 4-C6H5, 4-NO2, 4-OCH3, 4-Cl, 4-CH3  
Scheme 5. Synthesis of 3-[{2-[4-aryl-1,3-thiazol-2-yl]hydrazin-1-ylidene}methyl]-6-methyl-
4H-chromen-4-one derivatives EMAC 2046-2055. Reagents: (i) 2-propanol, AcOH; (ii) 2-propanol, 
reflux condition. 
 
General procedure for 3-[{2-[4-aryl-1,3-thiazol-2-yl]hydrazin-1-ylidene}methyl]-6-
methyl-4H-chromen-4-one derivatives 
 
6-methyl-chromone derivative were synthesized by a multi step reaction.  
The first synthetic step leads to the formation of 1-((6-methyl-4-oxo-4H-chromen-3-
yl) methylene) thiosemicarbazide by reacting 4-oxo-4H-chromene-6-methyl-3-
carbaldehyde and thiosemicarbazide in 2-propanol and acid acetic as catalyst.  
In the second step, the thiazole ring is formed by reaction between (E)-1-((6-methyl-
4-oxo-4H-chromen-3-yl) methylene) thiosemicarbazide and differently substituted α-
halogen-acetophenones as outlined in the Scheme 5. 
110 
 
All synthesized compounds were characterised by analytical and spectral data as 
listed in Table 17 and 18. 
 














Compound R M.W. Mp (C°) % Yield 
EMAC 2046 2,4-Cl 430.31 260 58 
EMAC 2047 4-F 379.41 232 74 
EMAC 2048 4-CN3 386.43 275 62 
EMAC 2049 3-NO2 406.41 273-275 68 
EMAC 2050 4-Br 440.31 244-245 76 
EMAC 2051 4-C6H5 437.51 246-248 95 
EMAC 2052 4-NO2 406.41 265-267 69 
EMAC 2053 4-OCH3 391.44 235 63 
EMAC 2054 4-Cl 395.86 237 74 
EMAC 2055 4-CH3 375.44 249 79 
111 
 











































































































M.W.: 261.3 g/mol; R.f.: 0.26 (DCM: methanol 20:1); M.P.: 234 °C; Yield: 80 % 
MS (ESI+): 262.06 ([M+H]+) 
The 
 


































MS (ESI+): 430.01 ([M+H]+) 
The 
 

































MS (ESI+): 380.08 ([M+H]+) 
The 
 
































MS (ESI+): 387.09 ([M+H]+) 
The 
 

































MS (ESI+): 407.08 ([M+H]+) 
The 
 






























MS (ESI+): 439.00 - 441.00 ([M+H]+) 
The 
 


































MS (ESI+): 438.13 ([M+H]+) 
The 
 






























MS (ESI+): 407.08 ([M+H]+) 
The 
 

































MS (ESI+): 392.10 ([M+H]+) 
The 
 
































MS (ESI+): 396.05([M+H]+) 
The 
 


































MS (ESI+): 376.10 ([M+H]+) 
The 
 




COMPOUNDS EMAC 2056-2071 
 















































R: H, 2-CN, 4-F, 2-Br
R': 4-OCH3, 3,4-Cl, 4-Cl, 4-NO2  
 
Scheme 6. Synthesis of 3-[{2-[4-aryl-1,3-thiazol-2-yl]hydrazin-1-ylidene}methyl]-6-methyl-
4H-chromen-4-one derivatives EMAC 2056-2071. Reagents: (i) Dimethoxyethane / argon flow, 





Compounds EMAC 2056-2071 were synthesized by a multi step reaction.  
The first synthetic step leads to the formation of 5-aryl-2-methoxybenzaldehyde by 
reacting 5-bromo-2-methoxybenzaldehyde with differentely substituted phenylboronic 
acids according to slightly modified Suzuky coupling reaction condition. [210]  
In the second step, thiosemicarbazones are formed by reaction between 5-aryl-2-
methoxybenzaldehyde, thiosemicarbazide and catalytic amount of CH3COOH in n-
propanol at room temperature. Finally, in the third step the thiazole ring is formed by 
reaction of the appropriate thiosemicarbazones with substituted α-halogen-
acetophenones, as outlined in the Scheme 6. 
 
All samples were measured in DMSO-d6 solvent at 278.1 K temperature on a Bruker 
AVANCE III spectrometer.  
In the signal assignments the proton and carbon chemical shifts are referred to the 
solvent (1H: δ = 2.49 ppm, 13C dowfield methyl signal: δ=34.89 ppm respectively).  
Melting points were determined on a Büchi-540 capillary melting points apparatus 
and are uncorrected. 
 
These compounds were synthesised and analysed during my research period in 
Budapest under the supervision of Prof. Peter Matyus. 
 
All synthesized compounds were characterised by analytical and spectral data as 

















Compound R R’ M.W. Mp (C°) % Yield 
EMAC 2056 H 4-OCH3 415.51 209 decomposition 81.5 
EMAC 2057 H 3,4-Cl 454.37 213 decomposition 92 
EMAC 2058 H 4-Cl 419.93 215 decomposition 91.3 
EMAC 2059 H 4-NO2 430.48 208 decomposition 89.4 
EMAC 2060 2-CONH2 4-OCH3 458.53 203 decomposition 70.5 
EMAC 2061 2-CONH2 3,4-Cl 497.4 221 decomposition 77.7 
EMAC 2062 2-CONH2 4-Cl 462.95 222 decomposition 84.7 
EMAC 2063 2-CONH2 4-NO2 473.5 208 decomposition 89.4 
EMAC 2064 4-F 4-OCH3 433.5 193 decomposition 83.65 
EMAC 2065 4-F 3,4-Cl 472.36 220 decomposition 91.4 
EMAC 2066 4-F 4-Cl 437.92 218 decomposition 98 
EMAC 2067 4-F 4-NO2 448.47 233 decomposition 91 
EMAC 2068 2-Br 4-OCH3 494.4 186 decomposition 82.3 
EMAC 2069 2-Br 3,4-Cl 533.27 225 decomposition 88 
EMAC 2070 2-Br 4-Cl 498.82 235 decomposition 87 
EMAC 2071 2-Br 4-NO2 509.38 237 decomposition 94 
121 
 

































EMAC 2059 H 4-NO2 n-propanol Water/Ethanol Orange solid 5 
EMAC 2060 2-CONH2 4-OCH3 n-propanol Ethanol Yellow solid 15 




EMAC 2062 2-CONH2 4-Cl n-propanol Ethanol Yellow solid 18 
EMAC 2063 2-CONH2 4-NO2 n-propanol Water/Ethanol Orange solid 18 












EMAC 2067 4-F 4-NO2 n-propanol Water/Ethanol Gold solid 8 


















General procedure for Suzuki cross-coupling reaction. 
 
The ortho-halogen compound (10 mmol) was dissolved in dimethoxyethane (15 
mL), and Pd(PPh3)4 (577.8 mg, 0.50 mmol,) was added to the solution at room 
temperature under argon flow. After stirring the mixture at room temperature for 10 min, 
2-formylphenylboronic acid (2.249 g, 15 mmol,) and aq 2M Na2CO3 solution (10.6 mL) 
were added and the reaction mixture was refluxed at 110 °C (oil temperature). When the 
reaction was complete (monitored by TLC, eluent: n-hexane - ethyl acetate 4:1), the 
reaction mixture was cooled and poured onto ice (100 g). The solution was filtered on 
Celite and washed with ethyl acetate (100 mL). The aqueous phase was extracted with 
ethyl acetate (3×40 mL). The combined organic layers were washed with water (1×20 mL), 
dried over MgSO4, evaporated under reduced pressure. The oily residue was purified by 
flash column chromatography on silica gel (eluent: n-hexane - ethyl acetate 5:1). [210] 
 




















M.W.: 212.24 g/mol; R.f.: 0.82 (exane-ethylacetate 1;1); HPLC: 97.336%; M.P.: 77°C-78°C; 
Yield:98.8% 
 
NMR: 1H-NMR (500 MHz, DMSO) δH 3.97 ( s, 3H, OCH3), 7.34 ( d, 1H, Ar-CH, J: 8.5), 7.36 ( 
m, 1H, J: 8, Ar-CH) 7.46 ( t, 2H, J: 8, Ar-CH) 7.65 ( d, 2H, J: 8, Ar-CH), 7.93 ( s, 1H, J: 2.5, Ar-
CH), 7.98 ( d, 1H, J: 8, J: 2.5, Ar-CH) 10.4 ( s,1H, CHO). 
 
13C-NMR (500 MHz, DMSO) δ 56.2 ( 1C, OCH3 ), 113.5 ( 1C, phenyl), 124.3, ( 1C, phenyl), 
125.6 ( 1C, phenyl), 126.3 ( 2C, phenyl), 127.4 ( 1C, phenyl), 129.0 ( 2C, phenyl), 132.6 ( 






























In this particular case, the hydrolysis of CN group into CONH2 group is observed.  
This is probably due to an hydrolysis reaction mediated by the basic reaction media 































M.W.: 255.28 g/mol; R.f.: 0.29 (exane-ethylacetate 1:7); HPLC: 98,00%; M.P.: 140°C; Yield: 
87.2% 
 
1H-NMR (500 MHz, DMSO) δH 3.96 ( s, 1H, OCH3), 7.34 ( bs, 2H, NH2), 7.29 ( d, 1H, J: 8.5, 
Ar-CH), 7.37 ( m,1H, Ar-CH), 7.40 ( m,1H, Ar-CH), 7.45 ( m,1H, Ar-CH), 7.48 ( m,1H, Ar-CH), 


























M.W.: 230.23 g/mol; R.f.: 0.41 (exane-ethylacetate 2,5:1); HPLC: 99.038%; M.P.: 81°C; 
Yield: 88.60% 
 
1H-NMR (500 MHz, DMSO) δH 3.96 ( s, 3H, OCH3), 7.28 ( m, 2H, J: 9, Ar-CH), 7.33 ( d, 1H, J: 
8.5, Ar-CH), 7.70 ( m, 2H, Ar-CH), 7.90 ( d, 1H, J:2.5, Ar-CH), 7.96 ( dd, 1H, J: 8.5, J: 2.5, Ar-
CH), 10.39 ( s, 1H, CHO). 
 
13C-NMR (500 MHz, DMSO) δ 56.2 ( 1C, OCH3), 113.5 ( 1C, phenyl), 115.8 ( 2C, phenyl), 
124.3 ( 1C, phenyl), 125.6 ( 1C, phenyl), 128.3 ( 2C, phenyl), 131.6 ( 1C, phenyl), 134.4 ( 

























M.W.: 291.14 g/mol; R.f.: 0.43 (exane-ethylacetate 4:1); HPLC: 94.15%; M.P.: 106°C-
107°C; Yield: 23.36% 
 
NMR: 1H-NMR (500 MHz, DMSO) δH 3.98 ( s, 3H, OCH3), 7.32 ( m, 1H, J: 8, Ar-CH), 7.33 ( d, 
1H, J: 8.5, Ar-CH), 7.40 ( m, 1H, J: 8, J: 2, J: 6, Ar-CH), 7.47 ( m, 1H, J: 2, Ar-CH), 7.69 ( d, 1H, 
J: 2, Ar-CH), 7.71 ( dd, 1H, J: 8.5, J: 2, Ar-CH), 7.74 ( m, 1H, Ar-CH), 10.39 ( s, 1H, COH).  
 
13C-NMR (500 MHz, DMSO) δ 56.2 ( 1C, OCH3), 112.7 ( 1C, phenyl), 121.8 ( 1C, phenyl), 
123.6 ( 1C, phenyl), 128.2 ( 1C, phenyl), 128.3 ( 1C, phenyl),129.6 ( 1C, phenyl), 131.4 ( 1C, 
phenyl), 132.7 ( 2C, phenyl), 133.1 ( 1C, phenyl), 140.4 ( 1C, phenyl), 161.0 ( 1C, phenyl), 





General method for the synthesis of thiosemicarbazones. 
 
In a flask equipped with a reflux condenser, equimolar amounts of 
thiosemicarbazide and of the appropriate ketone are reacted in n-propanol in the 
presence of a catalytic amount of AcOH. The mixture is allowed to react overnight, and 
the obtain solid is filtered and used without further purification.  
 


























M.W.: 285.36 g/mol; R.f.: 0.71 (exane-ethylacetate 1:1); HPLC: 95.933%; M.P.: 223.3°-
223.8°C; Yield: 97%  
 
NMR: 1H-NMR (500 MHz, DMSO) δH 3.87 ( s, 3H, OCH3), 7.15 ( d, 1H, J: 8.5, Ar-CH), 7.32 ( 
m, 1H, Ar-CH), 7.44 ( m, 2H, Ar-CH), 7.68 ( dd, 1H, J: 8.15, Ar-CH), 7.72 ( m, 2H, J: 8.5, Ar-
CH) 8.18-8.19 ( brs, 2H, NH2), 8.37 ( d, 1H, Ar-CH), 8.45 ( s, 1H, CH=N), 11.45 ( s, 1H, NH). 
 
13C-NMR (500 MHz, DMSO) δ 55.9 ( 1C, OCH3), 112.2 ( 1C, phenyl), 122.5 ( 1C, phenyl), 
123,8 ( 1C, phenyl), 126.5 ( 2C, phenyl), 126.9 ( 1C, phenyl), 128.7 ( 2C, phenyl), 129.4 ( 
1C, phenyl), 132.7 ( 1C, phenyl), 137.8 ( 1C, CH=N), 139.4 ( 1C, phenyl), 157.3 ( 1C, 
































M.W.: 328.39 g/mol; R.f.: 0.26 (exane-ethylacetate 1:4); HPLC: 88.22%; M.P.: 234°-235°C; 
Yield: 82.48% 
 
1H-NMR (500 MHz, DMSO) δH 3.86 ( s,3H, OCH3), 7.09 ( d, 1H, J:8.5, Ar-CH), 7.33 ( bs, 1H, 
NH2), 7.40 ( dd, 1H, Ar-CH), 7.40 ( m, 1H, Ar-CH), 7.41 ( m, 2H, Ar-CH), 7.46 ( m, 1H, Ar-
CH), 7.66 ( bs, 1H, NH2), 7.88 ( bs, 1H, NH2), 8.15 ( d, 1H, J: 2.5), 8.18 ( bs, 1H, NH2), 8.43 ( 
s, 1H, CH=N), 11.46 ( s, 1H, NH-CSNH2). 
 
13C-NMR (500 MHz, DMSO) δ 55.8 ( 1C, OCH3), 111.4 ( 1C, phenyl), 121.9 ( 1C, phenyl), 
125.8 ( 1C, phenyl), 126.7 ( 1C, phenyl), 127.3 ( 1C, phenyl), 129.0 ( 1C, phenyl), 130.0 ( 
1C, phenyl), 131.2 ( 2C, phenyl), 137.5 ( 1C, phenyl), 137.8 ( 1C, CH=N), 138.2 ( 1C, 
























F F  
 





NMR: 1H-NMR (500 MHz, DMSO) δH 3.87 ( s, 3H, OCH3 ), 7.14 ( d, 1H, J: 9, Ar-CH), 7.26 ( 
m, 2H, J: 8.5, Ar-CH), 7.67 ( dd, 1H, J: 8.5, J: 2, Ar-CH), 7.76 ( m, 2H, J: 8.5, J:2, Ar-CH), 8.21-
8.18 ( brd, 2H, NH2 ), 8.35 ( d, 1H, J: 2.5, Ar-CH), 8.44 ( s, 1H, CHN), 11.46 (s, 1H, NH). 
 
13C-NMR (500 MHz, DMSO) δ 55.9 ( 1C, OCH3), 112.2 ( 1C, phenyl), 115.4 ( 1C, phenyl), 
115.5 ( 1C, phenyl), 122.5 ( 1C, phenyl), 123.7 ( 1C, phenyl), 128.4 ( 1C, phenyl), 128,5 ( 
1C, phenyl), 129.3 ( 1C, phenyl), 131.7 ( 1C, phenyl), 135.8 ( 1C, phenyl), 137.6 ( 1C, 



























M.W.: 364.26 g/mol; R.f.: 0.725 (exane-ethylacetate 1:1); HPLC: 93.98%; M.P.: 219-220°C; 
Yield: 62.45% 
 
1H-NMR (500 MHz, DMSO) δH 3.88 (s, 3H, OCH3), 7.13 (d, 1H, J: 9), 7.39 (m, 1H, J: 1.5), 
7.39 (m, 2H), 7.45 (m, 1H, J: 1), 7.72 ( m, 1H, J: 8, J: 1.5), 8.10-8.06 (brs, 2H, NH), 8.14 ( d, 
1H, J: 2), 8.44 (s, 1H, CH=N), 11.43 (s,1H, NH). 
 
13C-NMR (500 MHz, DMSO) δ 55.9 (1C, OCH3), 111.2 (1C, phenyl), 121.9 (1C, phenyl), 
122.2 (1C, phenyl), 126.6 (1C, phenyl), 127.8 (1C, phenyl), 129.1 (1C, phenyl), 131.6 (1C, 
phenyl), 132.0 (1C, phenyl), 132.8 (1C, phenyl), 133.2 (1C, phenyl), 137.5 (1C, CH=N), 





General method for the synthesis of compound EMAC 2056-2071 
 
Equimolar amounts of thiosemicarbazone and α-halogen keton are reacted at RT n-
propanol. The mixture is stirred for 4 to 24 hours. Then the formation of a precipitate is 
observed which is filtered. The obtained solid is washed with ethyl ether and crystallised 
from ethanol, water/ethanol. 
 



























1H-NMR (500 MHz, DMSO) δH 3.78 ( s, 3H, OCH3), 3.90 ( s, 3H, OCH3), 6.97 ( m, 2H, J: 9), 
7.15 ( s, 1H, CH thiazole), 7.19 ( d, 1H, J: 9), 7.36 ( m, 1H, Ar-CH), 7.48 (m, 2H, Ar-CH), 7.62 
( m, 2H, J:7.5, Ar-CH), 7.67 ( d, 1H, J: 8.5, J: 2.5, Ar-CH), 7.78 ( m, 2H, J: 9, Ar-CH), 8.03 ( d, 
1H, J: 2.5), 8.42 ( s, 1H, CHN), 11.45 ( brs, 1H, NH) 
 
13C-NMR (500 MHz, DMSO) δ 55.9 ( 2C, OCH3), 101.7 ( 1C, thiazole), 114.0 ( 3C, phenyl), 
122.6 ( 1C, phenyl), 122.8 ( 1C, phenyl), 126.2 ( 2C, phenyl), 127.0 ( 3C, phenyl), 127.1 ( 
1C, phenl), 129.1 ( 3C, phenyl), 132.8 ( 1C, phenyl), 137.2 ( 1C, CH=N), 139.6 ( 1C, phenyl), 
































1H-NMR (500 MHz, DMSO) δH 3.90 ( s, 3H, OCH3), 7.19 ( d, 1H, J: 8.5, Ar-CH), 7.35 ( m, 2H, 
Ar-CH), 7.48 ( m, 2H, Ar-CH), 7.55 ( s, 1H, CH thiazole), 7.62 ( m, 1H, Ar-CH), 7.66 ( d, 1H, J: 
8.5), 7.67 ( dd, 1H, 8.5), 7.84 ( dd, 1H, J: 8.5, J: 2), 8.01 ( d, 1H, J: 2.5), 8.08 ( d, 1H, J: 2), 
8.40 ( s, 1H, CH=N), 12.2 ( brs, 1H, NH). 
 
13C-NMR (500 MHz, DMSO) δ 55.9 ( 1C, OCH3), 106.0 ( 1C, thiazole), 112.5 ( 1C, phenyl), 
122.6 ( 1C, phenyl), 122.7 ( 1C, phenyl), 125.6 ( 1C, phenyl), 126.2 ( 2C, phenyl), 127.1 ( 
1C, phenyl), 127.2 ( 1C, phenyl), 129.0 ( 2C, phenyl), 129.1 ( 1C, phenyl), 129.7 ( 1C, 
phenyl), 130.9 ( 1C, phenyl), 131.4 ( 1C, phenyl), 132.8 ( 1C, phenyl), 135.2 ( 1C, phenyl), 































1H-NMR (500 MHz, DMSO) δH 3.90 ( s, 3H, OCH3), 7.19 ( d, 1H, J: 8.5, Ar-CH), 7.36 ( m, 1H, 
Ar-CH), 7.39 ( s, 1H, CH thiazole), 7.46 ( m, 2H, Ar-CH), 7.48 ( m, 2H, Ar-CH), 7.62 ( m, 2H, 
J: 7.5, Ar-CH), 7.67 ( dd, 1H, J: 8.5, J: 2.5, Ar-CH), 7.87 ( m, 2H, J: 8.5, Ar-CH), 8.02 ( d, 1H, J: 
2.5, Ar-CH), 8.40 ( s, 1H, CH=N, Ar-CH), 12.24 ( brs, 1H, NH, Ar-CH). 
 
13C-NMR (500 MHz, DMSO) δ 55.9 ( 1C, OCH3), 104.5 ( 1C, thiazole), 112.5 ( 1C, phenyl), 
122.7 ( 1C, phenyl), 122.7 ( 1C, phenyl), 126.3 ( 2C, phenyl), 127.1 ( 1C, phenyl), 127.3 ( 
2C, phenyl), 128.6 ( 2C, phenyl), 129.0 ( 2C, phenyl), 129.1 ( 1C, phenyl), 131.9 ( 1C, 
phenyl), 132.8 ( 1C, phenyl), 133.4 ( 1C, phenyl), 136.8 ( 1C, CH=N), 139.6 ( 1C, phenyl), 






























1H-NMR (500 MHz, DMSO) δH 3.90 ( s, 3H, OCH3), 7.19 ( d, 1H, J: 8.5, Ar-CH), 7.36 ( m, 1H, 
Ar-CH), 7.48 ( m, 2H, Ar-CH), 7.63 ( m, 2H, J: 7.5, Ar-CH), 7.67 ( dd, 1H, J: 8.5, J: 2.5, Ar-CH), 
7.71 ( s, 1H, thiazole), 8.02 ( d, 1H, J: 2.5, Ar-CH), 8.11 ( d, 2H, J: 9, Ar-CH), 8.27 ( d, 2H, J: 
9, Ar-CH), 8.41 ( s, 1H, CH=N), 12.32 ( brs, 1H, NH). 
 
13C-NMR (500 MHz, DMSO) δ 55.9 ( 1C, OCH3), 108.6 ( 1C, thiazole), 112.5 ( 1C, phenyl), 
122.6 ( 1C, phenyl), 122.8 ( 1C, phenyl), 124.1 ( 2C, phenyl), 126.3 ( 2C, phenyl), 126.3 ( 
2C, phenyl), 127.1 ( 1C, phenyl), 129.0 ( 2C, phenyl), 129.2 ( 1C, phenyl), 132.8 ( 1C, 
phenyl), 137.1 ( 1C, CH=N), 139.6 ( 1C, phenyl), 140.6 ( 1C, phenyl), 146.2 ( 1C, phenyl), 

































1H-NMR (500 MHz, DMSO) δH 3.78 ( s, 3H, OCH3), 3.90 ( s, 3H, OCH3), 6.50 ( bs, 1H, 
CONH2), 6.96 ( d, 2H, J: 9, Ar-CH), 7.13 ( s + d, 2H, thiazole + Ar-CH), 7.30-7.50 ( m, 8H, Ar-
CH), 7.72 ( bs, 1H, CONH2), 7.86 ( d, 1H, J: 2.5), 12.19 ( bs, 1H, NH). 
 
13C-NMR (500 MHz, DMSO) δ 55.2 ( 1C, OCH3), 55.8 ( 1C, OCH3), 106.0 ( 1C, thiazole), 
111.6 ( 1C, phenyl), 122.0 ( 1C, phenyl), 124.8 ( 1C, phenyl), 126.8 ( 1C, phenyl), 127.3 ( 
2C, phenyl), 127.6 ( 1C, phenyl), 128.6 ( 2C, phenyl), 129.3 ( 1C, phenyl), 129.7 ( 1C, 
phenyl), 130.7 ( 1C, phenyl), 131.9 ( 1C, phenyl), 133.1 ( 1C, phenyl), 133.4 ( 1C, phenyl), 
136.9 ( 1C, CH=N), 137.3 ( 1C, phenyl), 138.3 ( 1C, phenyl), 149.1 ( 1C, thiazole), 156.4 ( 




































1H-NMR (500 MHz, DMSO) δH 3.89 ( s, 3H, OCH3), 7.13 ( d, 1H, J: 9, Ar-CH), 7.32 ( bs, 1H, 
NH2), 7.37 ( m, 1H, Ar-CH), 7.39 ( m, 1H, Ar-CH), 7.41 ( m, 1H, Ar-CH), 7.49 ( m, 2H, Ar-CH), 
7.53 ( s, 1H, thiazole), 7.66 ( d, 1H, J: 8.5, Ar-CH), 7,72 ( bs, 1H, NH2), 7.83 ( dd, 1H, J: 8.5, J: 
2, Ar-CH), 7.87 ( d, 1H, J: 2.5, Ar-CH), 8.08 ( d, 1H, J: 2, Ar-CH), 8.38 ( s, 1H, CH=N), 12.21 ( 
bs, 1H, NH).  
13C-NMR (500 MHz, DMSO) δ 55.8 ( 1C, OCH3), 106.0 ( 1C, thiazole), 111.6 ( 1C, phenyl), 
122.0 ( 1C, phenyl), 124.8 ( 1C, phenyl), 125.6 ( 1C, phenyl), 126.8 ( 1C, phenyl), 127.1 ( 
1C, phenyl), 127.6 ( 1C, phenyl), 129.3 ( 1C, phenyl), 129.6 ( 1C, phenyl), 129.7 ( 1C, 
phenyl), 130.7 ( 1C, phenyl), 130.9 ( 1C, phenyl), 131.4 ( 1C, phenyl), 133.1 ( 1C, phenyl), 
135.2 ( 1C, phenyl), 136.9 ( 1C, CH=N), 137.3 ( 1C, phenyl), 138.3 ( 1C, phenyl), 147.9 ( 1C, 


































1H-NMR (500 MHz, DMSO) δH 3.89 ( s,3H, OCH3), 7.13 ( d, 1H, J: 9, Ar-CH), 7.32 ( bs, 1H, 
CONH2), 7.37 ( s, 1H, thiazole), 7.37 ( m, 1H, Ar-CH), 7.40 ( m, 1H, Ar-CH), 7.41 ( dd, 1H, 
Ar-CH), 7.44 ( m, 1H, Ar-ch), 7.46 ( m, 2H, Ar-CH), 7.49 ( m, 2H, Ar-CH), 7.72 ( bs, 1H, 
CONH2), 7.86 ( m, 2H, Ar-CH), 7.87 ( d, 1H, Ar-CH), 12.19 ( bs, 1H, NH). 
 
13C-NMR (500 MHz, DMSO) δ 55.8 ( 1C, OCH3), 106.0 ( 1C, thiazole), 111.6 ( 1C, phenyl), 
122.0 ( 1C, phenyl), 124.8 ( 1C, phenyl), 126.8 ( 1C, phenyl), 127.3 ( 2C, phenyl), 127.6 ( 
1C, phenyl), 128.6 ( 2C, phenyl), 129.3 ( 1C, phenyl), 129.7 ( 1C, phenyl), 130.7 ( 1C, 
phenyl), 131.9 ( 1C, phenyl), 133.1 ( 1C, phenyl), 133.4 ( 1C, phenyl), 136.9 ( 1C, CH=N), 
137.3 ( 1C, phenyl), 138.3 ( 1C, phenyl), 149.1 ( 1C, thiazole), 156.4 ( 1C, phenyl), 168.4 ( 

































1H-NMR (500 MHz, DMSO) δH 3.89 ( s,3H, OCH3), 7.13 ( d, 1H, J: 9, Ar-CH), 7.32 ( bs, 1H, 
CONH2), 7.38 ( m, 1H, Ar-CH), 7.40 ( m, 1H, Ar-CH), 7.41 ( dd, 1H, Ar-CH), 7.44 ( m, 1H, Ar-
CH), 7.49 ( m, 1H, Ar-CH), 7.70 ( s, 1H, thiazole), 7.73 ( bs, 1H, CONH2), 7.88 ( d, 1H, J: 2.5, 
Ar-CH), 8.11 ( m, 2H, J: 9, Ar-CH), 8.27 ( m, 2H, J: 8.5, Ar-CH), 8.39 ( s, 1H, CH=N), 12.28 ( 
bs, 1H, NH). 
13C-NMR (500 MHz, DMSO) δ 55.9 ( 1C, OCH3), 108.6 ( 1C, thiazole), 111.7 ( 1C, phenyl), 
121.9 ( 1C, phenyl), 124.1 ( 2C, phenyl), 124.8 ( 1C, phenyl), 126.3 ( 2C, phenyl), 126.8 ( 
1C, phenyl), 127.6 ( 1C, phenyl), 129.3 ( 1C, phenyl), 129.7 ( 1C, phenyl), 130.8 ( 1C, 
phenyl), 133.1 ( 1C, phenyl), 137.1 ( 1C, CH=N), 137.3 ( 1C, phenyl), 138.3 ( 1C, phenyl), 
140.7 ( 1C, phenyl), 146.2 ( 1C, phenyl), 148.5 ( 1C, thiazole), 156.5 ( 1C, phenyl), 168.7 ( 




























F F  
 
NMR: 1H-NMR (500 MHz, DMSO) δH 3.78 ( s, 3H, OCH3), 3.90 ( s, 3H, OCH3), 6.97 ( m, 2H, 
J: 8.5, Ar-CH), 7.16 ( s, 1H, thiazole), 7.18 ( d, 2H, J: 8.5, Ar-CH), 7.30 ( m, 2H, Ar-CH), 7.64 
(dd, 2H, J: 8.5, J: 2.5, Ar-CH), 7.77 ( m, 2H, J: 8.5, Ar-CH), 7.98 ( d, 1H, J: 2, Ar-CH), 8.41 ( s, 
1H, CH=N), 12.28 ( brs, 1H, NH). 
 
13C-NMR (500 MHz, DMSO) δ 55.2 ( 1C, OCH3), 55.9 ( 1C, OCH3), 101.7 ( 1C, thiazole), 
112.5 ( 1C, phenyl), 114.0 ( 2C, phenyl), 115.7 ( 1C, phenyl), 115.9 ( 1C, phenyl), 122.7 ( 
1C, phenyl), 122.7 ( 1C, phenyl), 126.9 ( 1C, phenyl), 127.0 ( 2C, phenyl), 128.2 ( 1C, 
phenyl), 128.3 ( 1C, phenyl), 129.1 ( 1C, phenyl), 131.8 ( 1C, phenyl), 136.1 ( 1C, phenyl), 
137.1 ( 1C, CH=N), 149.4 ( 1C, thiazole), 156.7 ( 1C, phenyl), 158.9 ( 1C, phenyl), 161.6 ( 






























F F  
 
1H-NMR (500 MHz, DMSO) δH 3.90 ( s, 3H, OCH3), 7.18 ( d,1H, J: 9, Ar-CH), 7.30 ( m, 2H, 
Ar-CH), 7.55 ( s, 1H, thiazole), 7.64 ( dd, 1H, Ar-CH), 7.65 ( m, 2H, Ar-CH), 7.66 ( d, 1H, Ar-
CH), 7.83 ( dd, 1H, J: 8.5, J: 2, Ar-CH), 7.97 ( d, 1H, J: 2, Ar-CH), 8.08 ( d, 1H, J: 2, Ar-CH), 
8.39 ( s,1H, CHN), 12.26 ( brs, 1H, NH). 
 
13C-NMR (500 MHz, DMSO) δ 55.9 ( 1C, OCH3), 106.0 ( 1C, thiazole), 112.5 ( 1C, phenyl), 
115.7 ( 1C, phenyl), 115.9 ( 1C, phenyl), 122.6 ( 1C, phenyl), 122.7 ( 1C, phenyl), 127.2 ( 
2C, phenyl), 128.2 ( 2C, phenyl), 129.7 ( 2C, phenyl), 130.9 ( 1C, phenyl), 131.4 ( 1C, 
phenyl), 131.8 ( 1C, phenyl), 135.2 ( 1C, phenyl), 136.1 ( 1C, phenyl), 136.9 ( 1C, CH=N), 




























F F  
 
1H-NMR (500 MHz, DMSO) δH 3.90 ( s, 3H, OCH3), 7.18 ( d, 1H, J: 8.5,Ar-CH), 7.30 ( m, 2H, 
J: 8.5, Ar-CH), 7.39 ( s, 1H, thiazole), 7.46 ( m, 2H, J: 9, Ar-CH), 7.64 ( dd, 1H, Ar-CH), 7.65 ( 
m, 2H, Ar-CH), 7.87 ( m, 2H, J: 8.5, Ar-CH), 7.97 ( d, 1H, J: 2, Ar-CH), 8.40 ( s, 1H, CHN), 
12.25 ( brs, 1H, NH). 
 
13C-NMR (500 MHz, DMSO) δ 55.9 ( 1C, OCH3), 104.6 ( 1C, thiazole), 112.5 ( 1C, phenyl), 
115.7 ( 1C, phenyl), 115.9 ( 1C, phenyl), 122.7 ( 2C, phenyl), 127.3 ( 2C, phenyl), 128.2 ( 
2C, phenyl), 128.6 ( 2C, phenyl), 129.1 .( 2C, phenyl), 131.8 ( 1C, phenyl), 132.0 ( 1C, 
phenyl), 136.1 ( 1C, phenyl), 136.8 ( 1C, CH=N), 149.1 ( 1C, thiazole), 156.7 ( 1C, phenyl), 




























F F  
 
1H-NMR (500 MHz, DMSO) δH 3.90 ( s, 3H, OCH3), 7.18 ( d, 1H, J: 8.5, Ar-CH), 7.30 ( m, 2H, 
Ar-CH), 7.65 ( m, 3H, Ar-CH), 7.72 ( s, 1H, thiazole), 7.97 ( d, 1H, J: 2.5, Ar-CH), 8.11 ( m, 
2H, J: 9, Ar-CH), 8.27 ( m, 2H, J: 9, Ar-CH), 8.40 ( s, 1H, CHN), 12.32 ( brs, 1H, NH). 
 
13C-NMR (500 MHz, DMSO) δ 55.9 ( 1C, OCH3), 108.7 ( 1C, thiazole), 112.5 ( 1C, phenyl), 
115.7 ( 1C, phenyl), 115.9 ( 1C, phenyl), 122.6 ( 1C, phenyl), 122.7 ( 1C, phenyl), 124.1 ( 
2C, phenyl), 126.4 ( 2C, phenyl), 128.2 ( 1C, phenyl), 128.3 ( 1C, phenyl), 129.1 ( 1C, 
phenyl), 131.8 ( 1C, phenyl), 136.1 ( 1C, phenyl), 137.0 ( 1C, CH=N), 140.6 ( 1C, phenyl), 
































1H-NMR (500 MHz, DMSO) δH 3.77 ( s, 3H, OCH3), 3.91 ( s, 3H, OCH3), 6.96 ( m, 2H, J: 9, 
Ar-CH), 7.11 ( s, 1H, thiazole), 7.18 ( d, 1H, J: 8.5, Ar-CH), 7.32 ( m, 1H, Ar-CH), 7.40 ( dd, 
1H, J: 9, Ar-CH), 7.42 ( m, 1H, J: 9.5, Ar-CH), 7.48 ( m, 2H, Ar-CH), 7.75 ( m, 1H, Ar-CH), 
7.76 ( m, 1H, Ar-CH), 7.81 ( d, 1H, J: 2.5), 8.41 ( s, 1H, CH=N), 12.25 ( brs, 1H, NH).  
 
13C-NMR (500 MHz, DMSO) δ 55.1 ( 1C, OCH3), 55.9 ( 1C, OCH3), 101.6 ( 1C, thiazole), 
111.7 ( 1C, phenyl), 114.0 ( 1C, phenyl), 121.9 ( 1C, phenyl), 122.0 ( 1C, phenyl), 124.8 ( 
1C, phenyl), 125.5 ( 1C, phenyl), 127.0 ( 2C, phenyl), 127.6 ( 1C, phenyl), 128.1 ( 1C, 
phenyl), 129.3 ( 1C, phenyl), 131.4 ( 1C, phenyl), 131.5 ( 1C, phenyl), 132.9 ( 1C, phenyl), 
133.1 ( 1C, phenyl), 136.8 ( 1C, CH=N), 141.2 ( 1C, phenyl), 149.5 ( 1C, thiazole), 156.6 ( 

































1H-NMR (500 MHz, DMSO) δH 3.91 ( s, 3H, OCH3), 7.18 ( d, 1H, J: 9, Ar-CH), 7.32 ( m, 1H, 
Ar-CH), 7.40 ( dd, 1H, J: 9, J: 2.5, Ar-CH), 7.42 ( m, 1H, J: 7.5, J: 2, Ar-CH), 7.47 ( m,1H, Ar-
CH) 7.51 ( s,1H thiazole), 7,56 ( d, 1H, J: 8.5, Ar-CH), 7.75 ( m, 1H, J:6.5, J: 1.5, Ar-CH), 7.80 
( d, 1H, J: 2.5, Ar-CH), 7.82 ( dd, 1H, J: 6.5, J: 2, Ar-CH), 8.07 ( d, 1H, J: 2, Ar-CH), 8.39 ( 
s,1H, CH=N), 12.24 ( bs,1H, NH). 
 
13C-NMR (500 MHz, DMSO) δ 55.9 ( 1C, OCH3), 106.0 ( 1C, thiazole), 111.7 ( 1C, phenyl), 
121.9 ( 1C, phenyl), 122.0 ( 1C, phenyl), 125.5 ( 1C, phenyl), 125.6 ( 1C, phenyl), 127.1 ( 
1C, phenyl), 128.1 ( 1C, phenyl), 129.3 ( 1C, phenyl), 129.7 ( 1C, phenyl), 130.9 ( 1C, 
phenyl), 131.4 ( 1C, phenyl), 131.4 ( 1C, phenyl), 131.5 ( 1C, phenyl), 132.9 ( 1C, 
phenyl),133.1 ( 1C, phenyl), 135.2 ( 1C, phenyl), 136.7 ( 1C, CH=N), 141.2 ( 1C, phenyl), 































1H-NMR (500 MHz, DMSO) δH 3.91 ( s, 3H, OCH3), 7.18 ( d, 1H, J: 8.5, Ar-CH), 7.32 ( m, 1H, 
Ar-CH), 7.35 ( s, 1H, thiazole), 7.40 ( dd, 1H, J: 8.5, J: 2.5, Ar-CH), 7.42 ( m, 1H, Ar-CH), 7.45 
( m, 2H, J: 8.5, Ar-CH), 7.48 ( m, 1H, J: 1.5, Ar-CH), 7.75 ( m, 1H, J: 8, J: 2, Ar-CH), 7.8 ( d, 
1H, J: 2, Ar-CH), 7.85 ( m, 2H, J: 8.5, J: 2, Ar-CH), 8.4 ( s,1H, CH=N), 12.21 ( bs,1H, NH). 
 
13C-NMR (500 MHz, DMSO) δ 55.9 ( 1C, OCH3), 104.5 ( 1C, thiazole), 111.7 ( 1C, phenyl), 
121.9 ( 1C, phenyl), 122.0 ( 1C, phenyl), 125.5 ( 1C, phenyl), 127.2 ( 2C, phenyl), 128.1 ( 
1C, phenyl), 128.6 ( 2C, phenyl), 129.3 ( 1C, phenyl), 131.4 ( 1C, phenyl),131.5 ( 1C, 
phenyl), 131.9 ( 1C, phenyl), 131.9 ( 1C, phenyl), 133.1 ( 1C, phenyl), 133.4 ( 1C, phenyl), 
































1H-NMR (500 MHz, DMSO) δH 3.91 ( s, 3H, OCH3), 7.18 ( d, 1H, J: 8.5, Ar-CH), 7.32 ( m, 1H, 
Ar-CH), 7.40 ( dd, 1H, J: 8.5, J: 2.5, Ar-CH), 7.42 ( m, 1H, Ar-CH), 7.48 ( m, 1H, Ar-CH), 7.68 ( 
s, 1H, thiazole), 7.75. ( m, 1H, J: 8, J: 1, Ar-CH), 7.81 ( d, 1H, J: 2.5, Ar-CH), 8.10 ( m, 2H, J: 
9, Ar-CH), 8.26 ( m, 2H, J: 8.5, Ar-CH), 8.40 ( s, 1H, CH=N), 12.32 ( bs, 1H, NH). 
 
13C-NMR (500 MHz, DMSO) δ 55.9 ( 1C, OCH3), 108.6 ( 1C, thiazole), 111.7 ( 1C, phenyl), 
121.9 ( 1C, phenyl), 122.0 ( 1C, phenyl), 124.1 ( 2C, phenyl), 125.5 ( 1C, phenyl), 126.3 ( 
2C, phenyl), 128.1 ( 1C, phenyl), 129.3 ( 2C, phenyl), 131.4 ( 1C, phenyl), 132.9 ( 1C, 
phenyl), 133.1 ( 1C, phenyl), 136.8 ( 1C, CH=N), 140.6 ( 1C, phenyl), 141.2 ( 1C, phenyl), 








































R: 4-Cl, 4-F, 4-Br, 4-NO2, 4-C6H5, 4-CN, 2,4-F, 3-NO2, 4-CH3, 4-OCH3, H, 2,4-Cl  
 
Scheme 7. Synthesis of (Z)-3-(2-(4-arylthiazol-2-yl)hydrazono)indolin-2-one derivatives 
EMAC 2072-2083. Reagents: (i) 2-propanol, AcOH; (iii) 2-propanol, R.T. 
 
Indolinone derivative were synthesized by a multi step reaction.  
The first synthetic step leads to the formation of 1-(2-oxoindolin-3-
ylidene)thiosemicarbazide by reacting isatin and thiosemicarbazide in 2-propanol and 
acid acetic as catalyst.  
In the second step, the thiazole ring is formed by reaction between 1-(2-oxoindolin-
3-ylidene)thiosemicarbazide and differently substituted α-halogen-acetophenones as 
outlined in the scheme. 
 
NMR spectra were measured during my research period at the Semmelweis 
University in Budapest under the supervision of Prof. Peter Matyus. 
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All samples were measured in DMF-d7 solvent at 278.1 K temperature on a Bruker 
AVANCE III spectrometer. In the signal assignments the proton and carbon chemical shifts 
are referred to the solvent (1H: δ = 8.03 ppm, 13C dowfield methyl signal: δ=34.89 ppm 
respectively). In the 15N chemical shift assignments we applied the spectrometer’s digital 
reference which is calibrated to liq. NH3 δ= 0 ppm. 
For all investigated compound Z configuration was supported by NMR.  
This was based on the selective NOE experiments, where we observed NOE 
interaction between the indole NH and CH protons, while no correlation was seen 
between the indole CH and =N-NH- hydrogens. 
The geometry of the C=N double bond was defined by NOE experiments. In the case 




In our compounds only the NOE effect related to the indolinone protons was 
measured indicating that the proton in the position 4 of the indolinone ring and the 
hydrazine proton are too far to interact.  
This distance is only possible if the configuration is “Z”. (figure B) 
 
All synthesized compounds were characterised by analytical and spectral data as 
listed in Table 21 and 22. 
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Compound R M.W. Mp (C°) % Yield 
EMAC 2072 4-Cl 354.81 >250 73 
EMAC 2073 4-F 338.36 >250 57 
EMAC 2074 4-Br 399.26 >250 95 
EMAC 2075 4-NO2 365.37 >250 84 
EMAC 2076 4-C6H5 396.46 >250 96 
EMAC 2077 4-CN 345.38 >250 99 
EMAC 2078 2,4-F 356.35 >250 66 
EMAC 2079 3-NO2 365.37 >250 86 
EMAC 2080 4-CH3 334.39 >250 72 
EMAC 2081 4-OCH3 350.39 >250 84 
EMAC 2082 H 320.37 250 92 
EMAC 2083 2,4-Cl 389.26 >250 90 
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1H NMR (DMF) δ(ppm): 12.72 (s; 1H); 11.34 (s; 1H); 9.21 (s; 1H); 9.05 (s; 1H); 7.66-7.64 (m; 
1H); 7.42-7.34 (m; 1H); 7.17-7.10 (m; 1H); 7.06-7.02 (m; 1H) 
 
13C NMR (DMF) δ(ppm): 180.1; 163.3; 143.1; 132.4; 131.6; 122.8; 121.1; 120.7; 111.5 
 
























































1H NMR (DMF) δ(ppm): 13.55 (s, 1H); 11.43 (s; 1H); 8.07-8.02 (m; 2H); 7.82 (s; 1H); 7.63 
(dm; J=7.6 Hz; 1H); 7.58-7.53 (m; 2H); 7.41 (td; J=7.6 Hz; 1.1 Hz; 1H); 7.16 (td; J=7.6 Hz; 
1.0 Hz; 1H); 7.10 (dm; J=7.6 Hz; 1H) 
 
13C NMR (DMF) δ(ppm): 166.9; 164.0; 150.6; 142.1; 133.6; 133.1; 132.7; 130.9; 129.2; 
127.9; 122.8; 120.5; 120.3; 111.5; 107.7 
 
































































The NMR analysis supports a mixture of two tautomers:  
 
The major compound is: 
 
1H NMR (DMSO) δ(ppm): 13.33 (s; 1H); 11.25 (s; 1H); 7.97-7.90 (m; 2H); 7.60 (s; 1H); 7.53 
(dm; J: 7.5 Hz; 1H); 7.34 (tm; J: 7.5 Hz; 1H); 7.29-7.17 (m; 2H); 7.09 (tm; J: 7.5 Hz; 1H); 
6.99-6.92 (m; 1H) 
 
13C NMR (DMSO) δ(ppm): 166.4; 163.2; 161.9 (d; J= 244.6 Hz); 150.0; 141.3; 132.2; 130.6; 
130.5; 127.8 (d; J= 8.3 Hz) 122.4; 119.9; 119.8; 115.6 (d; J= 21.6 Hz); 111.1; 106.6  
 






































The minor compound is: 
 
1H NMR (DMSO) δ(ppm): 9.85 (s; 1H); 8.19 (dm; J: 7.4 Hz; 1H); 7.97-7.90 (m; 2H); 7.29-
7.17 (m; 2H); 7.15 (s; 1H); 6.99-6.92 (m; 1H); 6.86 (td; J: 7.5 Hz; 1.0 Hz; 1H); 6.72 (dm; J: 
7.5 Hz; 1H) 
 
13C NMR (DMSO) δ(ppm): 182.9; 166.5; 161.4 (d; J: 244.0 Hz); 149.2; 138.1; 132.2; 127.4 
(d; J: 8.0 Hz); 126.9; 124.6; 122.6; 120.0; 120.0; 115.3 (d; J: 21.3 Hz); 107.9; 104.4 
 
































































1H NMR (DMF) δ(ppm): 13.53 (s; 1H); 11.42 (s; 1H); 7.99-7.93 (m; 2H); 7.82 (s; 1H); 7.71-
7.65 (m; 2H); 7.61 (dm; J: 7.6 Hz; 1H); 7.39 (tm; J: 7.6 Hz; 1H); 7.14 (tm; J: 7.6 Hz; 1H); 7.08 
(dm; J: 7.6 Hz; 1H) 
 
13C NMR (DMF) δ(ppm): 167.0; 164.0; 150.7; 142.1; 133.9; 132.7; 132.1; 130.9; 128.1; 
122.8; 121.6; 120.5; 120.3; 111.5; 107.8 
 
































































1H NMR (DMF) δ(ppm): 13.55 (s; 1H); 11.42 (s;1H); 8.38-8.32 (m; 2H); 8.30-8.24 (m; 2H); 
8.12 (s; 1H); 7.62 (dm; J: 7.7 Hz; 1H); 7.40 (td; J: 7.7 Hz; 1.2 Hz; 1H); 7.15 (td; J: 7.7 Hz; 0.7 
Hz; 1H); 7.08 (dm; J: 7.7 Hz; 1H) 
 
13C NMR (DMF) δ(ppm): 167.3; 163.9; 149.7; 147.2; 142.2; 140.7; 133.1; 131.1; 127.0; 
124.5; 122.9; 120.4; 120.3; 111.6; 111.6 
 































































1H NMR (DMF) δ(ppm): 13.56 (s; 1H); 11.41 (s; 1H); 8.13-8.08 (m; 2H); 7.85-7.75 (m; 5H); 
7.63 (d; J: 7.6 Hz; 1H); 7.55-7.49 (m; 2H); 7.44-7.36 (m; 2H); 7.15 (tm; J: 7.6 Hz; 1H); 7.08 
(dm; J: 7.6 Hz; 1H) 
 
13C NMR (DMF) δ(ppm): 166.8; 164.0; 151.6; 142.1; 140.4; 140.3; 133.8; 132.6; 130.9; 
129.4; 127.9; 127.4; 127.0; 126.7; 122.8; 120.5; 120.2; 111.5; 107.1 
 






































































1H NMR (DMF) δ(ppm): 13.54 (s; 1H); 11.42 (s; 1H); 8.23-8.17 (m; 2H); 8.04 (s; 1H); 7.97-
7.93 (m; 2H); 7.62 (d; J: 7.6 Hz; 1H); 7.40 (tm; J: 7.6 Hz; 1H); 7.15 (tm; J: 7.6 Hz; 1H); 7.08 
(d; J: 7.6 Hz; 1H) 
 
13C NMR (DMF) δ(ppm): 167.2; 163.9; 150.1; 142.2; 138.8; 133.2; 133.0; 131.0; 126.8; 
122.9; 120.4; 120.3; 119.3; 111.6; 110.8; 110.6 
 


































































1H NMR (DMF) δ(ppm): 13.52 (s; 1H); 11.39 (s; 1H); 8.23-8.14 (m; 1H); 7.62 (d; J: 7.6 Hz; 
1H); 7.58(d; J: 2.4 Hz; 1H); 7.45-7.36 (m; 2H); 7.25 (td; J: 8.5 Hz; 2.5 Hz; 1H); 7.15 (td; J: 7.6 
Hz; 0.7 Hz; 1H); 7.07 (dm; J: 7.6 Hz; 1H) 
 
13C NMR (DMF) δ(ppm): 166.4; 164.0; 162.3 (dd; J: 248.0 Hz; 12.4 Hz); 160.4 (dd; J: 251.9 
Hz; 12.3 Hz); 144.7 (dd; J: 2.6 Hz; 0.9 Hz); 142.1; 132.8; 131.2 (dd; J: 9.6Hz; 4.8 Hz); 131.0; 
122.9; 120.5; 120.3; 119.1 (dd; J: 11.3Hz; 3.7 Hz); 112.3 (dd; J: 21.4Hz; 3.4 Hz); 111.5; 
111.2 (d; J: 15.0 Hz); 104.9 (t; J: 26.5 Hz) 
 
15N NMR (DMF) δ(ppm): 155.9; 135.5 
 




































































1H NMR (DMF) δ(ppm): 13.57 (s; 1H); 11.41 (s; 1H); 8.84-8.76 (m; 1H); 8.46 (dm; J: 8.1 Hz; 
1H); 8.26 (dm; J: 8.1 Hz; 1H); 8.09 (s; 1H); 7.80 (t; J: 8.1 Hz; 1H); 7.63 (d; J: 7.6 Hz; 1H); 
7.41 (tm; J: 7.6 Hz; 1H); 7.15 (tm; J: 7.6 Hz; 1H); 7.08 (dm; J: 7.6 Hz; 1H)  
 
13C NMR (DMF) δ(ppm): 167.3; 164.0; 149.5; 149.0; 142.2; 136.3; 133.0; 132.2; 131.0; 
130.7; 122.9; 122.9; 120.6; 120.4; 120.3; 111.5; 109.6 
 



































































1H NMR (DMF) δ(ppm): 13.53 (s; 1H); 11.38 (s; 1H); 7.91-7.86 (m; 2H); 7.66 (s; 1H); 7.62 
(d; J: 7.6 Hz; 1H); 7.39 (td; J: 7.6 Hz; 1.2 Hz; 1H); 7.30-7.25 (m; 2H); 7.15 (td; J: 7.6 Hz; 0.8 
Hz; 1H); 7.07 (dm; J: 7.6 Hz; 1H); 2.35 (s; 3H) 
 
13C NMR (DMF) δ(ppm): 166.6; 164.0; 152.0; 142.0; 138.0; 132.4; 132.1; 130.8; 129.7; 
126.1; 122.8; 120.5; 120.2; 111.5; 106.0; 20.8 
 

































































1H NMR (DMF) δ(ppm): 13.53 (s; 1H); 11.40 (s; 1H); 7.95-7.91 (m; 2H); 7.63-7.59 (dm; J: 
7.7 Hz; 1H); 7.56 (s; 1H); 7.39 (td; J: 7.7 Hz; 1.1 Hz; 1H); 7.15 (td; J: 7.7 Hz; 1.0 Hz; 1H); 
7.08 (dm; J: 7.7 Hz; 1H); 7.06-7.02 (m, 2H); 3.85 (s; 3H) 
 
13C NMR (DMF) δ(ppm): 166.6; 164.0; 159.9; 151.8; 142.0; 132.4; 130.8; 127.5; 127.5; 
122.8; 120.5; 120.2; 114.3; 111.5; 104.7; 55.3 
 






























































1H NMR (DMF) δ(ppm): 13.54 (s; 1H); 11.41 (s; 1H); 8.01-7.97 (m; 2H); 7.74 (s; 1H); 7.62 
(dm; J: 7.7 Hz; 1H); 7.49-7.44 (m; 2H); 7.42-7.34 (m; 2H); 7.17-7.10 (m; 1H); 7.08 (dm; J: 
7.7 Hz; 1H) 
 
13C NMR (DMF) δ(ppm): 166.8; 164.0; 151.9; 142.1; 134.7; 132.6; 130.9; 129.1; 128.3; 
126.1; 122.8; 120.5; 120.2; 111.5; 106.9 
 


































































1H NMR (DMF) δ(ppm): 13.51 (s; 1H); 11.39 (s; 1H); 8.05 (d; J: 8.5 Hz; 1H); 7.85 (s; 1H); 
7.75 (d; J: 2.2 Hz; 1H); 7.63 (dm; J: 7.6 Hz; 1H); 7.58 (dd; J: 8.5 Hz; 2.2 Hz; 1H); 7.40 (td; J: 
7.6 Hz; 1.2 Hz; 1H); 7.15 (td; J: 7.6 Hz; 1.0 Hz; 1H); 7.07 (dm; J: 7.6 Hz; 1H) 
 
13C NMR (DMF) δ(ppm): 166.1; 164.0; 147.1; 142.1; 133.6; 132.6; 132.9; 132.2; 132.1; 
131.0; 130.4; 128.1; 122.9; 120.5; 120.3; 112.9; 111.5 
 










































COMPOUNDS EMAC 2084-2096 
 




































R: 4-Cl, 4-F, 4-Br, 4-NO2, 4-C6H5, 4-CN, 2,4-F, 3-NO2, 3,4-Cl,  4-CH3, 4-OCH3, H, 2,4-Cl  
 
Scheme 8. Synthesis of 3-(2-(4-arylthiazol-2-yl)hydrazono)5-nitroindolin-2-one derivatives 
EMAC 2084-2096. Reagents: (i) 2-propanol, AcOH; (iii) 2-propanol, R.T. 
 
5-nitroindolinone derivative were synthesized by a multi step reaction.  
The first synthetic step leads to the formation of 1-(5-nitro-2-oxoindolin-3-
ylidene)thiosemicarbazide by reacting 5-nitroisatin with thiosemicarbazide in 2-propanol 
and catalytic amount of AcOH.  
In the second step, the thiazole ring is formed by reaction between 1-(5-nitro-2-
oxoindolin-3-ylidene)thiosemicarbazide and differently substituted α-halogen-
acetophenones as outlined in Scheme 8. 
 
All synthesized compounds were characterised by analytical and spectral data as 

















Compound R M.W. Mp (C°) % Yield 
EMAC 2084 4-Cl 399.81 >250 63 
EMAC 2085 4-F 383.36 >250 56 
EMAC 2086 4-Br 444.26 >250 61 
EMAC 2087 4-NO2 410.36 >250 67.5 
EMAC 2088 4-C6H5 441.46 >250 69.5 
EMAC 2089 4-CN 390.38 >250 69.3 
EMAC 2090 2,4-F 401.35 >250 66 
EMAC 2091 3-NO2 410.36 >250 43 
EMAC 2092 3,4-Cl 434.26 >250 50 
EMAC 2093 4-CH3 379.39 >250 69 
EMAC 2094 4-OCH3 395.39 >250 72 
EMAC 2095 H 365.37 >250 63 
EMAC 2096 2,4-Cl 434.26 >250 54 
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EMAC 2092 3,4-Cl 2-propanol Water/Ethanol Yellow solid 24 




EMAC 2094 4-OCH3 2-propanol Water/Ethanol Red-orange solid 24 































M.W.: 265.25 g/mol; R.f.: 0.28 (exane-ethylacetate 1:1); M.P.: >250°C; Yield: 97% 




























1H-NMR (500 MHz, DMSO) δH  7.11 ( d, 1H, J: 8.5, Ar-CH), 7.48 ( d, 1H, J: 8.5, Ar-CH), 7.76 
( s, 1H, thiazole), 7.87 ( d, 2H, J: 9, Ar-CH), 7.92 ( d, 2H, J: 9, Ar-CH), 8.6 ( s, 1H, Ar-CH), 































1H-NMR (500 MHz, DMSO) δH 7.11 (d, 1H, J: 8.5, Ar-CH), 7.48 (d, 1H, J: 8.5, Ar-CH), 7.35 
(d, 2H, J: 9, Ar-CH), 7.69 (s, 1H, thiazole), 8.25 (d, 2H, J: 9, Ar-CH), 8.6 (s, 1H, Ar-CH), 12.22 




























1H-NMR (500 MHz, DMSO) δH 7.12 (d, 1H, J: 8.5, Ar-CH), 7.50 (d, 1H, J: 8.5, Ar-CH), 7.77 
(s, 1H, thiazole), 7.86 (d, 2H, J: 9, Ar-CH), 8.22 (d, 2H, J: 9, Ar-CH), 8.6 (s, 1H, Ar-CH), 12.22 































1H-NMR (500 MHz, DMSO) δH 7.2 (d, 1H, J: 8.5, Ar-CH), 7.52 (d, 1H, J: 8.5, Ar-CH), 8.15 (s, 
1H, thiazole), 8.37 (d, 2H, J: 9; Ar-CH), 8.45 (d, 2H, J: 9, Ar-CH), 8.62 (s, 1H, Ar-CH), 12.25 


























1H-NMR (500 MHz, DMSO) δH 7.21 (d, 1H, J: 8.5, Ar-CH), 7.22 (t, 1H, Ar-CH), 7.32 (d, 2H, 
Ar-CH), 7.48 (m, 3H, Ar-CH), 7.54 (m, 4H, Ar-CH), 7.77 (s, 1H, thiazole), 8.6 (s, 1H, Ar-CH), 
































1H-NMR (500 MHz, DMSO) δH 7.11 (d, 1H, J: 8.5, Ar-CH), 7.48 (d, 1H, J: 8.5, Ar-CH), 8.05 
(s, 1H, thiazole), 8.00 (d, 2H, J: 9, Ar-CH), 8.22 (d, 2H, J: 9, Ar-CH), 8.06 (s, 1H, Ar-CH), 































1H-NMR (500 MHz, DMSO) δH 7.11 (d, 1H, J: 8.5, Ar-CH), 7.35 (d, 1H, J: 8.5, Ar-CH), 7.45 
(s, 1H, Ar-CH), 7.48 (d, 1H, J: 8.5, Ar-CH), 7.6 (s, 1H, thiazole), 8.28 (d, 1H, J: 8.5, Ar-CH), 






























1H-NMR (500 MHz, DMSO) δH 7.11 (d, 1H, J: 8.5, Ar-CH), 7.48 (d, 1H, J: 8.5, Ar-CH), 7.90 (t, 
1H, J: 8, Ar-CH), 8.1 (s, 1H, thiazole), 8.36 (d, 1H, J: 8, Ar-CH), 8.56 (d, 1H, J: 8, Ar-CH), 8.6 































1H-NMR (500 MHz, DMSO) δH 7.11 (d, 1H, J: 8.5, Ar-CH), 7.48 (d, 1H, J: 8.5, Ar-CH), 7.67 
(d, 1H, J: 8, Ar-CH), 7.72 (s, 1H, thiazole), 8.15 (d, 1H, J: 8, Ar-CH), 8.4 (s, 1H, Ar-CH), 8.6 (s, 































1H-NMR (500 MHz, DMSO) δH 2.35 (s, 3H, CH3), 7.11 (d, 1H, J: 8.5, Ar-CH), 7.37 (d, 2H, J: 9, 
Ar-CH), 7.48 (d, 1H, J: 8.5, Ar-CH), 7.76 (s, 1H, thiazole), 7.94 (d, 2H, J: 9, Ar-CH), 8.6 (s, 1H, 




























1H-NMR (500 MHz, DMSO) δH 3.85 (s, 3H, OCH3), 7.11 (d, 1H, J: 8.5, Ar-CH), 7.14 (d, 2H, J: 
8.5, Ar-CH), 7.48 (d, 1H, J: 8.5, Ar-CH), 7.66 (s, 1H, thiazole), 8.03 (d, 2H, J: 8.5, Ar-CH), 8.6 





























1H-NMR (500 MHz, DMSO) δH 7.11 (d, 1H, J: 8.5, Ar-CH), 7.47 (t, 1H, J: 8.5, Ar-CH), 7.48 (d, 
1H, J: 8.5, Ar-CH), 7.57 (d, 2H, J: 9, Ar-CH), 7.84 (s, 1H, thiazole), 8.1 (d, 2H, J: 9, Ar-CH), 8.6 




























1H-NMR (500 MHz, DMSO) δH 7.11 (d, 1H, J: 8.5, Ar-CH), 7.48 (d, 1H, J: 8.5, Ar-CH), 7.68 
(d, 1H, J: 8.5, Ar-CH), 7.85 (s, 1H, Ar-CH), 7.86 (s, 1H, thiazolo), 8.15 (d, 1H, J: 8.5, Ar-CH), 







Protein expression and purification 
 
The recombinant HIV-1 RT protein, whose coding gene was subcloned in the 
p6HRT_prot plasmid, was expressed in E. coli strain M15. [207, 210]  
The bacteria cells were grown up to an optical density (OD600) of 0.8 and induced 
with 1.7 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for 5 hrs.  
HIV-1 RT purification was carried out as described [211]. Briefly, cell pellets were 
resuspended in Lyses Buffer (20 mM 4-(2-hydroxyethyl)-1-piperazineethanesolfonic acid 
(Hepes) pH 7.5, 0.5 M NaCl, 5 mM β-mercaptoethanol, 5 mM imidazole, 0.4 mg/mL 
lysozime), incubated on ice for 20 min, sonicated and centrifuged at 30,000 x g for 1 hr.  
The supernatant was applied to a His-binding resin column and washed thoroughly 
with wash buffer (20 mM Hepes pH 7.5, 0.3 M NaCl, 5 mM β-mercaptoethanol, 60 mM 
imidazole, 10% glycerol).  
RT was eluted by imidazole gradient and the enzyme-containing fractions were 
pooled, dialyzed and aliquots were stored at –80 °C.  
 
RNase H polymerase-independent cleavage assay 
 
The HIV-1 RT associated RNase H activity was measured as described [200] in 100 µL 
reaction volume containing 50 mM Tris-HCl pH 7.8, 6 mM MgCl2, 1 mM dithiothreitol 
(DTT), 80 mM KCl, hybrid RNA/DNA (5’-GTTTTCTTTTCCCCCCTGA C-3’-Fluorescein, 5’-
CAAAAGAAAAGG GGGGACUG-3’-Dabcyl) and 3.8 nM RT. The reaction mixture was 
incubated for 1 hr at 37 °C. The enzymatic reaction is stopped with the addition to EDTA 
and measured with Victor3 (Perkin) at 490/528 nm.  
 
DNA polymerase assay 
 
The HIV-1 RT associated (RDDP) activity was measured using Invitrogen EnzCheck 
Reverse Transcriptase Assay Kit, in 50 µL volume containing 60 mM Tris-HCl pH 8.1, 8 mM 
MgCl2, 60 mM KCl, 13 mM Dithiothreitol, 100 µM dTTP, 2 nM HIV-1 RT and poly(A)-
oligo(dT). The reaction mixture was incubated for 30 minutes at 37°C. The enzymatic 
reaction is stopped with the addition to EDTA and measured with Victor3 (Perkin) at 
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1.1 Historical overview 
 
The range of human infections caused by the yeast C. albicans and several related 
species (spp.) is considerable.  
They range from relatively trivial conditions such as oral and genital thrush to fatal, 
systemic infections in patients who are already seriously ill with other diseases. In recent 
years there has been an increasing interest in Candida infections and in C. albicans in 
particular because fatal infections have become more prevalent and new Candida 
associated disorders have been recognized. 
The medical importance of Candida infections and the scientific value of C. albicans 
as a model for fungal cellular development have stimulated advances in our 
understanding of the epidemiology of candidosis, the pathogenesis of the disease and the 
genetics and biochemistry of C. albicans. 
Oral candidal infections appear to have been described as early as the 2
nd
 century 
AD by GALEN, who described as aphthas albus. 
It was not until the mid-19th century that the clinical nature of oral candidosis (syn. 
oral candidiasis) was defined and the etiologic agent identified. [1] 
There have been a wide variety of synonyms used for members of the genus 
Candida, 166 synonyms being recognized for C. albicans worldwide. [2] 
The genus Candida is within the class Deuteromycetes and has been described as a 
"taxonomic pit" into which yeasts without a known sexual stage or other remarkable 
phenotypic character have been thrown. [3] Its members are biologically diverse and 
include yeasts with ascomycetous and basidiomycetous affinities. 
There are currently between 150 and 200 species recognized in the genus. [3] 
The genus Candida includes characteristically white asporogenous (imperfect) 
yeasts capable of forming pseudohyphae. 
Within the genus, species are characterized primarily by colonial morphology, 
carbon utilization, and fermentation. [4] 
There are seven Candida spp. of major medical importance, the most important 
being C. albicans, the one most frequently isolated. It is believed to be the most virulent 
in man. 
The other Candida spp. encountered in human infections are C. tropicalis, C. 
glabrata, C. parapsilosis, C. stellatoidea, C. krusei, and C. kyfer. [1] 
Due to the relatively high DNA homology between C. albicans and C. stellatoidea, 
the latter has been reclassified as a sucrose-negative variant of C. albicans. [5] 
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A study has shown that there are two distinct types of sucrose-negative C. albicans, 
identified as C. stellatoidea types I and II. [6] 
In a more detailed analysis, these authors have concluded that type II is a sucrose-
negative mutant of C. albicans, whereas type I is indistinguishable from C. albicans. [7] 
C. albicans is a dimorphic yeast and is believed to be an obligate associate of warm-
blooded animals. 
In a review of the biology and genetics of C. albicans [4], it was shown that this 
species are an imperfect yeast having no sexual cycle. It is diploid, having lost the ability 




It has been postulated that most people usually carry a single strain of Candida at 
different body sites for a long time. [3] 
However, it has been shown that a few individuals may harbour more than one 
strain or species of Candida at the same time, and that in hospitalized and 
immunocompromised patients this occurs more commonly. [3] 
The intraoral commensal existence of Candida occurs in at least 50% of the 
population, and if sensitive enough tests were developed, possibly more than 90% of 
healthy individuals would be shown to carry this organism. [3] 
The gastrointestinal (GI) tract is believed to be the major habitat of the commensal 
Candida spp. The wide variation in the types of patients analysed and methods used in 
the analysis of the carriage rate of various sites in the GI tract allows the conclusion that 
Candida spp. are very common gut commensals. [3] 
It has been shown that, if present in sufficiently high numbers, C. albicans can 
spread from the human gut, causing fungaemia and funguria [8], and it is thought that the 
gut is the ultimate source of most forms of Candida infection. [3] 
It has been previously reported that the prevalence and density of C. albicans 
are greater in edentulous patients who wear dentures and who have erythematous 
candidosis than in normal subjects, suggesting that dentures may encourage the growth 
of Candida. 
However, it has been found that, although the occurrence of C. albicans was greater 
in these patients than in healthy controls, there was no difference in the concentration of 
C. albicans when present in these groups. [9] 
These authors [9] showed that it was not possible to equate specific numbers of 
Candida with health and disease, as previously proposed. [10] 
Oral candidosis in all groups of patients has been classified into four main 




Candida induced angular cheilitis was included as another category when the 
association between this particular lesion and its infective etiology was determined. [12] 
The advent of the association of oral candidosis and human immunodeficiency virus 
(HIV) infection has resuited in a modification of this terminology. [13,14] 
In particular, the term "atrophic" has been replaced by the term "erythematous" 
because "erythematous" describes the clinical picture whereas "atrophic" describes the 
histologic picture. 
Furthermore, as lesions are nearly always chronic in HIV infected patients, the 
terms "acute" and "chronic" seem unnecessary. 
 
3 Current Therapy 
 
Invasive fungal infection is a leading cause of morbidity and mortality among 
immunocompromised and debilitated patients, including those with hematological 
malignancy, solid organ or bone marrow transplantation, and neutropenia and those 
receiving systemic corticosteroid therapy. 
Candida species and Aspergillus species are the two predominant causative fungi, 
with the case fatality rates being 30% and 50% among those infected with members of 
these two fungal genera, respectively. [15,16] 
Over the past few decades, amphotericin B has been the mainstay treatment of 
candidiasis and aspergillosis, whereas fluconazole has been extensively used among 
patients with Candida albicans infection.  
After randomized controlled trials showed that extended-spectrum azoles 
(itraconazole, voriconazole, posaconazole) and echinocandins (anidulafungin, 
caspofungin, micafungin) had efficacies similar to those of amphotericin B and 
fluconazole, these newer antifungal agents have been used more frequently for the 
treatment of patients with probable or proven invasive fungal infection. [17-21] 
Current practice guidelines recommend amphotericin B formulations, fluconazole, 
and echinocandins as first-line therapy for patients with candidemia; and amphotericin B 
formulations or voriconazole are the drugs of choice for the primary therapy of invasive 
aspergillosis. [18-21] 
For patients who fail the primary therapy or who have intolerable adverse 
reactions, the common practice is to switch to a different class of antifungal agents. 
[22,23] 
With regard to the safety of antifungal therapies, amphotericin B desoxycholate is 
known for its infusion-related adverse effects and nephrotoxicity; approximately 30% of 
patients developed abnormal renal function, and treatment was discontinued in 5% of 
patients because of toxicity. [24,25] 
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Other amphotericin B formulations, including amphotericin B colloidal dispersion, 
amphotericin B lipid complex, liposomal amphotericin B (Ambisome), and other, newer 
antifungal agents, are associated with substantially fewer infusionrelated and nephrotoxic 
events. 
However, hepatotoxic reactions to antifungal agents were increasingly reported and 
ranged from mild and asymptomatic abnormalities in liver function test results to 
potentially fatal fulminant hepatic failure. [26-31] 
While individual reviews of new antifungal agents have been published [32-43], 
there has been no systematic evaluation of the toxicity associated with these treatments. 
Nevertheless we have a rich armamentarium of antifungal agents as schematized in 
Table 1. 
Table 1. Currently available antifungal drugs 
 
IMIDAZOLES 
TOPICAL: Bifonazole; Butoconazole; 
Clomidazole#; Clomitrazole; Croconazole; 
Econazole; Fenticonazole; Ketoconazole; 
Isoconazole; Miconazole#; Neticonazole; 
Omoconazole; Oxiconazole; Sertaconazole; 
Sulconazole; Tioconazole 
TRIAZOLES 
TOPICAL: Fluconazole#; Fosfluconazole; 
Terconazole 
SYSTEMIC: Fluconazole; Hexaconazole; 
















TOPICAL: Hamycin; Natamycin; Nystatin# 












ECHINOCANDINS: Anidafungin, Caspofungin;Micafungin 
Pyrimidine analogues / 
Thymidylate synthase inhibitors 
Flucytosine# 
Intracellular 
Mitotic inhibitors Griseofulvin# 
Others 
Bromochlorosalicylanilide;Methylrosaniline; Tribromometacresol; Undecylenic acid; Polynoxylin; 
Chlorophetanol; Chlorphenesin; Ticlatone; Sulbentine; Ethylparaben; Haloprogin; Salicylic acid 
Selenium sulfide; Ciclopirox; Amorolfine; Dimazole; Tolnaftate; Tolciclate; Sodium thiosulfate; 
Whitfield's ointment; Potassium iodide#; TaurolidineTea tree oil; citronella oil; lemon grass; orange oil; 
patchouli lemon; myrtlePCP: Pentamidine; Dapsone; Atovaquone 
# World Health Organization Essential Medicines (WHO-EM) list. 
 
As reported in Table 1, current fungal therapy is directed towards different cellular 
targets such as wall membrane construction (Ergosterol synthesis inhibitors, b-glucan 
synthase inhibitors) or nucleic acids synthesis (Thymidylate synthase inhibitors, Mitotic 
inhibitors). However the emergence of drug resistance, in particular in the case of 
7 
 
immuno-compromised patients and the lack of fungicidal agents with low toxicity, give 
rise to some worries. 
So far there is space for a deeper investigation and for the research of new more 
potent and possibly less toxic compounds. 





4 Results and discussion 
 
During my PhD work I have synthesised some cycloakyliden-hydrazothiazoles as 
anti-candida agents. 
The research group of medicinal chemistry of the department of life and 
environmental sciences has already synthesised similar compounds that exhibit potent 
activity towards several species of candida. [44-48] 
Thus, to achieve more information on the SARs of these compounds and to evaluate 
their activity towards Fluconazole resistant Candida species, we have synthesised 
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All the compounds were synthesised by direct reaction of the cyclic ketone (1.2 
mol) with thiosemicarbazide (1 mol) in n-propanol with catalytic amounts of acetic acid 
(10 drops) at reflux condition for 12-24 hours to obtain the corresponding 
thiosemicarbazones that was subsequently reacted with α-halogenoketones to yield the 
4-substituted thiazole ring derivatives as shown in Scheme 1. In the synthesis of final 
compounds water proved to be a more efficient, cheaper, and green solvent for our 
purpose. As a matter of fact, the reaction products precipitate on cooling down and can 




































n = 1, 2
R= H, 2-CH3, 3-CH3, 4-CH3




Scheme 1. Synthesis of cycloalkylidenehydrazothiazole derivatives EMAC 2097-2142. 
Reagents: (i) n-propanol, AcOH; (ii) H2O or n-propanol 
 
All synthesized compounds were characterised by analytical and spectral data as 
listed in Table 4 and 5. 
By this procedure derivatives EMAC 2097-2142 were prepared and submitted to 
biological tests. 
In particular, our aim was to identify those compounds that were active towards 
Fluconazole resistant C.albicans. 




Table 2. EMAC 2098-2100-2101-2103 activity 










CANDIDA albicans 25 
Fluconazole resistant “D”-ring 
















3.12 25 >25 >25 
Fluconazole 0.78 >100 >100 >100 
 
In the cyclohexylidene series all tested compounds exhibit a remarkable activity 
towards C.albicans ATCC 10231. MIC values range from 0.19 to 3.12 µg/ml. 
Noteworthy all compounds, with the exception of EMAC 2100, exhibit fungicidal 
activity when tested on C.albicans ATCC 10231. 
A different behavior is observed when compounds were tested against “C.albicans 
25 Fluconazole resistant”. In this case only compound EMAC 2098 and EMAC 2100 show 
remarkable MIC values (0.39 and 0.78 µg/ml respectively), while almost no activity is 
observed for  EMAC 2101 and EMAC 2103. Unfortunately, none of the tested compounds 
have interesting fungicidal activity when tested on “C.albicans 25 Fluconazole resistant”. 
Nevertheless these data are more than encouraging with respect to the activity 
exhibited by Fluconazole (Table 1 and 2).  
The introduction of a methyl substituent in the position 2 of the cyclohexylidene 







Table 3. EMAC 2104-2105-2107-2109-2110 activity 
 











CANDIDA albicans 25 
Fluconazole resistant “D”-ring 
MIC MCF MIC MCF 
 
EMAC 2104 
















0.78 3.12 1.56 3.12 
Fluconazole 0.78 >100 >100 >100 
 
Compound EMAC 2105, bearing a 4-bromophenyl moiety in the position 4 of the 
thiazole ring is active only towards C. albicans ATCC 10231, and its activity is comparable 
with that of Fluconazole but less potent  than its homologous EMAC 2098. 
It has neither fungicidal activity, nor efficacy against C. albicans 25 Fluconazole 
resistant. 
On the contrary, the 4-nitro-substituted derivative EMAC 2107 exhibits a similar 
activity profile with respect to its homologous EMAC 2100. 
Both compounds only exhibit fungistatic activity on both candida species.  
On the contrary, compounds EMAC 2104 and EMAC 2110 exhibit a very potent 
activity with respect to Fluconazole (Table 2). 
The 4-phenylthiazole derivative EMAC 2104 is particularly active against C.albicans 
25 Fluconazole resistant (MIC 0.19 µg/ml; MFC 1.56 µg/ml). 
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Although slightly less potent, compound EMAC 2110 is active towards both candida 
species. Moreover its fungicidal activity is comparable to that of EMAC 2104. 
These data are preliminary and more experiments are needed to rationalize the 
SARs of this class of compounds. 
In some cases cross–resistance with Fluconazole has been observed indicating that 
a similar mechanism of action might be postulated for EMAC derivatives. 
Nevertheless 5 compounds out of 9 are active against candida and in some cases 
the activity is conserved also against C. albicans 25 Fluconazole resistant. Thus although 
the mechanism of action might be the similar a different specific target is probably 
involved. 
Further studies on the mechanism of action, toxicity, and in vivo efficacy are 
needed. However, these preliminary data indicate the potential of EMAC derivatives as a 









COMPOUNDS EMAC 2097-2142 
 
All compounds are characterised by a cycloalkylidenehydrazothiazole core.  
The synthetic pathway is divided in two different step (Scheme 1). 
Unless otherwise noted, starting materials and reagents were obtains from 
commercial suppliers and were used without purification. 
All melting point were determined by the capillary method on a Stuart SMP11 
melting point apparatus and are uncorrected. 
All samples were measured in CDCl3 solvent at 278.1 K temperature on a Varian 
Unity 500 spectrometer. In the signal assignments the proton chemical shifts are referred 
to the solvent (1H: δ = 7.24 ppm,). Coupling constants J are expressed in hertz (Hz). 
Elemental analyses were obtained on a Perkin–Elmer 240 B microanalyser. 
Analytical data of the synthesised compounds are in agreement with the theoretical data. 
HPLC-MS/MS analysis was performed using an HPLC-MS/MS Varian (Varian Palo 
Alto, CA, USA) system fitted with a 1200 L triple quadrupole mass spectrometer equipped 
with an electrospray ionization source (ESI). A Varian MS workstation version 6.8 software 
was used for data acquisition and processing. Rapid identification was achieved with 
direct infusion of the purified molecule, dissolved in methanol, on the mass spectrometer 
source.  
TLC chromatography was performed using silica gel plates (Merck F 254), spots 
were visualised by UV light. 
All synthesized compounds were characterised by analytical and spectral data as 















Compound R R’ M.W. Mp (C°) % Yield 
EMAC 2097 Cyclohexyl [ H 271.38 189-190 [46-47]  79 
EMAC 2098 Cyclohexyl 4-Br 431.19 179-180 79 
EMAC 2099 Cyclohexyl 4-Cl 305.83 121-122 73 
EMAC 2100 Cyclohexyl 4-NO2 316.38 172-173 [48] 83 
EMAC 2101 Cyclohexyl 4-CH3 285.41 183-185 [48] 76 
EMAC 2102 Cyclohexyl 4-OCH3 301.41 152 77 
EMAC 2103 Cyclohexyl 4-CN 296.39 206-207 [48] 83 
EMAC 2104 Cyclohexyl-2-CH3 H 285.41 162-164 [46-47] 79 
EMAC 2105 Cyclohexyl-2-CH3 4-Br 364.3 130-131 [48] 77 
EMAC 2106 Cyclohexyl-2-CH3 4-Cl 319.85 187-188 [45] 71 
EMAC 2107 Cyclohexyl-2-CH3 4-NO2 330.4 163-164  [45] 85 
EMAC 2108 Cyclohexyl-2-CH3 4-OCH3 315.43 128-129 [45] 82 
EMAC 2109 Cyclohexyl-2-CH3 4-CN 391.33 200-201 [45] 79 
EMAC 2110 Cyclohexyl-2-CH3 4-F 303.4 178-180 [45] 79 
EMAC 2111 Cyclohexyl-4-CH3 H 285.41 191-192 [47] 66 
EMAC 2112 Cyclohexyl-4-CH3 4-Br 364.3 158-159 80 
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EMAC 2113 Cyclohexyl-4-CH3 4-Cl 319.85 177-179 [44] 74 
EMAC 2114 Cyclohexyl-4-CH3 4-NO2 330.4 175-177 [48] 75 
EMAC 2115 Cyclohexyl-4-CH3 4-CH3 299.43 158-160 [48] 83 
EMAC 2116 Cyclohexyl-4-CH3 4-OCH3 315.43 96-97 73 
EMAC 2117 Cyclohexyl-4-CH3 4-C6H5 361.5 181-182 70 
EMAC 2118 Cyclohexyl-4-CH3 4-CN 310.42 196-197 [48] 78 
EMAC 2119 Cyclohexyl-4-CH3 4-F 303.4 163-164 [48] 20 
EMAC 2120 Cyclohexyl-4-CH3 2,4-Cl 345.3 135-136 [48] 20 
EMAC 2121 Cyclohexyl-3-CH3 H 285.41 121-123 68 
EMAC 2122 Cyclohexyl-3-CH3 4-Br 364.3 168-169 41 
EMAC 2123 Cyclohexyl-3-CH3 4-Cl 319.85 195-199 [44] 44 
EMAC 2124 Cyclohexyl-3-CH3 4-NO2 303.04 164-165 76 
EMAC 2125 Cyclohexyl-3-CH3 4-CH3 299.43 171-174 [44] 85 
EMAC 2126 Cyclohexyl-3-CH3 4-OCH3 315.43 162-165 [44] 42 
EMAC 2127 Cyclohexyl-3-CH3 4-C6H5 361.5 128-130 79 
EMAC 2128 Cyclohexyl-3-CH3 4-CN 310.42 189-190 [44] 80 
EMAC 2129 Cyclohexyl-3-CH3 4-F 303.4 192-195 [44] 65 
EMAC 2130 Cyclohexyl-3-CH3 2,4-F 321.39 130-132 68 
EMAC 2131 Cyclohexyl-3-CH3 2,4-Cl 354.3 148-151 63 
EMAC 2132 Cyclopentyl  H 257.35 215 [47] 66 
EMAC 2133 Cyclopentyl 4-Br 336.25 213-215 [44] 87 
EMAC 2134 Cyclopentyl 4-Cl 291.8 223-225 [44] 84 
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EMAC 2135 Cyclopentyl 4-NO2 302.35 219-220 [44] 71 
EMAC 2136 Cyclopentyl 3-NO2 302.35 187-190 [44] 74 
EMAC 2137 Cyclopentyl 4-CH3 271.38 218-220 [44] 85 
EMAC 2138 Cyclopentyl 4-OCH3 287.38 214-217 [44] 77 
EMAC 2139 Cyclopentyl 4-CN 282.36 207-208 [44] 70 
EMAC 2140 Cyclopentyl 4-C6H5 333.45 235-237 [44] 69 
EMAC 2141 Cyclopentyl 2,4-F 293.33 183-185 [48] 49 
EMAC 2142 Cyclopentyl 2,4-Cl 326.24 162-164[48] 60 
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EMAC 2097 Cyclohexyl H Water Water/ethanol  Brown solid 32  





















EMAC 2103 Cyclohexyl 4-CN Water Ethanol  
Crystalline 
pale red solid 
26 





















EMAC 2109 Cyclohexyl-2-CH3 4-CN Water Water/ethanol  Red solid 28 








EMAC 2112 Cyclohexyl-4-CH3 4-Br Water Water/ethanol  Pale red solid 26 
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EMAC 2113 Cyclohexyl-4-CH3 4-Cl Water Water/ethanol  Brown solid 26 
EMAC 2114 Cyclohexyl-4-CH3 4-NO2 Water Water/ethanol  Yellow solid 24 




EMAC 2116 Cyclohexyl-4-CH3 4-OCH3 Water Water/ethanol  Pale red solid 26 




EMAC 2118 Cyclohexyl-4-CH3 4-CN Water Water/ethanol  Yellow solid 26 
EMAC 2119 Cyclohexyl-4-CH3 4-F Water Ethanol Yellow solid 24 
EMAC 2120 Cyclohexyl-4-CH3 2,4-Cl Water Water/ethanol  Brown solid 24 




EMAC 2122 Cyclohexyl-3-CH3 4-Br Water Acetonitrile  Brown solid 24 




EMAC 2124 Cyclohexyl-3-CH3 4-NO2 Water Water/ethanol  Yellow solid 26 
















EMAC 2129 Cyclohexyl-3-CH3 4-F Water Water/ethanol ì Pale red solid 26 
EMAC 2130 Cyclohexyl-3-CH3 2,4-F Water Water/ethanol ì Pale red solid 24 






































EMAC 2140 Cyclopentyl 4-C6H5 Water Water/ethanol  Yellow solid 24 












Synthesis of starting thiosemicarbazones 
 
The starting thiosemicarbazones have been synthesised by slightly modifying the 
procedures reported in the literature. [49] 
In a flask equipped with a reflux condenser, equimolar amounts of 
thiosemicarbazide and of the appropriate ketone are reacted in n-propanol in the 
presence of a catalytic amount of AcOH. The mixture is then refluxed for all the night, and 
the obtain solid is filtered and used without further purification.  
 

















M.W.: 171.26 g/mol; RF: 0.82 (eluent: ethyl acetate-hexane 20:1 ); Mp: 155°-156°C; Yield: 
87%, Aspect: crystalline pale yellow solid 
 
1
H-NMR: (500 MHz, CDCl3) δH 1.55 (br s, 6H, CH2, cyclohexyl), 2.19-2.23 (m, 2H, CH2, 
cyclohexyl), 2.38 (br s, 2H, CH2, cyclohexyl), 7.50 (br s, 1H, NH2), 7.93 (br s, 1H, NH2), 10.13 



















M.W.: 185.29 g/mol; RF: 0.77 (eluent: ethyl acetate-hexane 20:1); Mp: 154°-156°C; Yield: 





H-NMR: (500 MHz, CDCl3) 1.08-1.10 (d, J: 6.57, 3H,CH3); 1.77-2.62 (m, 9H, cyclohexyl); 


















M.W.: 185.29 g/mol; RF: 0.61 (eluent: ethyl acetate-hexane 20:1); Mp: 161°-162°C; Yield: 
66%, Aspect: light yellow powder 
 
1
H-NMR: (500 MHz, CDCl3) δH 0.94 (d, 3H, J: 6.5, CH3), 1.16 (m, 2H, CH2, cyclohexyl), 1.68 
(m, 1H, CH2, cyclohexyl),1.92 (m, 3H, CH2, cyclohexyl),2.19 (m, 1H, CH2, cyclohexyl), 2.28 
(m, 2H, CH2, cyclohexyl),2.71 (m, 1H, CH2, cyclohexyl), 6.53 (br.s, 1H, NH2), 7.27 (br.s, 1H, 


















M.W.: 185.29 g/mol; RF: 0.57 (eluent: ethyl acetate: hexane 20:1); Mp: 108°-110°C; Yield: 
65%, Aspect: pale yellow powder . 
 
1
H-NMR: (500 MHz, CDCl3) δH
 
 0.92 (m, 3H, CH3), 1.13 (m, 1H, CH2, cyclohexyl), 1.35 (m, 
1H, CH2, cyclohexyl), 1.57 (m, 2H, CH2, cyclohexyl), 1.69 (m, 1H, CH2, cyclohexyl), 1.81 (m, 
2H, CH2, cyclohexyl), 2.28 (m, 1H, CH2, cyclohexyl), 2.91 (m, 1H, CH2, cyclohexyl), 7.48 (s, 






















M.W.: 157.24 g/mol; RF: 0.60 (DCM-ethyl acetate-hexane 10:10:1); Mp: 151°-153°C; Yield: 
80%, Aspect: light yellow powder . 
 
1
H-NMR: (500 MHz, CDCl3) δH 1.73 (m, 2H, J: 9, J: 17.5, CH2, cyclopropyl), 1.84 (m, 2H, J: 9, 
J: 17.5, CH2, cyclopropyl), 2.25 (t, 2H, J: 9, J: 9.5, CH2, cyclopropyl), 2.35 (t, 2H, J: 9, J: 9.5, 





General method for the synthesis of compound EMAC 2097-2142 
 
Equimolar amounts of cycloalkylthiosemicarbazone and α-halogen keton are 
reacted at RT in water or2 -propanol. The mixture was stirring for a period ranging 
between 24-32 hours and, a forming product was formed. The mixture was stopped and 
the solid filtered. The product was washed with ethyl ether and crystallised from ethanol, 
water/ethanol; acetonitrile or hexane. 
 
According to this method, the following listed compounds have been synthesised. 
 




















H-NMR: (500 MHz, CDCl3 ) δH 1.67 (m, 2H, CH2, cyclohexyl), 1.78 (m, 4H, CH2, 
cyclohexyl), 2.40 (t, 2H, J: 6.3, CH2, cyclohexyl), 2.64 (t, 2H, J: 6.5, CH2, cyclohexyl), 6.68 (s, 
1H, CH, thiazole), 7.48 (m, 3H, CH, Phenyl), 7.72 (m, 2H, CH, Phenyl), 12.51 (br.s, 1H, NH, 
D2O exch.) 
 























H-NMR: (500 MHz, CDCl3 ) δH 1.67 (m, 2H, CH2, cyclohexyl), 1.78 (m, 4H, CH2, cyclohexyl), 
2.40 (t, 2H, J: 6.3, CH2, cyclohexyl), 2.63 (t, 2H, J: 6.5, CH2, cyclohexyl), 6.69 (s, 1H, CH, 
thiazole), 7.60 (m, 4H, CH, Phenyl), 12.45 (br.s, 1H, NH, D2O exch.) 





















H-NMR: (500 MHz, CDCl3 ) δH 1.67 (m, 2H, CH2, cyclohexyl), 1.72 (m, 4H, CH2, cyclohexyl), 
2.37 (m, 4H, CH2, cyclohexyl), 6.79 (s, 1H, CH, thiazole), 7.36 (d, 2H, J: 8.5, CH, Phenyl), 























H-NMR: (500 MHz, CDCl3) δH 1.70 (m, 6H, CH2, cyclohexyl), 2.31 (m, 2H, CH2, cyclohexyl), 
2.38 (m, 2H, CH2, cyclohexyl), 7.07 (s, 1H, CH, thiazole), 7.93 (d, 2H, J: 9.0, CH, Phenyl), 

























H-NMR: (500 MHz, CDCl3) δH 1.67 (m, 2H, CH2, cyclohexyl), 1.78 (m, 4H, CH2, cyclohexyl), 
2.39 (m, 5H, CH2, cyclohexyl + CH3), 2.64 (m, 2H, CH2, cyclohexyl), 6.60 (s, 1H, CH, 
thiazole), 7.28 (d, 2H, J: 7.8, CH, Phenyl), 7.60 (d, 2H, J: 8.2, CH, Phenyl), 12.49 (br.s, 1H, 























H-NMR: (500 MHz, CDCl3) δH 1.67 (m, 2H, CH2, cyclohexyl), 1.77 (m, 4H, CH2, cyclohexyl), 
2.39 (t, 2H, J: 6.3, CH2, cyclohexyl), 2.63 (t, 2H, J: 6.5, CH2, cyclohexyl), 3.85 (s, 3H, OCH3), 
6.50 (s, 1H, CH, thiazole), 6.99 (d, 2H, J: 8.8, CH, Phenyl), 7.65 (d, 2H, J: 8.8, CH, Phenyl), 


























H-NMR: (500 MHz, CDCl3) δH 1.65 (m, 4H, CH2, cyclohexyl), 1.74 (m, 2H, CH2, cyclohexyl), 
2.28 (m, 2H, CH2, cyclohexyl), 2.37 (m, 2H, CH2, cyclohexyl), 7.00 (s, 1H, CH, thiazole), 7.65 























H-NMR: (500 MHz, CDCl3 ) δH 1.19 (s, 3H, CH3), 1.33 (m, 1H, CH, cyclohexyl), 1.51 (m, 2H, 
CH2, cyclohexyl), 1.79 (m, 1H, CH , cyclohexyl), 1.86 (m, 1H, CH, cyclohexyl), 1.95 (m, 2H, 
CH2, cyclohexyl), 2.37 (m, 1H, CH, cyclohexyl), 2.60 (m, 1H, CH, cyclohexyl), 6.84 (s, 1H, 
CH, thiazole), 7.29 (m, 1H, CH, Phenyl), 7.38 (d, 2H, J: 7.7, CH, Phenyl), 7.79 (d, 2H, J: 6.6, 




























H-NMR: (500 MHz, CDCl3) δH 1.18 (s, 3H, CH3), 1.32 (m, 1H, CH, cyclohexyl), 1.51 (m, 2H, 
CH2, cyclohexyl), 1.90 (m, 4H, CH2, cyclohexyl), 2.37 (m, 1H, CH, cyclohexyl), 2.58 (m, 1H, 
CH, cyclohexyl), 6.84 (s, 1H, CH ,thiazole), 7.49 (d, 2H, J: 8.5, CH, Phenyl), 7.66 (d, 2H, J: 
























H-NMR: (500 MHz, CDCl3) δH 1.17 (s, 3H, CH3), 1.32 (m, 1H, CH, cyclohexyl), 1.54 (m, 2H, 
CH2, cyclohexyl), 1.80 (m, 1H, CH, cyclohexyl), 1.89 (m, 1H, CH, cyclohexyl), 1.99 (m, 2H, 
CH2, cyclohexyl), 2.39 (m, 1H, CH, cyclohexyl), 2.70 (m, 1H, CH, cyclohexyl), 6.79 (s, 1H, 





























H-NMR: (500 MHz, CDCl3) δH 1.19 (s, 3H, CH3), 1.33 (m, 1H, CH, cyclohexyl), 1.55 (m, 2H, 
CH2, cyclohexyl), 1.81 (m, 1H, CH, cyclohexyl), 1.91 (m, 1H, CH, cyclohexyl), 1.98 (m, 2H, 
CH2, cyclohexyl), 2.39 (m, 1H, CH , cyclohexyl), 2.62 (m, 1H, CH, cyclohexy), 7.07 (s, 1H, 


























H-NMR: (500 MHz, CDCl3 ) δH 1.16 (s, 3H, CH3), 1.34 (m, 1H, CH, cyclohexyl), 1.55 (m, 2H, 
CH2, cyclohexyl), 1.80 (m, 1H, CH, cyclohexyl), 1.98 (m, 2H, CH2, cyclohexyl), 2.19 (m, 1H, 
CH, cyclohexyl), 2.44(m, 1H, CH, cyclohexyl), 3.02 (m, 1H, CH, cyclohexyl), 3.85 (s, 3H, 
OCH3), 6.50 (s, 1H, CH, thiazole), 6.99 (d, 2H, J: 8.4, CH, phenyl), 7.66 (d, 2H, J: 8.4, CH, 




























H-NMR: (500 MHz, CDCl3) δH 1.18 (s 3H, CH3), 1.29 (m, 1H, CH, cyclohexyl), 1.52 (m, 2H, 
CH2, cyclohexyl), 1.88 (m, 4H, CH2, cyclohexyl), 2.37 (m, 1H, CH, cyclohexyl), 2.60 (m, 1H, 
CH, cyclohexyl), 7.00 (s, 1H , CH, thiazole), 7.65 (d, 2H, J: 8.3, CH, phenyl), 7.88 (d, 2H, J: 


























H-NMR: (500 MHz, CDCl3) δH 1.16 (s, 3H, CH3), 1.35 (m, 1H, CH, cyclohexyl), 1.58 (m, 2H, 
CH2, cyclohexyl), 1.81 (m, 1H, CH, cyclohexyl), 1.99 (m, 2H, CH2, cyclohexyl), 2.20 (m, 1H, 
CH, cyclohexyl), 2.44 (m, 1H, CH, cyclohexyl), 3.01 (m, 1H, CH, cyclohexyl), 6.62 (s, 1H, CH, 


























H-NMR: (500 MHz, CDCl3) δH 0.92 (d, 3H, J: 6.5, CH3), 1.04 (m, 1H, CH2, cyclohexyl), 1.21 
(m, 1H, CH2, cyclohexyl), 1.63 (m, 1H, CH2, cyclohexyl), 1.77 (m, 1H, CH2, cyclohexyl), 1.85 
(m, 2H, CH2, cyclohexyl), 2.21 (m, 1H, CH2, cyclohexyl), 2.51 (m, 1H, CH2, cyclohexyl), 2.63 
(m, 1H, CH2, cyclohexyl), 6.81 (s, 1H, thiazole), 7.27 (t, 1H, J: 7.5, Ar-CH ), 7.36 (t, 2H, J: 7.5, 

























H-NMR: (500 MHz, CDCl3) δH 0.97 (d, 3H, J: 7, CH3), 1.20 (m, 2H, CH2, cyclohexyl), 1.70 
(m, 1H, CH2, cyclohexyl), 1.90 (m, 2H, CH2, cyclohexyl), 2.00 (m, 1H, CH2, cyclohexyl), 2.26 
(m, 1H, CH2, cyclohexyl), 2.54 (m, 1H, CH2, cyclohexyl), 2.79 (m, 1H, CH2, cyclohexyl), 6.78 




























H-NMR: (500 MHz, CDCl3) δH 0.98 (d, 3H, J: 6.5, CH3), 1.23 (m, 2H, CH2, cyclohexyl), 1.72 
(m, 1H, CH2, cyclohexyl), 1.94 (m, 2H, CH2, cyclohexyl), 2.09 (m, 1H, CH2, cyclohexyl), 2.78 
(m, 1H, CH2, cyclohexyl), 2.54 (m, 1H, CH2, cyclohexyl), 2.93 (m, 1H, CH2, cyclohexyl), 6.73 

























H-NMR: (500 MHz, CDCl3) δH 0.97 (d, 3H, J: 6.5, CH3), 1.15 (m, 1H, CH2, cyclohexyl), 1.25 
(m, 1H, CH2, cyclohexyl), 1.70 (m, 1H, CH2, cyclohexyl), 1.94 (m, 3H, CH2, cyclohexyl), 2.26 
(m, 1H, CH2, cyclohexyl), 2.54 (m, 1H, CH2, cyclohexyl), 2.66 (m, 1H, CH2, cyclohexyl), 7.06 



























H-NMR: (500 MHz, CDCl3) δH 0.97 (d, 3H, J: 6.5, CH3), 1.21 (m, 2H, CH2, cyclohexyl), 1.71 
(m, 1H, CH2, cyclohexyl), 1.92 (m, 2H, CH2, cyclohexyl), 2.05 (m, 1H, CH2, cyclohexyl), 2.27 
(m, 1H, CH2, cyclohexyl), 2.37 (s, 3H, CH3), 2.54 (m, 1H, CH2, cyclohexyl), 2.90 (m, 1H, CH2, 
cyclohexyl), 6.69 (s, 1H, thiazole), 7.23 (d, 2H, J: 8, Ar-CH), 7.63 (d, 2H, J: 8, Ar-CH), 12.52 

























H-NMR: (500 MHz, CDCl3) δH 0.94 (d, 3H, J: 6.5, CH3), 1.08 (m, 1H, CH2, cyclohexyl), 1.23 
(m, 1H, CH2, cyclohexyl), 1.66 (m, 1H, CH2, cyclohexyl), 1.86 (m, 3H, CH2, cyclohexyl), 2.23 
(m, 1H, CH2, cyclohexyl), 2.53 (m, 1H, CH2, cyclohexyl), 2.68 (m, 1H, CH2, cyclohexyl), 3.83 

























H-NMR: (500 MHz, CDCl3) δH 0.95 (d, 3H, J: 6.5, CH3), 1.12 (m, 1H, CH2,, cyclohexyl), 1.24 
(m, 1H, CH2, cyclohexyl), 1.67 (m, 1H, CH2, cyclohexyl), 1.89 (m, 3H, CH2, cyclohexyl), 2.25 
(m, 1H, CH2, cyclohexyl), 2.54 (m, 1H, CH2, cyclohexyl), 2.69 (m, 1H, CH2, cyclohexyl), 6.87 
(s, 1H, thiazole), 7.35 (t, 1H, J: 7, Ar-CH), 7.45 (t, 2H, J: 7.5, Ar-CH), 7.63 (d, 4H, J: 8, Ar-CH), 
7.85 (d, 2H, J: 8, Ar-CH), NH not detected 
 
EMAC 2118 






















H-NMR: (500 MHz, CDCl3) δH 0.98 (d, 3H, J: 7, CH3), 1.23 (m, 2H, CH2, cyclohexyl), 1.73 
(m, 1H, CH2, cyclohexyl), 1.95 (m, 2H, CH2, cyclohexyl), 2.09 (m, 1H, CH2, cyclohexyl), 2.28 
(m, 1H, CH2, cyclohexyl), 2.55 (m, 1H, CH2, cyclohexyl), 2.89 (m, 1H, CH2, cyclohexyl), 6.92 




























H-NMR: (500 MHz, CDCl3) δH 0.98 (d, 3H, J: 7, CH3), 1.24 (m, 2H, CH2, cyclohexyl), 1.73 
(m, 1H, CH2, cyclohexyl), 1.96 (m, 2H, CH2, cyclohexyl), 2.15 (m, 1H, CH2, cyclohexyl), 2.29 
(m, 1H, CH2, cyclohexyl), 2.55 (m, 1H, CH2, cyclohexyl), 3.02 (m, 1H, CH2, cyclohexyl), 6.63 





























H-NMR: (500 MHz, CDCl3) δH 0.97 (s, 3H, CH3), 1.24 (m, 2H, CH2, cyclohexyl), 1.73 (m, 1H, 
CH2, cyclohexyl), 1.96 (m, 2H, CH2, cyclohexyl), 2.17 (m, 1H, CH2, cyclohexyl), 2.29 (m, 1H, 
CH2, cyclohexyl), 2.54 (m, 1H, CH2, cyclohexyl), 3.04 (m, 1H, CH2, cyclohexyl), 6.97 (s, 1H, 



























H-NMR: (500 MHz, CDCl3) δH 0.98 (m, 3H, J: 6.5, J: 13, CH3), 1.17 (m, 1H, CH2, cyclohexyl), 
1.56 (m, 2H, CH2, cyclohexyl), 1.85 (m, 3H, CH2, cyclohexyl), 2.15 (m, 1H, CH2, cyclohexyl), 
2.51 (m, 1H, CH2, cyclohexyl), 2.64 (m, 1H, CH2, cyclohexyl), 6.82 (d, 1H, J: 2.5, thiazol), 


























H-NMR: (500 MHz, CDCl3) δH 1.10 (m, 3H, J: 6, CH3), 1.26 (m, 1H, CH2, cyclohexyl), 1.57 
(m, 1H, CH2, cyclohexyl), 1.83 (m, 2H, CH2, cyclohexyl), 2.08 (m, 3H, CH2, cyclohexyl), 2.57 
(m, 1H, CH2, cyclohexyl), 3.03 (m, 1H, CH2, cyclohexyl), 6.70 (s, 1H, thiazole), 7.59 (d, 2H, J: 




























H-NMR: (500 MHz, CDCl3) δH 1.07 (m, 3H, J: 6.5, CH3), 1.26 (m, 1H, CH2, cyclohexyl), 1.56 
(m, 1H, CH2, cyclohexyl), 1.82 (m, 2H, CH2, cyclohexyl), 2.08 (m, 3H, CH2, cyclohexyl), 2.52 
(m, 1H, CH2, cyclohexyl), 3.04 (m, 1H, CH2, cyclohexyl), 6.69 (s, 1H, thiazole), 7.47 (d, 2H, J: 


























H-NMR: (500 MHz, CDCl3) δH 1.01 (m, 3H, J: 6, CH3), 1.21 (m, 1H, CH2, cyclohexyl ), 1.56 
(m, 1H, CH2, cyclohexyl), 1.64 (m, 2H, CH2, cyclohexyl), 1.82 (m, 1H, CH2, cyclohexyl), 1.93 
(m, 1H, CH2, cyclohexyl), 2.18 (m, 1H, CH2, cyclohexyl), 2.49 (m, 1H, CH2, cyclohexyl), 2.61 
(m, 1H, CH2, cyclohexyl), 7.07 (s, 1H, thiazole), 7.93 (d, 2H, J: 8.5, Ar-CH), 8.24 (d, 2H, J: 





























H-NMR: (500 MHz, CDCl3) δH 1.05 (m, 3H, J: 6, CH3), 1.21 (m, 1H, CH2, cyclohexyl), 1.53 
(m, 1H, CH2, cyclohexyl), 1.71 (m, 1H, CH2, cyclohexyl), 1.82 (m, 1H, CH2, cyclohexyl), 1.91 
(m, 1H, CH2, cyclohexyl), 2.01 (m, 1H, CH2, cyclohexyl), 2.09 (m, 1H, CH2, cyclohexyl), 2.38 
(s, 3H, CH3), 2.53 (m, 1H, CH2, cyclohexyl), 2.99 (m, 1H, CH2, cyclohexyl), 6.64 (s, 1H, 


























H-NMR: (500 MHz, CDCl3) δH 1.08 (m, 3H, J: 6.5, CH3), 1.23 (m, 1H, CH2, cyclohexyl), 1.54 
(m, 1H, CH2, cyclohexyl), 1.75 (m, 1H, CH2, cyclohexyl), 1.83 (m, 1H, CH2, cyclohexyl), 1.93 
(m, 1H, CH2, cyclohexyl), 2.04 (m, 1H, CH2, cyclohexyl), 2.12 (m, 1H, CH2, cyclohexyl), 2.51 
(m, 1H, CH2, cyclohexyl), 3.05 (m, 1H, CH2, cyclohexyl), 3.85 (s, 3H, OCH3), 6.52 (s, 1H, 

























H-NMR: (500 MHz, CDCl3) δH 1.00 (m, 3H, J: 6.5, CH3), 1.15 (m, 1H, CH2, cyclohexyl), 1.41 
(m, 1H, CH2, cyclohexyl), 1.72 (m, 1H, CH2, cyclohexyl), 1.78 (m, 1H, CH2, cyclohexyl), 1.83 
(m, 1H, CH2, cyclohexyl), 1.87 (m, 1H, CH2, cyclohexyl), 1.88 (m, 1H, CH2, cyclohexyl), 2.54 
(m, 1H, CH2, cyclohexyl), 2.63 (m, 1H, CH2, cyclohexyl), 6.88 (s, 1H, thiazole), 7.36 (t, 1H, J: 
7.5, Ar-CH), 7.45 (t, 2H, J: 7.5, Ar-CH), 7.63 (m, 4H, J: 7.5, J: 8.5, Ar-CH), 7.86 (d, 2H, J: 8.5, 


























H-NMR: (500 MHz, CDCl3) δH 1.02 (m, 3H, J: 6.5, CH3), 1.20 (m, 1H, CH2, cyclohexyl), 1.52 
(m, 1H, CH2, cyclohexyl), 1.83 (m, 4H, CH2, cyclohexyl), 2.18 (m, 1H, CH2, cyclohexyl), 2.51 
(m, 1H, CH2, cyclohexyl), 2.69 (m, 1H, CH2, cyclohexyl), 6.97 (s, 1H, thiazol), 7.69 (d, 2H, J: 




























H-NMR: (500 MHz, CDCl3) δH 1.05 (m, 3H, J: 6.5, CH3), 1.22 (m, 1H, CH2, cyclohexyl), 1.52 
(m, 1H, CH2, cyclohexyl), 1.94 (m, 4H, CH2, cyclohexyl), 2.17 (m, 1H, CH2, cyclohexyl), 2.50 
(m, 1H, CH2, cyclohexyl), 3.00 (m, 1H, CH2, cyclohexyl), 6.63 (s, 1H, thiazole), 7.16 (m, 2H, 



























H-NMR: (500 MHz, CDCl3) δH 1.05 (m, 3H, J: 6.5, CH3), 1.24 (m, 1H, CH2, cyclohexyl), 1.56 
(m, 1H, CH2, cyclohexyl), 1.77 (m, 1H, CH2, cyclohexyl), 1.83 (m, 1H, CH2, cyclohexyl), 1.93 
(m, 1H, CH2, cyclohexyl), 2.11 (m, 2H, CH2, cyclohexyl), 2.51 (m, 1H, CH2, cyclohexyl), 2.97 
(m, 1H, CH2, cyclohexyl), 6.94 (s, 1H, thiazole), 6.97 (m, 1H, Ar-CH), 7.07 (m, 1H, J: 8, Ar-






























H-NMR: (500 MHz, CDCl3) δH 1.05 (m, 3H, J: 6.5, CH3), 1.23 (m, 1H, CH2, cyclohexyl), 1.54 
(m, 1H, CH2, cyclohexyl), 1.75 (m, 1H, CH2, cyclohexyl), 1.82 (m, 1H, CH2, cyclohexyl), 1.92 
(m, 1H, CH2, cyclohexyl), 1.99 (m, 1H, CH2, cyclohexyl), 2.15 (m, 1H, CH2, cyclohexyl), 2.50 
(m, 1H, CH2, cyclohexyl), 2.98 (m, 1H, CH2, cyclohexyl), 6.98 (s, 1H, thiazole), 7.41 (d, 1H, J: 






















H-NMR: (500 MHz, CDCl3) δH 1.78 (m, 2H, J: 6.5, J: 13.5, CH2, cyclopropyl), 1.88 (m, 2H, J: 
7, J: 14, CH2, cyclopropyl), 2.28 (t, 2H, J: 7.5, J: 14.5, CH2, cyclopropyl), 2.29 (t, 2H, J: 7, J: 
14.5, CH2, cyclopropyl), 6.80 (s, 1H, thiazole), 7.29 (t, 1H, J: 7.5, J: 1.5 Ar-CH), 7.38 (t, 2H, J: 


























H-NMR: (500 MHz, CDCl3) δH 1.83 (m, 2H, J: 6.5, J: 13.5, CH2, cyclopropyl), 1.92 (m, 2H, J: 
7, J: 13.5, CH2, cyclopropyl), 2.47 (t, 2H, J: 7.5, J: 14.5, CH2, cyclopropyl), 2.51 (t, 2H, J: 7.5, 
J: 14.5, CH2, cyclopropyl), 6.76 (s, 1H, thiazole), 7.55 (d, 2H, J: 8.5, Ar-CH), 7.61 (t, 2H, J: 8, 






















H-NMR: (500 MHz, CDCl3) δH 1.82 (m, 2H, J: 6.5, J: 13.5, CH2, cyclopropyl), 1.92 (m, 2H, J: 
7, J: 14, CH2, cyclopropyl), 2.47 (t, 2H, J: 7.5, J: 14.5, CH2, cyclopropyl), 2.51 (t, 2H, J: 7.5, J: 
14.5, CH2, cyclopropyl), 6.74 (s, 1H, thiazole), 7.40 (d, 2H, J: 9, Ar-CH), 7.67 (t, 2H, J: 8.5, 



























H-NMR: (500 MHz, CDCl3) δH 1.81 (m, 2H, J: 7, J: 14, CH2, cyclopropyl), 1.92 (m, 2H, J: 7, J: 
14, CH2, cyclopropyl), 2.57 (t, 2H, J: 7, J: 14, CH2, cyclopropyl), 2.50 (t, 2H, J: 7, J: 14, CH2, 























H-NMR: (500 MHz, CDCl3) δH 1.82 (m, 2H, J: 7, J: 13.5, CH2, cyclopropyl), 1.92 (m, 2H, J: 7, 
J: 14, CH2, cyclopropyl), 2.35 (t, 2H, J: 7, J: 14, CH2, cyclopropyl), 2.51 (t, 2H, J: 7, J: 14, CH2, 
cyclopropyl), 6.98 (s, 1H, thiazole), 7.56 (t, 1H, J: 8, Ar-CH), 8.10 (d, 2H, J: 7.5, Ar-CH), 8.14 

























H-NMR: (500 MHz, CDCl3) δH 1.84 (m, 2H, J: 7, J: 14, CH2, cyclopropyl), 1.93 (m, 2H, J: 7, J: 
14, CH2, cyclopropyl), 2.38 (s, 3H, CH3) 2.52 (t, 2H, J: 7, J: 14, CH2, cyclopropyl), 2.56 (t, 2H, 
J: 7, J: 14, CH2, cyclopropyl), 6.65 (s, 1H, thiazole), 7.26 (d, 2H, J: 8, Ar-CH), 7.62 (d, 2H, J: 8, 
























H-NMR: (500 MHz, CDCl3) δH 1.83 (m, 2H, J: 7, J: 14, CH2, cyclopropyl), 1.93 (m, 2H, J: 7, J: 
14, CH2, cyclopropyl), 2.52 (t, 2H, J: 7, J: 14, CH2, cyclopropyl), 2.57 (t, 2H, J: 7, J: 14, CH2, 
cyclopropyl), 3.84 (s, 3H, OCH3), 6.55 (s, 1H, thiazole), 6.97 (d, 2H, J: 8, Ar-CH), 7.66 (d, 2H, 























H-NMR: (500 MHz, CDCl3) δH 1.83 (m, 2H, J: 7, J: 14, CH2, cyclopropyl), 1.93 (m, 2H, J: 7, J: 
14, CH2, cyclopropyl), 2.47 (t, 2H, J: 7, J: 14, CH2, cyclopropyl), 2.52 (t, 2H, J: 7, J: 14, CH2, 
cyclopropyl), 6.79 (s, 1H, thiazol), 7.37 (t, 1H, J: 7, Ar-CH), 7.46 (t, 2H, J: 7.5, Ar-CH), 7.62 






















H-NMR: (500 MHz, CDCl3) δH 1.80 (m, 2H, J: 7, J: 14, CH2, cyclopropyl), 1.90 (m, 2H, J: 7, J: 
14, CH2, cyclopropyl), 2.28 (t, 2H, J: 7, J: 14, CH2, cyclopropyl), 2.50 (t, 2H, J: 7, J: 14, CH2, 




























H-NMR: (500 MHz, CDCl3) δH 1.85 (m, 2H, J: 7, J: 14, CH2, cyclopropyl), 1.94 (m, 2H, J: 7, J: 
14, CH2, cyclopropyl), 2.53 (t, 2H, J: 7, J: 14, CH2, cyclopropyl), 2.62 (t, 2H, J: 7, J: 14, CH2, 
cyclopropyl), 6.94 (s, 1H, thiazole), 6.97 (m, 1H, JH-F : 5.5, Ar-CH), 7.06 (m, 1H, J: 8.5, J: 2.5, 
























H-NMR: (500 MHz, CDCl3) δH 1.85 (m, 2H, J: 7, J: 14, CH2, cyclopropyl), 1.93 (m, 2H, J: 7, J: 
14, CH2, cyclopropyl), 2.53 (t, 2H, J: 7, J: 14, CH2, cyclopropyl), 2.63 (t, 2H, J: 7, J: 14, CH2, 
cyclopropyl), 6.98 (s, 1H, thiazol), 7.41 (d, 1H, J: 8.5, J: 1.5, Ar-CH), 7.63 (s, 1H, J: 1.5, Ar-




5.2 Microbiology  
 
5.2.1 Antifungal agents 
 
EMAC 2097-2142 (Figure 1-5) belongs to a series of isothiosemicarbazone cyclic 
analogues they are obtained by the reaction of equimolar amounts of 
cycloalkylthiosemicarbazone and α-halogenoketone in water or 2-propanol. A foaming 
product is formed which is filtered. The obtained solid is crystallized from water/ethanol. 
Amphotericin B was purchased from Sigma Chemicals Co. (St Louis, MO, USA). 
Fluconazole was obtained from a commercially available iv formulation (Diﬂucanw, Pﬁzer 
Italia S.p.A.) at 200 mg/100 mL in saline. EMAC compounds and amphotericin B 
were dissolved in dimethyl sulphoxide at 10 mg/mL, for antifungal susceptibility studies, 
and stored at 20°C. The working solution were prepared in the same medium employed 
for the tests. To avoid interference from the solvent, [50] the highest DMSO 
concentration was 1%. 
 




MICs were determined by the broth microdilution method according to the NCCLS 
reference document M27-A. [51] RPMI 1640 medium (Sigma Chemicals) without sodium 
bicarbonate, supplemented with L-glutamine (Gibco, Invitrogen) and buffered with 0.165 
M MOPS (Sigma Chemicals) at pH 7.0 was used as test medium. Two-fold dilutions of the 
drugs with concentrations in the range 0.008–200 mg/L were obtained in RPMI 1640 and 
dispensed into the wells of plastic microdilution trays. Starting inoculum suspensions 
were obtained by the spectrophotometric method of inoculum preparation, adjusted to 
10
6
 cfu/mL and then diluted in test medium to 2 x 10
4
 cells/mL. A 100 mL yeast inoculum 
was added to each well of the microdilution trays to obtain ﬁnal concentrations of the 
drugs ranging between 0.004–100 mg/L and ﬁnal inocula of 10
4
 cells/mL. The inoculated 
plates were incubated overnight at 35°C in a humid atmosphere. After agitation, plates 
were read visually with the aid of a reading mirror and spectrophotometrically with an 
automatic plate reader (Sunrise Tecan, Grödig/Salzburg, Austria) set at 450 nm. For EM-
01D2 and amphotericin B, MICs were determined at the lowest concentration at which a 
100% inhibition of growth compared with drug-free control wells was observed. The MICs 
of ﬂuconazole were read as the lowest concentration of drug that inhibits growth by 80%. 
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MICs determined either visually or by spectrophotometric evaluation showed excellent 
agreement. 
 
Minimum fungicidal concentration assays.  
 
After the MIC determination, a 100 mL sample from each well was seeded on plates 
of Sabouraud dextrose agar. Plates were incubated for 72 h at 35°C. The minimum 
fungicidal concentration (MFC) was deﬁned as the minimum concentration of compound 
that resulted in the growth of less than two colonies representing the killing of > 99% of 
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1.1 Historical overview 
 
Monoamine oxidase are key role enzymes in the catabolism of amines like 
dopamine (DA), norepinephrine (NE), epinephrine, serotonin (5HT), and 2-
phenylethylamine (PEA). [1] 
 
 
Figure 1. Representation of MAO-B homodimer bound on mitochondrial membrane 
 
Two isoforms of the enzyme, differing for substrates and selectivity of inhibitors [2], 
are known, named MAO-A and MAO-B. 
5HT and NE are preferentially deaminated by the A isoform, while β-
phenylethylamine and benzylamine are MAO-B substrates.  
Moreover, in mammals the inhibition of MAO-B leads to an increase of the DA and 
5HT levels as well as to a neuroprotective effect. [3] 
Both MAO isoforms are important in the metabolism of monoamine 
neurotransmitters and, as a result, MAO inhibitors (MAOi) are studied for the treatment 
of several psychiatric and neurological disorders.  
4 
 
In particular, MAO-B inhibitors are coadjuvant in the treatment of both Parkinson’s 
(PD) [4] and Alzheimer’s diseases (AD) [5], while MAO-A inhibitors are used as 
antidepressant and anxiolytic drugs. [6] 
Furthermore, the activity of MAO-B is enhanced by aging and in AD patients. [3,5]  
In addition to this, the deamination reaction, promoted by MAO-B, leads to the 
production of hydrogen peroxide and to other reactive oxygen species responsible for 
neurological damaging. [7-9] 
Also, in the case of PD, a correlation between free radical production and 
development of the pathology has been observed. [10] 
On the basis of the above we can assume that neurodegenerative disorders are 
associated with the production of oxidative stress, with an increased MAO-B activity, and 
with a decrease in the elimination rate of free radical species. [5-14] 
On the contrary, MAO-A does not increase with age, suggesting that a totally 
independent mechanism regulates the expression of the two enzymatic isoforms. [12,14] 
We have recently designed and synthesised some 1-thiocarbamoyl-3,5-diaryl-4,5-
dihydro-(1H)-pyrazole (I), 2-thiazolyl hydrazones (II), and series of 1-(N-
methyl)thiocarbamoyl-3-aryl-4,5-dihydro-1(H)-pyrazoles (III) and 1-thiocarbamoyl-3-aryl-
4,5-dihydro-1(H)-pyrazoles both, highly active and selective towards MAO-B isoform 
(Figure 2). [15-17]  
The synthesis, the MAO inhibition, and the pharmacophoric features of a series of 
1-acetyl-3-aryl-4,5-dihydro-1(H)-pyrazoles have been reported by Chimenti and 
colleagues. [18]  
In particular, it has been observed that the absence of substituents in position 5 of 


























Figure 2. Previously studied MAO inhibitors 
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More recently we reported on the synthesis and biological assessment of novel 2-
thiazolylhydrazones and the computational analysis of their recognition by monoamine 
oxidase B. [19] 
In particular it was highlighted the importance of fluorine atom interacting with the 
water close to the cofactor and the influence of steric bulkiness of substituents in the 
arylidene moiety. Free energy perturbation (FEP) analysis confirmed experimental data. 
 
2 Results and Discussion 
 
Recently, rasagiline, (N-propargyl-1-R-aminoindan,Azilect), a novel selective and 
irreversible MAO-B inhibitor, has been approved for PD therapy [20] while safinamide, a 
selective and reversible MAO-B inhibitor, is currently undergoing clinical phase III for the 
treatment of early stages of PD. [21] 
On this basis, as part of my PhD project, I focused my interest on the synthesis of 
potential MAO-B inhibitors. 
Firstly I have synthesized a series of chalcones EMAC 2143-2154 bearing a 3,4-
dichloro moiety. This substitution demonstrated to be particularly efficient in a series of 
3-Acetyl-2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoles. [22] 
All compounds were characterized with the usual analytic and spectroscopic 
methods and submitted to biochemical assay. 
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Figure 3. Structures of compounds EMAC 2143-2154 
 
We have, also, synthesized a series of 3,5-dihydropyrazole-1-carbothioamide, 
keeping the same aryl substituents  as in the chalcone series. 
The synthesis was accomplished by reacting chalcones EMAC 2143-2154 with 
thiosemicarbazide in ethanol and KOH alcoholic solution.  
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Scheme 1. Synthesis of (E)-3-(3,4-dichlorophenyl)-1-arylprop-2-en-1-one derivatives EMAC 
2143-2154. Reagents: (i) ethanol, NaOH 10 %; Synthesis of 5-(3,4-dichlorophenyl)-3-aryl-4,5-
dihydropyrazole-1-carbothioamide EMAC 2155-2164. (ii) thiosemicarbazide, ethanol, KOH  EtOH 
5% 
 
The first step consist of the formation of the chalcone derivative, synthesized via 
Claisen-Schmidt condensation of substituted acetophenone with 3’,4’-
dichlorobenzaldehyde under basic conditions in ethanol. Crude chalcones were purified 
by recrystallization from a suitable solvent. [23, 24]. 
All synthesized compounds were characterised by analytical and spectral data as 
listed in Table 3-6. 
All samples were measured in CDCl3 solvent at 278.1 K temperature on a Varian 
Unity 500 spectrometer and on a Varian Unity 300 spectrometer- 
In the signal assignments the proton chemical shifts are referred to the solvent (1H: 
δ= 7.24 ppm,).  
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In all investigated molecules the NMR analysis supports the “E” configuration 
(Figure 3), according to the double bond protons coupling constants that ranges from 15 








Figure 3. (E)-3-(3,4-dichlorophenyl)-1-arylprop-2-en-1-one 
 
The second step of the synthetic route is the reaction of the chalcone compound 
with thiosemicarbazide under basic condition ( KOH 5% in ethanol) to generate the 











Figure 4. 5-(3,4-dichlorophenyl)-3-aryl-4,5-dihydropyrazole-1-carbothioamide 
 
NMR spectroscopy was particularly efficient in the characterization of all the 
compounds. 
In the case of pyrazolines three sets of double doublets signals, in the region of 3.00 
and 6.05 ppm are diagnostic not only of the formation of the pyrazoline ring, but also of 
the exact position of the double bond within the dihydropyrazole nucleus. 
In fact, the two protons (B and C), on the carbon 4 of the pyrazoline ring, couple in 
cis and in trans with different vicinal constants with the proton of carbon 5 (A) (JA-B, JA-C) 
and between them with a geminal characteristic constant (JB-C), giving rise to the 
characteristic fine structure of three double doublets in the 
1












J cis Hb ≈ 4
J trans Hc ≈ 12
Hb
J cis Ha ≈ 4
J geminal Hc ≈ 15
Hc
J trans Ha ≈ 12
J geminal Hb ≈ 15
 
 








The activity of compounds EMAC 2143-2154 and EMAC 2155-2164 was measured 





Table 1. EMAC 2143-2154 IC50 values and MAO-B selectivity ratios [IC50 (MAO-A]/[ IC50 
(MAO-B] for the inhibitory effects of the test drugs on the enzymatic activity of human 










“D”-ring  MAO-A ( IC 50) MAO-B ( IC 50) RATIO 
 




















EMAC 2147 5.46 ± 0.43 μM
a
 1.15 ± 0.08 nM 4.748 
OH
 
EMAC 2148 12.31 ± 0.73 μM
a
 59.98 ± 3.63 nM 205 
Cl
 










EMAC 2151 4.48 ± 0.47 μM
a
 4.42 ± 0.21 nM 1.014 
NO2  




EMAC 2153 *** 3.78 ± 024 nM 26.738 
S
 
EMAC 2154 ** 60.97 ± 4.73 nM 1.640 
R-(-)-deprenyl 67.25 ± 1.02 µMa 19.60 ± 0.86 nM 3431.12 
All IC50 values shown in this table are the mean ± S.E.M. from five experiments. Level of statistical significance: 
a
P < 0.01 versus the corresponding IC50 values obtained against MAO-B, as determined by ANOVA/Dunnett´s. 
** Inactive at 100 µM (highest concentration tested). 





Values obtained under the assumption that the corresponding IC50 against MAO-A or MAO-B is 100 µM. 
All compounds exhibited good activity towards the B isoform of the enzyme 
corroborating the hypothesis that the introduction of the 3,4-dichloro moiety leads to the 
selectivity towards MAO B (Table 1). 
According to these results also the nature of the “D” ring seems to play a key role in 
determining both activity and selectivity. 
When a hydroxyl substituent is introduced, either in the position 4 or in the position 
3 of the D ring, a decrease in the isoform selectivity was observed. This behavior is also 
observed in the case of the 4-nitro substitution. 
Surprisingly when a nitro group is introduced in the position 3 of the D ring the best 
selectivity and activity are observed. Moreover, also the introduction of methyl or 3,4-di-
chloro substitution leads to active and selective compounds (ie EMAC 2144, EMAC 2145, 
and EMAC 2153). 
Generally all compounds are more active and/or selective with respect to R-(-)-
deprenyl that has been used as standard for the biochemical assay. 
Compounds EMAC 2155-2164 were characterized and submitted to biochemical 





Table 2. EMAC 2155-2164 IC50 values and MAO-B selectivity ratios [IC50 (MAO-A]/[ IC50 
(MAO-B] for the inhibitory effects of the test drugs on the enzymatic activity of human 








“D”-ring  MAO-A ( IC 50) MAO-B ( IC 50) RATIO 
 
EMAC 2155 ** **  
CH3
 
EMAC 2156 ** **  
CH3
 
EMAC 2157 ** **  
OCH3
 
EMAC 2158 ** **  
OH
 





EMAC 2160 ** ** ** 
Cl
 
EMAC 2161 ** **  
Br
 




EMAC 2163 *** ***  
S
 
EMAC 2164 ** **  
R-(-)-deprenyl 67.25 ± 1.02 M 19.60 ± 0.86 nM 3431.12 
All IC50 values shown in this table are the mean ± S.E.M. from five experiments. Level of statistical 
significance: 
a
P < 0.01 versus the corresponding IC50 values obtained against MAO-B, as determined by 
ANOVA/Dunnett´s. 
** Inactive at 100 µM (highest concentration tested). 
*** 100 µM inhibits the corresponding MAO activity by approximately 40-50%. At higher concentration 
the compounds precipitate. 
# 
Values obtained under the assumption that the corresponding IC50 against MAO-A or MAO-B is the 
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highest concentration tested (100 µM). 
Only compound EMAC 2159 is weakly active towards the A isoform of the enzyme.  
It might be conceivable that the 3,4-phenyl moiety in the position 5 of the 
dihydropyrazole ring is constrained in an unfavourable position to interact with the 
enzyme with respect to previously studied analogous compounds. [22] 
In all probability, in the case of derivatives EMAC 2143-2154, an optimal orientation 
of the two aryl substituents, with respect to the pyrazoline compounds, and a higher 
flexibility concur to the observed high activity and selectivity. 
To achieve a better comprehension of this behaviour we performed the alignment 
of the lowest energy conformers of compound EMAC 2144 and of the two enantiomers of 
compound EMAC 2156. 
 
 
Figure 6. A Pharmacophoric alignment of compounds EMAC 2144, (S) and (R)-EMAC 2156; B 
alignment of compounds EMAC 2144, (S) and (R)-EMAC 2156 based on 3,4-dichlorophenyl moiety 
superimposition 
 
In both cases a different orientation of the 4-methylphenyl substituent is observed 
and, in all probability, this leads to the decrease of activity of the pyrazoline derivatives 
with respect to the chalcone series. 
However we are performing docking experiments and dynamic simulations in order 
to achieve a more detailed picture of the behaviour of such compounds and to rationalise 
these data. 
Meanwhile we are concentrating our efforts on the synthesis of other heterocyclic 
rings (ie dihydroisoxazoles) bearing similar substitutions whit the aim of obtaining new 










The synthetic pathway is divided in two different step (Scheme 1). 
Unless otherwise noted, starting materials and reagents were obtains from 
commercial suppliers and were used without purification. 
All melting point were determined by the capillary method on a Stuart SMP11 
melting point apparatus and are uncorrected. 
All samples were measured in CDCl3 solvent at 278.1 K temperature on a Varian 
Unity 500 spectrometer and on a Variant Unity 300 spectrometer. In the signal 
assignments the proton chemical shifts are referred to the solvent (1H: δ = 7.24 ppm,). 
Coupling constants J are expressed in hertz (Hz). 
Elemental analyses were obtained on a Perkin–Elmer 240 B microanalyser. 
Analytical data of the synthesised compounds are in agreement with the theoretical data. 
HPLC-MS/MS analysis was performed using an HPLC-MS/MS Varian (Varian Palo 
Alto, CA, USA) system fitted with a 1200 L triple quadrupole mass spectrometer equipped 
with an electrospray ionization source (ESI). A Varian MS workstation version 6.8 software 
was used for data acquisition and processing. Rapid identification was achieved with 
direct infusion of the purified molecule, dissolved in methanol, on the mass spectrometer 
source.  
TLC chromatography was performed using silica gel plates (Merck F 254), spots 
were visualised by UV light. 
All synthesized compounds were characterised by analytical and spectral data as 











Compound “D” ring M.W. Mp (C°) % Yield 
EMAC 2143 
 
277.15 93-95 95 
EMAC 2144 CH3
 




291.17 111-113 94 
EMAC 2146 OCH3
 
307.17 125 93 
EMAC 2147 OH
 




293.14 135-136 92 
EMAC 2149 Cl
 
311.59 119-120 96 
EMAC 2150 Br
 
356.04 143-144 97 
EMAC 2151 NO2
 
322.14 221-222 95.5 
EMAC 2152 
NO2  































































































































































Compound “D” ring M.W. Mp (C°) % Yield 
EMAC 2155 
 
350.27 165-166 75 
EMAC 2156 CH3
 




364.29 182-183 86 
EMAC 2158 OCH3
 
380.29 215-216 85.5 
EMAC 2159 OH
 




366.26 229-230 85.5 
EMAC 2161 Cl
 
384.71 242-243 87 
EMAC 2162 Br
 




































































































































Synthesis of starting (E)-3-(3,4-dichlorophenyl)-1-arylprop-2-en-1-one derivatives. 
 
The starting (E)-3-(3,4-dichlorophenyl)-1-arylprop-2-en-1-one derivatives have been 
synthesised by according to the procedures reported in the literature. [23,24] 
In a flask equipped with a reflux condenser, a mixture of acetophenone (1.2 mol) 
was dissolved in ethanol and treated with a solution of sodium hydroxide in water 10%. 
After stirring the mixture for 10 min, a solution of 3,4-dichlorobenzaldehyde (1 mol) was 
added. The mixture was stirred at room temperature for 24 h and and the precipitate that 
formed was filtered off. The filtrate was washed with ethyl ether and recrystallized from 
water/ethanol (1:1) to offer pure compounds. 
 

















H-NMR (500 MHz, DMSO) δH 7.5 ( m, 5H, Ar-CH + CH=CH), 7.61 ( t, 1H, J: 7.5, Ar-CH), 



















H-NMR (500 MHz, DMSO) δH 2.45 ( s, 3H, CH3 ), 7.31 ( d, 2H, J: 7.5, Ar-CH), 7.45 ( d, 1H, J: 
8, Ar-CH), 7.49 ( d, 1H, J:8.5, Ar-CH), 7.5 ( d, 1H, J: 16, CH=CH), 7.68 ( d, 1H, J: 16, CH=CH), 























H-NMR (500 MHz, DMSO) δH 2.45 ( s, 3H, CH3), 7.41 ( m, 2H, Ar-CH), 7.48 ( m, 3H, Ar-CH 



















H-NMR (500 MHz, DMSO) δH 3.90 ( s, 3H, OCH3), 6.99 ( d, 2H, J: 8.5, Ar-CH), 7.45 ( d, 1H, 
J: 8, Ar-CH), 7.49 ( d, 1H, J:9, Ar-CH), 7.51 ( d, 1H, J: 15.5, CH=CH), 7.67 ( d, 1H, J: 16, 



















H-NMR (500 MHz, DMSO) δH 6.93 ( d, 2H, J: 8.5, Ar-CH), 7.27 ( s, 1H, OH), 7.48 ( m, 4H, 






















H-NMR (500 MHz, DMSO) δH 7.15 ( d, 1H, J: 8, J: 2.5, AR-CH), 7.41 ( t, 1H, J: 8, Ar-CH), 
7.58 ( s, 1H, J: 2), 7.68 ( m, 2H, Ar-CH), 7.73 ( d, 1H, J: 15.5, CH-CH), 7.83 ( d, 1H, J: 8.5, J: 



















H-NMR (500 MHz, DMSO) δH 7.47 (m, 5H, Ar-CH + CH=CH), 7.7 ( d, 1H, J: 15.5, CH=CH), 



















H-NMR (500 MHz, DMSO) δH 7.47 (m, 3H, J: 15.5, Ar-CH + CH=CH), 7.66 ( d, 2H, J: 8.5, Ar-






















H-NMR (500 MHz, DMSO) δH 7.5 ( m, 3H, J: 15.5, Ar-CH + CH=CH), 7.76 ( m, 2H, J: 15.5, 
Ar-CH + CH=CH), 8.15 ( d, 2H, J: 8, Ar-CH), 8.37 ( d, 2H, J: 8, Ar-CH) 
 


















H-NMR (500 MHz, DMSO) δH 7.5 ( d, 1H, J: 8, Ar-CH), 7.52 ( d, 1H, J: 8, Ar-CH), 7.53 ( 
d,1H, J: 16, CH=CH), 7.74 ( t, 1H, J: 8), 7.77 ( s, 1H, Ar-CH), 7.78 ( d, 1H, J: 16, CH=CH), 8.35 






















H-NMR (500 MHz, DMSO) δH 7.42 ( d, 1H, J: 15.5, CH=CH), 7.47 ( d, 1H, J: 8, Ar-CH), 7.52 
( d, 1H, J: 8.5, Ar-CH), 7.6 ( d, 1H, J: 8, Ar-CH), 7.72 ( d, 1H, J: 15.5, CH=CH), 7.74 ( s, 1H, Ar-






















H-NMR (500 MHz, DMSO) δH 7.2 ( t, 1H, J: 4, J: 5, thiop.), 7.38 ( d, 1H, J: 15.5, CH=CH), 
7.45 ( d, 1H, J: 8.5, Ar-CH), 7.5 ( d, 1H, J: 8.5, Ar-CH), 7.72 ( d, 1H, J: 5, thiop.), 7.72 ( d, 1H, 





Synthesis of 5-(3,4-dichlorophenyl)-3-aryl-4,5-dihydropyrazole-1-carbothioamide. 
 
5-(3,4-dichlorophenyl)-3-aryl-4,5-dihydropyrazole-1-carbothioamide was synthe- 
sised by reacting 1 mol of chalcone 1.2 mol of thiosemicarbazide and KOH in ethanol as 
depicted in Scheme 1. After 24 hours the precipitate that formed was filtered off. The 
filtrate was washed with ethyl ether and recrystallized from water/ethanol (1:1) to offer 
pure compounds. 
 






















H-NMR (300 MHz, DMSO) δH 3.17 ( dd, 1H, J: 4, J: 17.9; pyr), 3.86 ( dd, 1H , J: 12, J: 17.9, 
pyr), 5.99 ( dd; 1H, J: 4, J: 15, pyr), 6.08 (brs, 2H, NH2 ), 7.08 (d, 1H, J: 2.16, J: 8.32, Ar-CH), 
7.30 (s, 1H, J: 2.16, Ar-CH), 7.40 ( d, 1H, J: 8.32, Ar-CH), 7.46 ( m, 3H, Ar-CH), 7.72 ( d, 2H, 


























H-NMR (300 MHz, DMSO) δH 2.46 ( s, 3H, CH3), 3.32 ( dd, 1H, J: 4, J: 18, pyr), 3.99 ( dd, 
1H , J: 12, J: 18, pyr), 6.03 ( dd; 1H, J: 4, J: 12, pyr), 7.22 (d, 1H, J: 2, J: 8.32, Ar-CH), 7.39 ( 
d, 2H, J: 8.32, Ar-CH), 7.49 (s, 1H, Ar-CH), 7.70 ( d, 1H, J: 8.34, Ar-CH), 7.88 ( d, 2H, J: 8.01, 
























H-NMR (300 MHz, DMSO) δH 2.40 ( s, 3H, CH3), 3.16 ( dd, 1H, J: 4, J: 18, pyr), 3.84 ( dd, 
1H , J: 11.6, J: 18, pyr), 5.98 ( dd; 1H, J: 4, J: 11.6, pyr), 6.10 (brs, 2H, NH2), 7.07 (d, 1H, J: 
2.17, J: 8.32, Ar-CH), 7.32 (m, 3H, Ar-CH), 7.39 ( d, 1H, J: 8.32, Ar-CH), 7.5 ( m, 1H, Ar-CH), 


























H-NMR (300 MHz, DMSO) δH 3.31 ( dd, 1H, J: 3, J: 18, pyr), 3.92 (s, 3H, OCH3), 3.98 ( dd, 
1H , J: 11.5, J: 18, pyr), 6.02 ( dd; 1H, J: 3, J: 11.5, pyr), 7.12 (d, 2H, J: 8, Ar-CH), 7.21 ( d, 
1H, J: 8, Ar-CH), 7.48 (s, 1H, Ar-CH), 7.70 ( d, 1H, J: 8.6, Ar-CH), 7.93 ( d, 2H, J: 8.6, Ar-CH), 























H-NMR (300 MHz, DMSO) δH 3.26 ( dd, 1H, J: 3, J: 18, pyr), 3.45 ( dd, 1H , J: 11.2, J: 18, 
pyr), 6.00 ( dd; 1H, J: 3, J: 11.2, pyr), 6.93 (d, 2H, J: 8.5, Ar-CH), 7.21 (d, 1H, J: 1.8, J: 8.34, 
Ar-CH), 7.47 ( s, 1H, Ar-CH), 7.70 ( d, 1H, J: 8.34, Ar-CH), 7.82 ( d, 2H, J: 8.5, Ar-CH) 7.93 ( 


























H-NMR (300 MHz, DMSO) δH 3.27 ( dd, 1H, J: 3, J: 18, pyr), 3.99 ( dd, 1H , J: 11.6, J: 18, 
pyr), 6.02 ( dd; 1H, J: 3, J: 11.6, pyr), 7.00 (d, 1H, J: 8, Ar-CH), 7.22 (d, 1H, J: 8, Ar-CH), 7.38 
( m, 3H, Ar-CH), 7.48 ( s, 1H, Ar-CH), 7.70 ( d, 1H, J: 8, Ar-CH) 8.02 ( brs, 1H, NH2), 8.24 























H-NMR (300 MHz, DMSO) δH 3.34 ( dd, 1H, J: 4, J: 18, pyr), 4.00 ( dd, 1H , J: 11.5, J: 18, 
pyr), 6.04 ( dd; 1H, J: 4, J: 11.5, pyr), 7.22 (d, 1H, J: 8.5, Ar-CH), 7.49 (s, 1H, Ar-CH), 7.70 ( 
d, 2H, J: 8.3, Ar-CH), 7.78 ( d, 1H, J: 8.5, Ar-CH), 7.79 ( d,2H, J: 8.3, Ar-CH), 8.16 ( brs, 1H, 


























H-NMR (300 MHz, DMSO) δH 3.34 ( dd, 1H, J: 4, J: 18, pyr), 4.00 ( dd, 1H , J: 11.5, J: 18, 
pyr), 6.04 ( dd; 1H, J: 4, J: 11.5, pyr), 7.22 (d, 1H, J: 8.5, Ar-CH), 7.49 (s, 1H, Ar-CH), 7.70 ( 
d, 2H, J: 8.3, Ar-CH), 7.78 ( d, 1H, J: 8.5, Ar-CH), 7.79 ( d,2H, J: 8.3, Ar-CH), 8.16 ( brs, 1H, 


























H-NMR (300 MHz, DMSO) δH 3.38 ( dd, 1H, J: 4, J: 18.5, pyr), 3.99 ( dd, 1H , J: 12, J: 18.5, 
pyr), 6.05 ( dd; 1H, J: 4, J: 12, pyr), 7.22 (d, 1H, J: 8.5, Ar-CH), 7.50 (s, 1H, Ar-CH), 7.70 ( d, 
1H, J: 8.34, Ar-CH), 7.84 ( d, 1H, J: 8.34, Ar-CH), 7.91 ( d, 1H, J: 8.5, Ar-CH), 8.32 (m, 3H, 


























H-NMR (300 MHz, DMSO) δH 3.38 ( dd, 1H, J: 4, J: 18, pyr), 4.05 ( dd, 1H , J: 11.4, J: 18, 
pyr), 6.07 ( dd; 1H, J: 4, J: 11.4, pyr), 7.22 (d, 1H, J: 8.4, Ar-CH), 7.27 (t, 1H, J: 3.8, J: 4.7, 
thiofene), 7.50 ( s, 1H, Ar-CH), 7.60 ( d, 1H, J: 3.8, thiofene), 7.71 ( d, 1H, J: 8.4, Ar-CH), 





3.2 Pharmacologic studies 
 
3.2.1. Determination of MAO isoform activity 
 
The potential effects of the test drugs on human monoamineoxidase (hMAO) 
activity were investigated by measuring their effects on the production of hydrogen 
peroxide H2O2 from p-tyramine (a common substrate for both hMAO-A and hMAO-B), 
using the Amplex®Red MAO assay kit (Molecular Probes, Inc., Eugene, Oregon, USA) and 
microsomal MAO isoforms prepared from insect cells (BTI-TN-5B1-4) infected with 
recombinant baculovirus containing cDNA inserts for hMAO-A or hMAO-B (SigmaeAldrich 
Química S.A., Alcobendas, Spain). The production of H2O2 catalysed by MAO isoforms can 
be detected using 10-acetyl-3,7-dihydroxyphenoxazine (Amplex®Red reagent), a non-
ﬂuorescent, highly sensitive and stable probe that reacts with H2O2 in the presence of 
horseradish peroxidase to produce a ﬂuorescent product: resoruﬁn. In this study, hMAO 
activity was evaluated using the above method following the general procedure described 
previously by us. [25] 
Brieﬂy, 0.1 ml of sodium phosphate buffer (0.05 M, pH 7.4) containing the test 
drugs (new compounds or reference inhibitors) in various concentrations and adequate 
amounts of recombinant hMAO-A or hMAO-B required to oxidize (in the control group) 
165 p mol of p-tyramine/min were incubated for 15 min at 37 °C in the corresponding 
wells from a 96-well ﬂatbottom microtiter plate (BD, Franklin Lakes, NJ, USA) placed in 
the dark ﬂuorimeter chamber. After this incubation period, the reaction was started by 
adding (ﬁnal concentrations) 200 mM Amplex®Red reagent, 1 U/ml horseradish 
peroxidase and 1 mM p-tyramine as a common substrate for both hMAO-A and hMAO-B. 
The production of H2O2 and, consequently, of resoruﬁn was quantiﬁed at 37°C in a Multi-
Detection microplate ﬂuorescence reader (FLX800TM, Bio-Tek®Instruments, Inc., 
Winooski, VT, USA) based on the ﬂuorescence generated (excitation 545 nm, emission 
590 nm) over a 15 min period, a period in which the ﬂuorescence increased linearly from 
the beginning. Control experiments were carried out simultaneously by replacing the test 
drugs (new compounds and reference inhibitors) with appropriate dilutions of the 
vehicles. In addition, the possible ability of the above test drugs to modify the 
ﬂuorescence generated in the reaction mixture due to non-enzymatic inhibition (e.g., for 
directly reacting with Amplex®Red reagent) was determined by adding these drugs to 
solutions containing only the Amplex®Red reagent in a sodium phosphate buffer. The 
speciﬁc ﬂuorescence emission (used to obtain the ﬁnal results) was calculated after 
subtraction of the background activity, which was determined from vials containing all 
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components except the MAO isoforms, which were replaced by a sodium phosphate 
buffer solution.  
3.2.2 Data presentation and statistical analysis 
 
Unless otherwise speciﬁed, results shown in the text and table are expressed as 
mean ± standard error of the mean (S.E.M.) from n experiments. Signiﬁcant differences 
between two means (P < 0.05 or P < 0.01) were determined by one-way analysis of 
variance (ANOVA) followed by the Dunnett’s post-hoc test.  
To study the possible effects of the test drugs (new compounds or reference 
inhibitors) on MAO isoform enzymatic activity, the variation of ﬂuorescence per unit of 
time (ﬂuorescence arbitrary U/min) and, indirectly, the rate of H2O2 production and, 
therefore, the p mol/min of resoruﬁn produced in the reaction between H2O2 and 
Amplex®Red reagent was evaluated. For this purpose, several concentrations of resoruﬁn 
were used to prepare a standard curve with X = p mol resoruﬁn and Y = ﬂuorescence 
arbitrary U. Note that the value of resoruﬁn production is similar to the p mol of p-
tyramine oxidized to p-hydroxyphenylacetaldehyde per min since the stoichiometry of 
the reaction (p-tyramine oxidized by MAO isoforms/resoruﬁn produced) is 1:1.  
In these experiments, the inhibitory activity of the tested drugs (new compounds 
and reference inhibitors) is expressed as IC50, i.e. the concentration of these compounds 
required to reduce by 50% the control MAO isoform enzymatic activity, estimated by 
leasts-quares linear regression, using the Origin
TM
 5.0 program (Microcal Software, Inc., 
Northampton, MA, USA), with X = log of tested compound molar concentration and Y = 
the corresponding percentage of inhibition of control resoruﬁn production obtained with 
each concentration. This regression was performed using data obtained with 4-6 different 
concentrations of each tested compound which inhibited the control MAO isoform 
enzymatic activity by between 20 and 80%. In addition, the corresponding MAO-B 
selectivity ratios (SI A/B) [IC50 (MAO-A)]/[IC50 (MAO-B)] were calculated. 
 
3.2.3  Drugs and chemicals 
 
The drugs used in the experiments were the new compounds, moclobemide (a 
generous gift from F. Hoffmann-La Roche Ltd., Basel, Switzerland), R-(-)-deprenyl 
hydrochloride, iproniazid phosphate (purchased from SigmaeAldrich, Spain), resoruﬁn 
sodium salt, clorgyline hydrochloride, p-tyramine hydrochloride and horseradish 
peroxidase (supplied in the Amplex® Red MAO assay kit from Molecular Probes). 
Appropriate dilutions of the above drugs were prepared every day immediately 
before use in deionized water from the following concentrated stock solutions kept at -20 
°C: the new compounds (0.1 M) in dimethylsulfoxide (DMSO); R-(-)-deprenyl, 
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moclobemide, iproniazid, resoruﬁn, clorgyline, p-tyramine and horseradish peroxidase 
(0.1 M) in deionized water. 
Due to the photosensitivity of some chemicals (e.g., Amplex®Red reagent), all 
experiments were performed in the dark. In all assays, neither deionized water (Milli-Q®, 
Millipore Ibérica S.A., Madrid, Spain) nor appropriate dilutions of the vehicle used (DMSO) 
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1.1 Historical overview 
 
In a recent study published in Nature Chemistry a method to quantitatively visualize 
DNA G-quadruplex structures in human cells has been reported.  
This work clear links between concentrations of four-stranded quadruplexes and 
the process of DNA replication, which is pivotal to cell division and production. 
Furthermore, it corroborates the application of stabilizing ligands in a cellular 
context to target G-quadruplexes and interfere with their function. [1] 
G-quadruplex structures are nucleic acid arrangements assumed by guanine-rich 




Figure 1. Chemical structure of the G-quartet that is formed by Hoogsteen base pairs of 
four guanine bases 
 





) which are required to stabilize the structure through their 
coordination to the guanyl oxygens. The overlapping of G-quartet tetrads leads to the 
formation of more complex structures called G-quadruplexes. These sequences are found 
in crucial positions of the genome, such as telomeric ends, ribosomal DNA (rDNA), RNA or 
gene promoter regions (for es. c-myc, bcl-2 or c-kit). [2] 
Their composition and location is conserved through evolution and, additionally, 
several proteins are devoted to recognize or resolve them, [3] thus indicating regulatory 
roles of these structures in multiple biological processes. [4]  
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In normal cells the telomeric DNA is gradually shortened after each replication cycle 
until a critical limit is reached (“Hayflick Limit”), leading to cellular senescence and, 
ultimately, to apoptosis. The enzyme telomerase, which has a reverse transcriptase 
subunit (hTERT) and an RNA component (hTERC), adds TTAGGG repeats to telomeres 
providing their elongation and, subsequently, cell immortalization (Figure 2). [5] 
 
 
Figure 2. Telomerase mechanism of action 
 
A number of studies highlighted that immortality of cancer cells is due, at least in 
part, to constitutive expression of telomerase, while somatic cells either entirely lack 
telomerase or exceptionally express low levels. Its action is detected in most primary 
human tumour specimens and tumour-derived cell lines, such as those of the prostate, 
breast, colon, lung and liver.  
Hence, inhibition of this enzyme can selectively prevent cancer cells growth.  
Several small molecule inhibit telomerase directly, e.g GRN163L, BIBR1532 and AZT 
(Figure 3). [6, 7] 
 
 
Figure 3. Agents targeting hTERC and hTERT of telomerase enzyme 
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A different approach is the stabilization of G-quadruplex-DNA. 
G-quadruplex-DNA stabilizers preclude the binding of telomerase and its associated 
proteins to telomeres and, thereby, stop the elongation process of telomerase indirectly.  
Equally important is the stabilization of G-quadruplex in promoter regions or in 
rDNA and rRNA to achieve selective gene regulation. [8-10]
  
Quadruplexes can be formed from one, two or four separate strands of DNA (or 
RNA) and can show a wide variety of topologies, depending on combinations of strand 
orientation, loops size and glycoside conformation sequence.  
These different arrangements are dictated not only by the nucleic acid sequence, 
but, as in the case of the human telomeric DNA, a given sequence can fold into a variety 
of different conformations according to environmental transitions. [11] 
Indeed, whereas the crystal structure of the DNA G-quadruplex assumed by wild 
type Tel22 AG3[T2AG3]3 in K
+
 is parallel stranded, [12] multiple G-quadruplex 




Figure 4. Schematic and 3D representation of the a) antiparallel or basket-type (PDB code 
143D), [13] b) parallel or propeller-like (PDB code 1KF1),[12] c) hybrid type-1 (PDB code 2HY9) 
[14] and d) hybrid type-2 (PDB code 2JPZ)[15] DNA G-quadruplex conformations of d(AG3[T2AG3]3) 
sequence 
Several studies have been devoted to develop novel G-quadruplex binders (Figure 
5). [16]  
6 
 
The common structural feature of all these ligands is an extended polyaromatic 
(often heteroaromatic) planar chromophore, generally composed of three or four fused 
rings, bearing one or more positive charge(s). 
The natural product telomestatine, composed of one thiazoline and seven oxazole 
rings, was reported to be a potent nanomolar telomerase inhibitor, with evidence 
indicating that its mechanism of action also involves a G-quadruplex complex. [17]  
 
 
Figure 5. Some of the human telomeric DNA G-4 binders available in literature 
 
An essential requirement for telomerase inhibition and antitumor effect is the low 
concentration of inhibitor, which needs to be below acute toxicity levels, otherwise 
generalized cytotoxic effect outside tumours will take place.  
In some cases, it was reported that antitumor agents that bind to duplex DNA, may 
develop their cytotoxic activity by interfering with transcription or with the correct 
function of DNA topoisomerases or other enzymes involved in DNA replication. 
G4-binders may be accommodated in multiple sites of the structure: mainly they 
can stack on the G-tetrads, but they can also be located into the grooves or can interact 





Figure 6. Binding modes: a) Schematic representation of possible ligand-quadruplex binding 
modes a) stacking or intercalation between internal tetrads b) groove recognition; c) interaction 
with single strand loops d) simultaneously end stacking and loop interaction or simultaneously 
end stacking and binding into the grooves b) stacking (BRACO-19, pdbcode 3CDM [19]); c) groove 
and loop interaction (distamycin, pdbcode 2KVY [20]) 
 
Although some of them achieved preclinical and clinical phase, none reached the 
market so far. The major limitations associated to their questionable biological use are 
the poor selectivity for quadruplex DNA, the propensity to aggregate in aqueous media, 
the poor water-solubility, and the chemical instability. [21] 





2 Fluorenone derivatives 
 
A small series of fluorenone derivatives demonstrated to selectively bind the human 







compound R compound R 
1 -(CH2)2OH 6 -(CH2)2N(CH3)2 
2 -(CH2)3OH 7 -(CH2)3N(CH3)2 
3 -CH2CH(OH)CH3 8 -(CH2)2N(CH2CH3)2 
4 -(CH2)OH 9 -(CH2)2-Morph 
5 -(CH2)O(CH2)2OH 10 -(CH2)3-Morph 
 
Figure 7. Chemical structures of first series of fluorenones compounds 1–10 
 
Among them the most interesting were the compounds 9 and 10 substituted with 
morpholino side-chain able to interact selectively with the DNA G-quadruplex (Figure 7). 
Consistent diﬀerential eﬀects on the binding preferences of the morpholino 
derivatives 9 and 10 were conﬁrmed by molecular modeling, demonstrating a major role 





Figure 8. Best docking pose of compound 10 into G-quadruplex with parallel conformation 
(pdbcode 1KF1) 
 
Considering these preliminary interesting results, an optimization of the fluorenone 
analogues was performed using the GRID method. [23] 
On the basis of the GRID MIFs (Molecular Interaction Fields) [24] visualization 
results, it was decided to insert a quaternary nitrogen at the morpholino side chain 
because NM3 (Trimethyl Ammonium cation) probe mapped as energetically favoured 





Figure 9. NM3 (quaternary nitrogen) MIFs maps obtained with GRID software in the G-
quadruplex with parallel conformation 
 
A series of nine novel compounds were designed and synthesized with the following 
chemical features: 
-quaternary nitrogen at the morpholino side chain; 
-variable linker between the morpholino and fluorenone rings (from 0 to 3 
methylenes); 




































































                     IC50 [µM] 
compound 
M14 A549 
11 >200 183±5.3 
12 >200 >200 
13 79.5±3.2 70.5±2.9 
14 72.2±4.6 45±3.9 
15 >200 123±4.8 
16 >200 >200 
17 145±5.5 94.16±4.5 
18 105±4.9 61.5±4.9 
19 >200 >200 
 
Table 1. Summary of the in vitro results of compounds 11–19 against melanoma (M14) and 
lung (A549) cancer cell lines 
 
Docking experiments coupling opensource AutoDock[25] with our collaborators in-
house docking code MolInE [26] were performed and a good correlation with 
experimental data was achieved (Table 2). 
 
Lig MolInE    AutoDock   Consensus  A549 
 1KF1 143D 2HY9 2JPZ 1KF1 143D 2HY9 2JPZ MolInE AD Both IC50 (μM) 
13 -41.9 -36.2 -34.5 -40.4 -41.4 -37.1 -40.6 -43.8 -38.3 -40.7 -39.5 70.5 
14 -46.3 -37.6 -45.5 -43.8 -41.3 -41.0 -39.6 -48.7 -43.3 -42.7 -43.0 45.0 
17 -41.1 -36.3 -34.3 -41.0 -31.2 -33.8 -32.4 -40.6 -38.2 -34.5 -36.3 94.0 
18 -39.6 -35.7 -39.5 -45.5 -36.0 -36.9 -41.7 -38.1 -40.1 -38.2 -39.1 61.5 
 
Table 2. Docking results obtained with the X-ray (1KF1), NMR (143D) and hybrid optimized 
(2HY9 and 2JPZ) PDB models in complex with the most active compounds 
 
Computational results indicated that the 2-substituted derivatives (13, 14, 17, and 
18) perform better than their 4-substituted analogues. Moreover the quaternarisation of 




A small increment of G-quadruplex melting point was registered. 
 
Figure 11. Competition dialysis results for compounds 11–19 against three polymorphforms 
of DNA: duplex, triplex, and G-quadruplex as indicated 
 
Furthermore compound 18 induced an appealing stabilization of pu24-l, a portion of 




Figure 12. Relative variations of G-quadruplex structure melting temperatures with 
reference to human telomeric sequence at K+50 mm concentration. Data refer to 30 mM ligand 




3 Results and Discussion 
New derivatives were designed and their ability to stabilize G-quadruplex structures 
was simulated by carrying out docking experiments following the same protocol applied 
before. The DNA G-quadruplex polymorphism including parallel, anti-parallel and hybrid 
conformations of the human telomeric repeated sequence was considered (Figure 4). 
Furthermore it has been investigated also the ability of the new series to stabilize the c-
myc promoter region (Figure 13). 
 
 
Figure 13. a) Sequence and b) Schematic and c) 3D representation of c-myc (1XAV[28]) 
 
All combinations of double substitution were investigated and the most promising 
compounds resulted to be the 2,7 substituted.  
 
Thus a synthetic route was set (Scheme 1): the first step consists of the formation of 
the dichloride of the 9-oxo-9H-fluorene-2,7-dicarboxylic acid. Then the acid dichloride is 
reacted with the morpholinomethyleneamine side-chain to obtain compounds EMAC 
2165-2166. The last step consists of a quaternization of morpholiniun nitrogen with CH3I 








































Y= N, O, C, NCH3
n= 1, 2, 3
9-oxo-9H-fluorene-2,7-dicarboxylic acid 9-oxo-9H-fluorene-2,7-dicarbonyl dichloride
 
 
Scheme 1. Synthetic pathway to compounds EMAC 2165-2172. Reagents: (i) SOCl2, reflux 









































EMAC 2165 EMAC 2166
EMAC 2167 EMAC 2168
 
Figure 14. Structure of compounds EMAC 2165-2168 
 




Figure 15. Screening of selected compounds by fluorescence melting experiment 





The good ability to stabilize the G-quadruplex both telomeric and promoter 
confirms the results obtained by the computational studies.  
In particular compounds EMAC 2166 and EMAC 2168 show a remarkable and 
selective effect on the stabilization of pu24 C-myc promoter, indicating that the optimal 
length of the methylene spacer for this specific target is three. 
Moreover, as it was previously observed, the introduction of the positive charge on 
the morpholine nitrogen is well tolerated and may constitute an advantage for the water-
solubility of these series of ligands.  
In order to understand the binding mode of these derivatives, preliminary docking 
experiments have been performed (Figure 16). 
 
 
Figure 16. Best pose complex structure of the unimolecular G-quadruplex formed by the c-







The conformational polymorphism of the G-quadruplex DNA human telomeric 
repeated sequence is an issue to face with in structure-based research projects. 
The fluorenone scaffold has been used as starting point for lead optimization 
workflow. This was carried out with different computational approaches.  
The new synthesized derivatives are able to induce increments not only of the DNA 
human telomeric sequence melting temperature but also of the c-myc promoter 
intramolecular G-quadruplex portion (∆Tm ~19 °C).  
Therefore 2,7 functionalized fluorenone could represent a promising scaffold for 
the development of potent stabilizers of c-myc promoter G-quadruplex as antineoplastic 
agents. In fact the overexpression of mutated c-myc protoncogene is often associate with 
a significant number of human malignancies, including colon and cervical cancers, 
myeloid leukemias, B and T cell lymphomas, and glioblastomas (8).  
At the moment we are synthesizing new 2,7 substituted fluorenone derivatives 
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Scheme 2: Synthetic pathway to new fluorenone EMAC 2169-2172. Reagents: (i) CHCl3, 





COMPOUNDS EMAC 2165-2168 
 
Unless otherwise noted, starting materials and reagents were obtains from 
commercial suppliers and were used without purification. 
All melting point were determined by the capillary method on a Stuart SMP11 melting 
point apparatus and are uncorrected. 
All samples were measured in CDCl3 solvent at 278.1 K temperature on a Varian 
Unity 500 spectrometer. In the signal assignments the proton chemical shifts are referred 
to the solvent (1H: δ = 7.24 ppm,). Coupling constants J are expressed in hertz (Hz). 
Elemental analyses were obtained on a Perkin–Elmer 240 B microanalyser. 
Analytical data of the synthesised compounds are in agreement with the theoretical data. 
HPLC-MS/MS analysis was performed using an HPLC-MS/MS Varian (Varian Palo 
Alto, CA, USA) system fitted with a 1200 L triple quadrupole mass spectrometer equipped 
with an electrospray ionization source (ESI). A Varian MS workstation version 6.8 software 
was used for data acquisition and processing. Rapid identification was achieved with 
direct infusion of the purified molecule, dissolved in methanol, on the mass spectrometer 
source.  
TLC chromatography was performed using silica gel plates (Merck F 254), spots 























In a flask equipped with a reflux condenser 9-oxo-9H-fluorene-2,7-dicarboxylic acid 
( 7.46 mmol) was dissolved in sulfuryl dichloride that was added in excess (15 ml). The 
reaction was monitored with TLC (eluent ethyl acetate:hexane 1:1,5). After 24 hours 
under vigorous stirring at reflux condition, the precipitate that formed was filtered off. 
The filtrate was washed with isopropyl ether to offer pure compounds that appeared like 
a yellow crystalline solid. 
 




























In a flask equipped with a reflux condenser 1g of 9-oxo-9H-fluorene-2,7-dicarbonyl 
dichloride (7.46 mmol) was dissolved in 10 ml of chloroform. 
After vigorous stirring for 3 minute, 2-morpholinoethanamide was added in excess (9.84 
mmol). The reaction was heated under reflux and monitored by TLC (eluent: ethyl 
acetate:hexane 1:1.5). After 2 hours the reaction was completed . A solid was filtered off 





M.W.: 492.57 g/mol; R.F.: 0.47 ( eluent: ethyl acetate:hexane 1:1,5); M.P.: 270 °C; Yield: 
60% 
1
H-NMR (300 MHz, CDCl3) δH 2.57 ( m, 8H, morpholino), 2.67 ( m, 4H, CH2), 3.61 ( m, 4H, 
CH2), 3.77 ( m, 8H, morpholino), 7.02 ( brs, 2H, NH), 7.59 ( d, 2H, J: 7.7, Ar-CH), 7.96 ( s, 
























In a flask equipped with a reflux condenser 1g of 9-oxo-9H-fluorene-2,7-dicarbonyl 
dichloride ( 7.46 mmol) was dissolved 10 ml of chloroform. After vigorous stirring for 3 
minute, 2-morpholinopropylamide was added in excess ( 9.84 mmol). The reaction was 
heated under reflux and monitored by TLC ( eluent: ethyl acetate:hexane 1:1.5). After 2 
hours the reaction was completed .and solvent removed under vacuum. A greasy solid 
was obtain, which was friabilysed in acetone. 
The desired pure compound appeared like a yellow crystalline solid.  
 




H-NMR (500 MHz, DMSO) δH 1.71 ( m, 4H, CH2), 2.37 ( m, 8H, morpholino), 3.31 ( m, 8H, 
CH2 morpholino), 3.58 ( m, 8H, CH2), 7.98 ( d, 2H, J: 7.5, Ar-CH), 8.12 ( s, 2H, Ar-CH), 8.15 ( 





























0.3 g of N2,N7-bis(2-morpholinoethyl)-9-oxo-9H-fluorene-2,7-dicarboxamide ( 0.61 
mmol), K2CO3 ( 2.4mmol), CH3I ( 2.4 mmol) and DMF were introduced in a flask equipped 
with a reflux condenser. The reaction was heated under reflux and after 3 hours it can be 
observe the colour changes from yellow to orange. The reaction was monitoreted with 
TLC ( eluent: ethyl acetate:hexane 1:1.5) and after 4 hours it was completed. At R.T. it can 
be observed the formation of a crystalline yellow solid. A solid was filtered off and 
characterised. 
 




H-NMR (400 MHz, DMSO) δH 3.08 ( s, 8H, morpholino), 3.3 ( m, 14H, CH3 + CH2 
morpholino), 4.00 ( m, 4H, CH2),4.45 ( m, 4H, CH2), 8.00 ( d, 2H, J: 7.5, Ar-CH), 8.01 ( s, 2H, 

























CH3I / K2CO3 / DMF
∆
 
N2,N7-bis(2-morpholinopropyl)-9-oxo-9H-fluorene-2,7-dicarboxamide (0.61 mmol, 
0.33 g), K2CO3 (2.4mmol), CH3I (2.4 mmol) and DMF were introduced in a flask equipped 
with a reflux condenser. The reaction was heated under reflux and after 3 hours it can be 
observed the colour changes from orange to dark green. The reaction was monitoreted 
with TLC ( eluent: ethyl acetate:hexane 1:1.5) and after 4 hours it was completed. At R.T. 
24 
 
it can be observed the formation of a crystalline yellow solid. The solid was filtered off 
and characterised. 




H-NMR (500 MHz, DMSO) δH 1.71 ( m, 4H, CH2), 2.36 ( m, 8H, morpholino), 3.31 ( m, 
14H, CH3 + CH2 morpholine), 3.58 ( m, 8H, CH2), 7.98 ( d, 2H, J: 7.5, Ar-CH), 8.12 ( s, 2H, Ar-
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Scheme 3. Synthetic pathway to compounds EMAC 2169-2172. Reagents: (i) CHCl3, reflux 
























































































Scheme 4: Synthesis of 1-(3-aminiopropyl)-4-methylpiperazine. Reagents: (i) Xylene, reflux 
condition; (ii) Hydrazine monohydrate, ethanol/methanol, reflux condition 
 
 















A solution of N-(3-bromopropyl)phthalimide (15 mmol), in xylene (30 ml), was 
added dropwise to a solution of 1-methylpiperazine (33 mmol), in xylene at 70°C. the 
mixture was heated under reflux for 20 hours, precipitate was removed by filtration and 
the filtrate was concentrated. The crude product was purified by silica gel 
chromatography with CH2Cl2:MeOH 9:1 to give the desired pure compound, that 
appeared as an dark yellow oil.  
 
M.W.: 287.36 g/mol; Yield: 72% 


























A solution of N-(3-(4-methylpiperazin-1-yl)propyl)phthalimide (10.8 mmol) and 
hydrazine monohydrate ( 13 mmol) in ethanol ( 30 ml) and methanol ( 30 ml) was 
refluxed for 4 hours. After cooling to R.T., concentrated HCl ( 1,2 ml) was added and the 
mixture heated under reflux for another hours. After removing the solvent, water ( 50 ml) 
was added, the mixture stirred and insoluble material removed by filtration. 
Solid K2CO2 ( 0.6 eq) and CH2Cl2 ( 50 ml) was added to the aqueous layer; the mixture was 
stirred and filtered. The organic layer was washed with water (3x20ml). The combined 
aqueous layer were washed with ethanol. Water was removed from the organic layer, 
which were then dried and evaporated to give the pure desired compound as an oil.  
 
M.W.: 157.26 g/mol; Yield: 39% 







































Scheme 5: Synthesis of 1-(3-aminioethyl)-4-methylpiperazine. Reagents: (i) Xylene, reflux 
condition; (ii) Hydrazine monohydrate, ethanol/methanol, reflux condition 
 














A solution of N-(2-bromoethyl)phthalimide ( 15 mmol), in xylene (30 ml), was added 
dropwise to a solution of 1-methylpiperazine ( 33 mmol), in xylene at 70°C.  
The mixture was heated under reflux for 20 hours, precipitate was removed by filtration 
and the filtrate was concentrated. 
The crude product was purified by silica gel chromatography with CH2Cl2:MeOH 9:1 to 
give the desired pure compound, that appeared as a pale pink solid.  
 
M.W.: 273.33 g/mol; M.P.: 199°-220°C; Yield: 62% 



























A solution of N-(2-(4-methylpiperazin-1-yl)ethyl)phthalimide (10.8 mmol) and 
hydrazine monohydrate (13 mmol) in ethanol (30 ml) and methanol (30 ml) was refluxed 
for 4 hours. After cooling to R.T., concentrated HCl (1,2 ml) was added and the mixture 
heated under reflux for another hours. After removing the solvent, water (50 ml) was 
added, the mixture stirred and insoluble material removed by filtration. Solid K2CO2 (0.6 
eq) and CH2Cl2 (50 ml) was added to the aqueous layer; the mixture was stirred and 
filtered. The organic layer was washed with water (3x20ml). The combined aqueous layer 
were washed with ethanol. Water was removed from the organic layer, which were then 
dried and evaporated to give the pure desired compound as a brown yellow solid.  
 
M.W.: 143.23 g/mol; Yield: 34% 






























1g of 9-oxo-9H-fluorene-2,7-dicarbonyl dichloride (3.28 mmol) was introduced in a 
flask equipped with a reflux condenser with 10 ml of chloroform. After stirring for 3 
minute, 1-(2-aminoethyl)-4-methylpiperazine was added in excess (9.84 mmol). The 
reaction was heated under reflux and monitored by TLC (eluent: ethyl acetate:hexane 
1:1.5). After 2 hours the reaction was completed. A solid was filtered off and the desired 
pure compound appeared like a yellowish crystalline solid  
 
M.W.: 518.65 g/mol; M.P.: >250 °C; Yield: 83% 































1g of 9-oxo-9H-fluorene-2,7-dicarbonyl dichloride (3.28 mmol) was introduced in a 
flask equipped with a reflux condenser with 10 ml of chloroform. After stirring for 3 
minute, 1-(2-aminoethyl)-4-methylpiperazine was added in excess (9.84 mmol). The 
reaction was heated under reflux and monitored by TLC (eluent: ethyl acetate:hexane 
1:1.5). After 2 hours the reaction was completed. A solid was filtered off and the desired 
pure compound appeared like a yellowish crystalline solid  
 
M.W.: 546.7 g/mol; M.P.: >250 °C; Yield: 83% 



































0.32 g of 2-N,7-N-bis[2-(4-methylpiperazin-1-yl)ethyl]-9-oxo-9H-fluorene-2,7-
dicarboxamide (0.61 mmol), K2CO3 (2.4mmol), CH3I (2.4 mmol) and DMF were introduced 
in a flask equipped with a reflux condenser. The reaction was heated under reflux and 
after 3 hours it can be observed the colour changes  from yellow to orange. The reaction 
was monitoreted with TLC ( eluent: ethyl acetate:hexane 1:1.5) and after 4 hours it was 
completed. At  R.T. it can be observed the formation of a yellow crystalline solid. A solid 
was filtered off and characterised. 
 
M.W.: 548.72 g/mol; M.P.: >250°C; Yield: 60% 



































0.33 g of 2-N,7-N-bis[3-(4-methylpiperazin-1-yl)propyl]-9-oxo-9H-fluorene-2,7-
dicarboxamide ( 0.61 mmol), K2CO3 ( 2.4 mmol), CH3I ( 2.4 mmol) and DMF were 
introduced in a flask equipped with a reflux condenser The reaction was heated under 
reflux and after 3 hours it can be observed the colour changes  from orange to dark 
green. The reaction was monitoreted with TLC ( eluent: ethyl acetate:hexane 1:1.5) and 
after 4 hours it was completed. At  R.T. it can be observed the formation of  a yellow 
crystalline solid. A solid was filtered off and characterised. 
 
M.W.: 576.77 g/mol; M.P.: >250°C; Yield: 70% 
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